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Abstract
USING GENETIC INFORMATION IN RISK PREDICTION FOR ALCOHOL DEPENDENCE
By Jia Yan, B.A.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy in Human and Molecular Genetics and Master of Science in Genetic Counseling at
Virginia Commonwealth University.
Virginia Commonwealth University, 2012.
Major Director: Danielle M. Dick, PhD
Associate Professor of Psychiatry, Psychology, and Human and Molecular Genetics
Family-based and genome-wide association studies (GWAS) of alcohol dependence (AD) have
reported numerous associated variants. The clinical validity of these variants for predicting AD
compared to family history has not yet been reported. These studies aim to explore the aggregate
impact of multiple genetic variants with small effect sizes on risk prediction in order to provide a
clinical interpretation of genetic contributions to AD. Data simulations showed that given AD’s
prevalence and heritability, a risk prediction model incorporating all genetic contributions would
have an area under the receiver operating characteristic curve (AUC) approaching 0.80, which is
often a target AUC for screening. Adding additional environmental factors could increase the
AUC to 0.95. Using the Collaborative Study on the Genetics of Alcoholism (COGA) and the
Study of Addiction: Genes and Environment (SAGE) GWAS samples, we used several different
sources to capture genetic information associated with AD in discovery samples, and then tested
genetic sum scores created based on this information for predictive accuracy in validation

samples. Scores were assessed separately for single nucleotide polymorphisms (SNPs) associated
in candidate gene studies and in GWAS analyses. Candidate gene sum scores did not exhibit
significant predictive accuracy, but SNPs meeting less stringent p-value thresholds in GWAS
analyses did, ranging from mean estimates of 0.549 for SNPs meeting p<0.01 to 0.565 for SNPs
meeting p<0.50. Variants associated with subtypes of AD showed that there is similarly modest
and significant predictive ability for an externalizing subtype. Scores created based on all
individual SNP effects in aggregate across the entire genome accounted for 0.46%-0.57% of the
variance in AD symptom count, and have AUCs of 0.527 to 0.559. Additional covariates and
environmental factors that are correlated with AD increased the AUC to 0.865. Family history
was a better classifier of case-control status than genetic sum scores, with an AUC of 0.686 in
COGA and 0.614 in SAGE. This project suggests that SNPs from candidate gene studies and
genome-wide association studies currently have limited clinical validity, but there is potential for
enhanced predictive ability with better detection of genetic factors contributing to AD.
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Chapter 1: Introduction

Background and significance
Alcohol dependence (AD) is a complex psychiatric condition that is influenced by both
genetic and environmental factors (Stacey et al., 2009). It affects 4-5% of individuals at
any given time in the United States and accounts for 10% of disability-adjusted life years
lost (Hasin et al., 2007; Rehm et al., 2009). It results in numerous unintentional and
intentional injuries and impacts other diseases such as maternal and perinatal disorders,
liver cirrhosis, cancer, diabetes mellitus, cognitive impairments, and cardiovascular
diseases (Rehm et al., 2009; Stavro et al., 2012). The World Health Organization
estimated that harmful alcohol use results in 20-30% of liver cirrhosis, liver and
esophageal cancer, epilepsy, homicide, and motor vehicle accidents worldwide (World
Health Organization, 2004). The substantial contribution of AD to the global burden of
disease makes efforts to identify differential susceptibility to AD an important public
health need (Rehm et al., 2009). Based on twin studies, AD has an estimated heritability
of around 50-60% for both men and women (Heath et al., 1997; Kendler et al., 1992;
Prescott and Kendler, 1999). Gene-finding studies have reported numerous genetic loci
associated with alcohol dependence. The existence of public interest in genetic
counseling and genetic testing for alcohol dependence stresses the importance of
coupling gene-finding studies with the evaluation of predictive accuracy and clinical
1

utility of genetic information for alcohol dependence (Gamm et al., 2004b; Khoury et al.,
2009). This study explores the clinical validity of using information about specific
genetic variants, family history, and additional factors such as marital status, religious
attendance, educational attainment, and income, in risk prediction for alcohol
dependence.
Alcohol dependence is defined by the DSM-IV-TR as three or more of the
following symptoms over a twelve-month period: tolerance, withdrawal, excessive
consumption, inability to reduce alcohol use, spending a great deal of time on obtainment
of alcohol, giving up or reducing important social, occupational, or recreational activities
due to alcohol use, and continued use despite adverse physical or psychological
consequences (4th ed.; DSM–IV; American Psychiatric Association, 1994). Development
of AD involves initiation of use and a process by which compulsive behavior arises
following controlled drinking initiation. Addiction has been described as encompassing
three stages characterized by aspects of impulsivity and compulsion: “binge/intoxication”,
“withdrawal/negative affect”, and “preoccupation/anticipation”, or craving (Koob and
Volkow, 2010). AD is a prevalent disorder in the United States. According to the
National Institute on Alcohol Abuse and Alcoholism (NIAAA)’s latest National
Epidemiologic Survey on Alcohol and Related Conditions (NESARC) for Alcohol Use
and Alcohol Use Disorders in 2001-2002, the 12-month prevalence of alcohol
dependence in the United States was 3.81%, with a prevalence rate of 5.42% in males and
2.32% in females (Grant et al., 2004). The lifetime prevalence of alcohol dependence has
been reported to range from 5.4% in the National Comorbidity Survey (NCS) (Kessler et
al., 2005) to 12.5% in NESARC, with alcohol use disorders twice as common in men as
2

they are in women (Hasin et al., 2007). A study from the National Longitudinal Alcohol
Epidemiological survey showed that of the general population, approximately 40%
reported having some history of alcoholism in their family and approximately 7-9% of
the population reported having both first and second-degree relatives with AD (Gamm et
al., 2004a; Grant, 2000) . The World Health Organization estimates that more than 200
million people in the world are affected with AD (Ginter and Simko, 2009).

Genetics of alcohol dependence
Human linkage and association studies and animal studies have shown numerous genetic
variants and key pathways associated with AD and other substance use disorders, with
multiple genetic contributions of small effect contributing to risk (Gelernter and Kranzler,
2009; Kalsi et al., 2009). Many studies of the genetics of alcohol dependence have
revealed phenotypic and etiological complexities, finding genetic influences across a
variety of alcohol phenotypes, including alcohol dependence that is co-morbid with other
drug dependence and externalizing and internalizing disorders such as conduct disorder,
adult antisocial personality disorder, and major depressive disorder, and intermediate
phenotypes and alcohol-related traits including impulsivity, sensation-seeking, and
behavioral disinhibition. Studies show unique and shared genetic etiology for these
comorbid phenotypes, as well as genetic variants that contribute to intermediate
phenotypes and alcohol-related traits, which could in turn influence risk for dependence
(Kendler et al., 2012; Dick et al., 2008a; Kertes et al., 2011; Knopik et al., 2004; Buscemi
and Turchi, 2011).
Among the first studies investigating the etiology of alcohol dependence were
3

family studies that reported evidence for familial transmission of AD (Merikangas, 1990;
Merikangas et al., 1985; Radouco-Thomas et al., 1979). Because family members can
share both genetic and environmental factors, intergenerational family studies of AD
cannot distinguish clearly between the two. Twin studies, however, are genetically
informative in delineating the etiological contributions of genetic and environmental
factors. These studies compare the phenotypic similarities and differences between
monozygotic twins, who share 100% of their genetic variation, and dizygotic twins, who
share on average 50% of their genetic variation. Both types of twin pairs also have a
common shared environment as well as unique environmental factors specific to each
twin. These studies have found that about 50-60% of the variability in alcohol
dependence is attributable to additive genetic factors, and that the rest of the variability in
AD is due primarily to unique unshared environmental factors (Kendler et al., 1992;
Heath et al., 1997; Prescott and Kendler, 1999).
The search for specific genetic loci contributing to alcohol dependence began with
linkage studies, which investigate the co-segregation of genetic markers with a disease or
trait within a family. Linkage studies assess the occurrence of co-segregation more than
expected by Mendel’s Law of Independent Assortment, with the assumption that
segregation between a genetic marker and disease status occurs when the marker has a
close physical distance to the disease locus and therefore lower likelihood of separation
from the disease locus during meiotic recombination. Because the chromosomal location
of genetic markers used in linkage studies are known, linkage study results help localize
disease regions (White et al., 1989; Botstein et al., 1980). Studies of large, densely
affected families and sibling pairs with alcohol dependence have uncovered regions
4

across multiple chromosomes that showed evidence for linkage. Genome-wide linkage
studies in the Collaborative Study on the Genetics of Alcoholism (COGA) sample have
found linkage of alcohol dependence diagnoses to chromosome 4q near the ADH gene
cluster, and also on chromosomes, 1, 2, 3, 7, and 8 (Reich et al., 1998; Nurnberger et al.,
2001; Schuckit et al., 2001; Foroud et al., 2000). A study by the National Institute on
Alcohol Abuse and Alcoholism (NIAAA) identified a region on chromosome 11 and also
a region on chromosome 4q in a sample from a Southwest American Indian tribe, near
the GABRB1 gene (Long et al., 1998). The 4q region was further supported in the Irish
Affected Sib Pair Study of Alcohol Dependence (IASPSAD) sample (Prescott et al.,
2006).
Linkage studies uncover chromosomal regions at low resolutions, on the order of 1
centimorgan (cM) or roughly 1 megabase (Mb), and are more suited for diseases of
Mendelian etiology, which have single-gene contributions of larger effect sizes. Followup studies fine-mapping chromosomal regions using association analyses are necessary to
discover specific genes (Boehnke, 1994; Ciaranello and Ciaranello, 1991). Association
analyses, on the other hand, are designed to discover specific alleles that are correlated
with disease status. Association studies are based on the observation that patterns of
linkage disequilibrium (LD), or correlations among alleles more than expected by chance,
are maintained across the genome. These correlations exist often because of close
physical distance, which reduces the likelihood that recombination events between the
two loci occur across generations. A map of the LD structure of the human genome has
allowed for LD-based tagging of the entire genome using common single nucleotide
polymorphisms (SNPs). Haplotype blocks consisting of groups of alleles that are
5

correlated and inherited together can be captured by a reduced number of informative
SNPs. These SNPs have been used to test for associations with disease status, with the
idea that SNPs that are associated with disease status are either in LD with causal loci
(indirect association), or are themselves causative (direct association) (International
HapMap Consortium, 2003) .
Candidate gene studies of alcohol dependence have investigated the correlation
between specific genetic variants and alcohol dependence. Candidate genes are typically
selected as positional candidates, or genes that are located in or near linkage regions for
alcohol-related phenotypes, and/or functional candidates, which are genes involved in
specific biological pathways that are hypothesized to influence risk for addiction
(Gelernter and Kranzler, 2009; Zhu and Zhao, 2007). Association methods include
family-based association, which assesses for increased frequency of transmission of
specific alleles from parents to affected offspring using the transmission disequilibrium
test and population-based association, which tests for allele frequency differences
between cases and matched-controls for a disorder using regression methods (Buscemi
and Turchi, 2011). Many candidate genes have been found to be associated with AD. A
number of promising candidates that have been replicated in independent samples have
emerged. Some of the candidate genes and pathways that are currently thought to be
involved in AD include the following:

Alcohol Metabolism
The most robustly replicated candidate genes with the largest estimated effect sizes
encode enzymes that play primary roles in alcohol metabolism: alcohol and aldehyde
6

dehydrogenases. The breakdown of ethanol occurs primarily in the liver, the first step of
which involves oxidation of ethanol to acetaldehyde, a reaction that is catalyzed by
alcohol dehydrogenases (ADH). The second step is catalyzed by aldehyde
dehydrogenases (ALDH), which results in oxidation of acetaldehyde to acetate. The
accumulation of acetaldehyde leads to adverse physiological reactions to alcohol, such as
nausea, flushing, and tachycardia (Edenberg, 2007a). Variants of the ADH and ALDH
genes that confer differences in the elimination of alcohol and the accumulation of
acetaldehyde – and subsequently symptoms following alcohol consumption – have been
found to influence risk for alcohol dependence (Strat et al., 2008). Both coding and
noncoding variations have been associated with AD, with allele frequencies varying
across populations of different ancestry.
The ALDH2*2 Glu504Lys allele results in nearly inactive ALDH2, and therefore
lack of conversion of acetaldehyde to acetate, resulting in nausea, tachycardia, and in
particular, a severe flushing response following alcohol intake (Edenberg, 2007a).
Carriers of this allele have been found to have a significantly decreased risk for AD
(heterozygotes in East Asian populations have been found to have a fivefold reduction in
risk for AD) (Mathews et al., 2012; Chen et al., 1999). The frequency of ALDH2*2 is
common in East Asian populations, but rare in European and African populations (Oota
et al., 2004). Variants in the ALDH1A1 gene have also been associated with AD and
drinking behavior in different populations, including American Indian, Finnish, and East
Indian samples (Ehlers et al., 2004; Lind et al., 2008; Moore et al., 2007). ADH1B*2 and
ADH1C*1, which encode enzymes that have greater activity in the conversion of alcohol
into acetaldehyde, have been shown to have protective effects against AD in East Asian
7

populations, perhaps due to the increased feelings of nausea resulting from toxicity of a
larger quantity of acetaldehyde (Choi et al., 2005; Crabb et al., 1989; Crabb et al., 1993;
Edenberg, 2007b; Li et al., 2011). ADH1B*2 has also been found to have a protective
effect among individuals of Jewish descent (Hasin et al., 2002a; Hasin et al., 2002b) and
in a group of Mexican American men in the United States (Konishi et al., 2004). The
variant has been associated in African American individuals, though it has a smaller
frequency in the population (Whitfield, 2002). Studies of the seven ADH genes in
European Americans have found association of AHD1B (Whitfield, 2002) and of ADH4
variants with AD (Edenberg et al., 2006; Luo et al., 2005b; Edenberg, 2007a; Guindalini
et al., 2005). More recently, despite the substantially lower frequency of the ADH1B*2
allele in European American populations, ADH1B*2 has been found also to have a
protective effect on alcohol dependence in European Americans and African Americans
(Bierut et al., 2012). In a German sample, a genome-wide significant finding was found
for a SNP between the ADH1B and ADH1C genes that is in LD with the functional
ADH1C Arg272Gln variant, which has been previously associated with alcohol
consumption (Frank et al., 2012; Macgregor et al., 2009). Convergent evidence from
linkage, candidate gene, and genome-wide association studies, coupled with knowledge
of the biological function of ADHs and animal and expression studies, support the
importance of ADH genes for AD (Ehlers et al., 2010; Chen et al., 2005).

Reward Pathways
Reward pathways have been found to be involved in alcohol initiation, tolerance,
preference, consumption, abuse, and dependence (Strat et al., 2008). Genes that play a
8

role in neurotransmitter systems, including ones involving dopamine, gammaaminobutyric acid (GABA), opioids, glutamate, and serotonin, have been key candidate
genes for AD (Palmer et al., 2012).
GABA, the major inhibitory neurotransmitter in the central nervous system, has
been implicated in risk for AD. Variants in the GABA inhibitory pathway have been
associated with AD across multiple samples, particularly for the GABAA receptor,
GABRA2. In the COGA high-density family sample with multiple first-degree relatives
diagnosed with AD, Edenberg et al. found evidence for association of multiple SNPs in
the GABRA2 gene with alcohol dependence and increased power in the beta frequency
band measured by electroencephalography, which is an endophenotype for AD
(Edenberg et al., 2004). This association has been replicated in several additional studies
(Covault et al., 2004; Lappalainen et al., 2005; Drgon et al., 2006; Fehr et al., 2006;
Soyka et al., 2008; Enoch et al., 2006; Bierut et al., 2010). The lack of association
between GABRA2 and AD has also been reported (Matthews et al., 2007). This nonreplication has been attributed to a difference in phenotype; the sample in which the
negative finding was seen had minimal comorbidity with other drug dependence and
psychiatric phenotypes (Matthews et al., 2007). In fact, further study showed that
GABRA2 was associated with AD that is comorbid with other drug dependence (Agrawal
et al., 2006). GABRG3, GABRA1, GABRA6, and GABRB1 are several additional GABA
receptor genes reported to be associated with AD (Dick et al., 2004; Dick et al., 2006b;
Noble et al., 1998; Song et al., 2003).
Genes encoding dopamine receptors have been associated with AD, including the
dopamine D2 receptor, DRD2 and the dopamine D4 receptor gene, DRD4. An increased
9

frequency of the DRD2 A1 allele of the Taq1A restriction fragment length polymorphism
has been associated with AD. There have been a number of studies investigating this
association, with mixed results. The first reports of association showed that the Taq1A1
restriction fragment length polymorphism was associated with AD in a sample of
postmortem brain tissue in severe alcoholics and controls (Blum et al., 1990; Blum et al.,
1991). Since then, there have been a number of studies that replicated this finding in
independent associations with AD (Comings et al., 1994; Blum et al., 1990; Blum et al.,
1991; Noble et al., 1991; Amadeo et al., 1993; Amadeo et al., 2000; Foley et al., 2004;
Hietala et al., 1997; Ishiguro et al., 1998; Konishi et al., 2004; Kono et al., 1997).
However, there have also been many failures to replicate (Arinami et al., 1993; Bolos et
al., 1990; Cook et al., 1992; Chen et al., 2001; Cruz et al., 1995; Edenberg et al., 1998;
Gelernter and Kranzler, 1999; Gelernter et al., 1991; Goldman et al., 1992; Lee et al.,
1999; Lobos and Todd, 1998; Lu et al., 1996; Sander et al., 1995; Sander et al., 1999;
Suarez et al., 1994; Turner et al., 1992). The discordance across studies has been
attributed to differences in phenotypic severity, co-occurrence of other phenotypes such
as polysubstance abuse and impulsive and compulsive behaviors - coined “reward
deficiency syndrome” by Blum et al. (Blum et al., 1996), and population stratification
(Dick et al., 2007d). A later study found that the Taq1A polymorphism that had been
thought to be located in the DRD2 gene was actually located 10 kb downstream in the
ANKK1 gene (Neville et al., 2004). A comprehensive study of SNPs across both DRD2
and ANKK1 found associations for SNPs in both genes, with stronger evidence for SNPs
in the 5’ region of ANKK1, particularly for AD with medical complications (Dick et al.,
2007d).
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Several genes related to serotonin (5-hydroxytryptamine, 5-HT) have been
suggested to play a role in AD. Specifically, a functional insertion-deletion variant in the
serotonin transporter protein (5-HTT)-linked promoter region (5-HTTLPR) affects
regulation of 5-HT levels and has been associated with AD; however, results have been
controversial, with a large number of both positive and negative findings (reviewed in
Dick and Foroud, 2003). A meta-analysis of 17 studies, comprised of 3,489 alcoholics
and 2,325 controls, showed that the short (S) allele was associated with AD, with an odds
ratio of 1.18 (Feinn et al., 2005). A gain-of-function 5-HT3 receptor gene (HTR3B)
variant has also been associated with alcohol dependence in a treatment-seeking sample
of individuals of African descent (Enoch et al., 2011).
The muscarinic acetylcholine receptor M2 (CHRM2) has been associated with AD
and the endophenotype event-related oscillations (EROs) (Wang et al., 2004). Evidence
for this association has been seen in other independent samples (Luo et al., 2005a;
Kendler et al., 2011). Further study has suggested that CHRM2 is particularly important
in AD that is comorbid with other drug dependence (Dick et al., 2007a) and associated
with the severity of alcohol dependence (Jung et al., 2011). It has also been implicated in
risk during adolescence, showing an association with adolescent substance use and
behavioral disinhibition (Hendershot et al., 2011) and interaction with parental
monitoring in risk for externalizing (Dick et al., 2011). Variants in the gene have also
been associated with nicotine dependence (Mobascher et al., 2010), major depressive
disorder (Wang et al., 2004) and IQ (Dick et al., 2007c).

Genome-wide association studies of alcohol dependence
11

More recently, a number of genome-wide association studies (GWAS) have been
performed for alcohol dependence and alcohol-related phenotypes. GWA-studies, which
assess common markers across the genome for association with a common disorder, are
an a priori approach to gene finding (Visscher et al., 2012). Compared with a linkage
study, which is more suited to detecting loci with larger effects sizes, an association study
is a more powerful method that requires fewer markers and a smaller sample size to
detect common variants of small effect for diseases. For example, in a nonparametric
linkage analysis of affected sib pairs, an allele with moderate frequency (0.10-0.50) and
modest genotypic relative risk (GRR) of 1.5 would have a probability of allele sharing
between siblings of only 50.5% - 51%, which is close to the null hypothesis of 0.50. In an
association study, however, the degree of overtransmission from heterozygous parents to
affected offspring for an allele of this effect would be around 60%. The number of
families required to detect an allele with a GRR of 1.5 effect using linkage analysis
would be on the order of 17,000-67,000, compared with only 949-2218 for an association
study to detect the same effect (Risch and Merikangas, 1996).
Genome-wide association studies for AD have supported previous candidate gene
studies, as well as reported many new genes and pathways in risk for alcohol-related
phenotypes (Treutlein and Rietschel, 2011b; Treutlein et al., 2009; Frank et al., 2012;
Bierut et al., 2010; Edenberg et al., 2010; Agrawal et al., 2011; Heath et al., 2011; Lind et
al., 2010; Schumann et al., 2011; Wang et al., 2012; Wang et al., 2011; Zuo et al., 2012;
Kendler et al., 2011; Zuo et al., 2011). Although many of the reported genome-wide
association studies to date have reported variants that did not meet the genome-wide
significance threshold of p < 5x10-8, many have reported variants that were associated
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with low p-values (p < 1x10-5). Additional details about specific AD GWAS are
summarized in Chapter 4. Briefly, several results from AD GWAS reports include the
following: two correlated SNPs in the 3’ flanking region of the peroxisomal trans-2enoyl-CoA reductase gene (PECR) (Treutlein et al., 2009); a group of chromosome 11
genes (SLC22A18, PHLDA2, NAP1L4, SNORA54, CARS, and OSBPL5) (Edenberg et al.,
2010); the semaphorin 3E gene (SEMA3E) (Lind et al., 2010); MARK1, which is involved
in phosphorylation of microtubule-associated proteins (Lind et al., 2010); DDX6, which
encodes a putative RNA helicase, and KIAA1409, which is thought to be part of a sodium
channel complex (Lind et al., 2010); The KIAA0040 gene was associated with AD in both
Zuo et al.’s study (2012) and Wang et al.’s meta-analysis (2011); THSD7B, NRD1, and
PKNOX2 in Wang et al. (2011). Studies of quantitative traits such as alcohol
consumption have identified a genome-wide significant association with the AUTS2 gene
(Schumann et al., 2011) and evidence of association for the TMEM108 and ANKS1A
genes (Heath et al., 2011). In a study of an alcohol factor score, Kendler et al. (2011)
found the most significant SNP to be KCNMA1, AKAP9, and PIGG in the EA sample and
CEACAM6, KCNQ5, SLC35B4, and MGLL in the AA sample, and found support for
previously associated candidate genes for ADH1C, NFKB1, and ANKK1 in the EA
sample and ADH5, POMC, and CHRM2 in the AA sample (Kendler et al., 2011).

Environmental factors influencing risk for alcohol dependence
Additional factors that contribute to AD have been implicated in numerous studies. A
study investigating risk factors predicting problem drinking in a sample of 30-year old
Danish men identified low birth weight, number of life crises in childhood, ratings of
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childhood unhappiness and antisocial personality disorder as powerful independent
predictors of problem drinking, accounting for 46% of the variance in problem drinking
(Knop et al., 2003). Childhood maltreatment has also been implicated as an
environmental risk for substance use disorders such as AD implicated in numerous
studies, including physical abuse, neglect, and a particularly specific risk for substance
use disorders in cases of child sexual abuse (Clark and Winters, 2002; Dinwiddie et al.,
2000; Kendler et al., 2000; McLaughlin et al., 2010; Nelson et al., 2002; Sartor et al.,
2007). Religiosity has also been shown to have a protective main effect on risk for
substance use disorders (Kendler et al., 2003a; Koopmans et al., 1999) . In independent
samples, educational attainment has been found to be associated with AD (Grant et al.,
2012). Socioregional residence has been shown to influence both religiosity and alcohol
use (Dick et al., 2001). Marital status has also been shown to be associated with AD
(Dick et al., 2006a). In data from the National Longitudinal Alcohol Epidemiology Study
and the National Epidemiologic Study on Alcohol and Related Conditions, marital status
and educational attainment were associated with alcohol dependence and income was
associated with alcohol abuse (Caetano et al., 2011). Hicks et. al. assessed six
environmental risk factors – academic achievement and engagement, antisocial and prosocial peer affiliations, mother-child and father-child relationship problems, and stressful
life events – and found that each risk factor had a significant correlation with
externalizing disorders in adolescence such as substance use disorders and antisocial
behavior (Hicks et al., 2009).
These studies stress the important role that specific environmental variables play
in the risk for alcohol use behaviors and AD. In addition to having a main effect on AD
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risk, many of these “environmental” factors, have a moderating effect on, and a
correlation with, genetic risk factors for AD (Dick et al., 2001; Hicks et al., 2009;
Caetano et al., 2011; Dick et al., 2006a; Koopmans et al., 1999). Ultimately, a
combination of multiple genetic and environmental factors should be used to predict and
treat disease.

Psychiatric genetic counseling and testing
The field of genetic counseling for single gene, Mendelian disorders of high penetrance
utilizes a large range of testing options that often have high clinical validity. In contrast,
genetic counseling for phenotypes of complex etiology, including alcohol dependence,
schizophrenia, and the majority of cancer and autism cases, is limited to a general
discussion of genetic and environmental contributions to pathogenesis and the use of
empiric risk estimates rather than direct genetic testing (Harper, 2004). Psychiatric
genetic counseling is different from genetic counseling for single gene conditions of high
penetrance in regard to both the degree of uncertainty and the availability of testing.
Despite these differences, the principles of genetic counseling for each are the same. As
defined by the National Society of Genetic Counselors (National Society of Genetic
Counselors' Definition Task Force et al., 2006):

Genetic counseling is the process of helping people understand and adapt to the
medical, psychological and familial implications of genetic contributions to
disease. This process integrates:
- Interpretation of family and medical histories to assess the
chance of disease occurrence or recurrence.
- Education about inheritance, testing, management, prevention,
resources and research.
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-

Counseling to promote informed choices and adaptation to the
risk or condition.

Individuals seek genetic counseling for psychiatric disorders due to a variety of
reasons, including finding out a cause for the disorder and obtaining risk assessments for
the recurrence of a disorder. Affected individuals may be concerned with the risk of
passing the disorder to their children. Individuals and their families could be struggling to
understand the etiology of the condition. Family members of an individual with a
psychiatric condition may be concerned with their own risks for developing the
condition, as well as the risks for their children. They may face psychosocial issues
specific to having a family member with a disorder, such as the “survivor guilt”
sometimes experienced by siblings and other family members without symptoms. Parents
of affected individuals may also harbor guilt related to the belief that they played a part in
causing the illness in their children. Families may face stigma in society. Having a better
understanding of the psychiatric condition affecting their family could help them better
develop coping strategies and form behaviorally adaptive practices (Austin and Honer,
2007).
Genetic counseling seeks to address these issues. Risk assessment during a genetic
counseling session involves gathering a targeted family history to trace psychiatric
features, along with distinct physical and cognitive features associated with some
psychiatric conditions, through a three-generation pedigree (Peay et al., 2008). The nature
of uncertainty in psychiatric phenotypes is addressed through education about the
environmental and genetic contributions to psychiatric conditions. Currently, populationbased empiric risk estimates based on family history and degree of relatedness to an
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affected individual, are quoted during counseling about recurrence risks (Harper, 1998).
Table 1.1 and 1.2 below illustrate the empiric risk to relatives of persons with specific
psychiatric disorders.
Table 1.1 Empiric risk for common psychiatric disorders in firstdegree relatives
Psychiatric Disorder

General Population

First-degree relative

Schizophrenia

1%

5-16%

Bipolar Disorder

1-5%

4-18% (BPD)
9-25% (UPD)

Major Depression

5-35% (females)
5-15% (males)

10-25%

Obsessive Compulsive Disorder

1-3%

10%

Panic Disorder

2-6%

8-31%

Adapted from Hill and Sahhar, 2006
BPD = bipolar depression; UPD = unipolar depression

Table 1.2 Empiric risk for schizophrenia in relatives of a person with
schizophrenia
Relationship to person with
schizophrenia

Lifetime risk

General population

1%

First-degree relative
Identical twin

40-48%

Fraternal twin

10-17%

Sibling

9%

Parent

6-13%

Offspring

13%

Second-degree relative
Aunt/uncle

2%

Niece/nephew

4%

Granchild

5%

Third-degree relative
First cousin

2%

Adapted from (Finn and Smoller, 2006)

Traditional empiric risk for AD for family members of an individual affected with AD
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from several studies are reviewed in Table 1.3 (from (Merikangas, 1990).
Table 1.3 Familial empiric risk for AD
Relationship to person with AD
Sibling

Recurrence risk
11%

Sister

1-8%

Brother

11.8-12.4%

Parent

29.8%

Mother

1.6-6%

Father

16.1-22%

Parents and siblings as a group

35.6%

Grandfathers

11%

There exist limitations to risk assessment that focuses primarily on empiric risk
estimates derived from family history information obtained in family-based population
studies. As is the case with any risk estimate derived from a population sample, empiric
risk may not be applicable for a specific individual due to differences in both genetic and
environmental background, particularly since empiric risk can vary widely across
multiple studies. Furthermore, empiric risk may not be available for families with
multiple psychiatric phenotypes or across all family relationships (Austin and Peay,
2006). Genetic information that has better-characterized risk estimates and is more
specific to the individual may provide more accurate recurrence risk assessments than
family history alone.

Attitudes toward genetic counseling and testing for psychiatric disorders in general
A number of studies investigating attitudes towards genetic counseling in individuals
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who are affected and their families have shown both a desire for genetic counseling and
an interest in genetic testing (Peay and Sheidley, 2008; Austin and Honer, 2007; Hill and
Sahhar, 2006). A survey of 31 individuals with bipolar disorder showed that more than
75% of them wanted genetic counseling. More than 70% of 48 family members of
individuals with schizophrenia wanted genetic counseling (Austin and Honer, 2007).
Several studies assessing interest in genetic testing in independent samples of individuals
affected with a range of psychiatric disorders and their family members show upwards of
more than 80% of individuals possessing a desire to test for genes implicated in
psychiatric disorders. In a survey of 48 members of families with multiple affected
members, 83% wanted genetic testing for genes of small effect. In regard to prenatal
testing for psychiatric conditions, of 65 members of the Alliance for the Mentally Ill,
77% believed that it should be available for bipolar disorder, 85% for schizophrenia and
autism, 70% for attention deficit disorder, and 55% for panic disorder. Even if there is an
absence of childhood preventative treatment for a disorder, 68% of the 48 members of the
bipolar support group sample, which included families and friends of affected individuals,
endorsed testing for children (reviewed in Smoller et al, pp 30-31, 2008). Further
investigation into whether or not individuals were interested in genetic testing for major
depressive disorder revealed that individuals were more likely to be interested in testing
if they had a personal history of mental illness, a greater than average self-estimated risk
for depression, had perceived benefits for genetic testing, and – unexpectedly, believed
that evidence for a genetic component for mental illness would increase social stigma
(Wilde et al., 2011). Potential for discrimination and interference with privacy decreased
interest in a genetic test for major depressive disorder (Wilde et al., 2010).
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Attitudes towards genetic testing for alcohol dependence
Survey studies specific to interest in risk assessment for alcohol dependence
suggest that there may be considerable interest in genetic counseling and potential genetic
testing to determine personal risk for alcohol dependence (Gamm et al., 2004b). Of the
general population, 60-77% has been reported to share a belief that AD is “a lot” or to
“some” extent due to genetic effects (Gamm et al., 2004b). In one study of 27 individuals
with at least one first degree relative with alcohol dependence and an average of three
additional second and third degree relatives with alcohol dependence, 63% said that they
would choose to undergo a genetic test to determine their own risk for alcohol
dependence if a genetic test for alcohol dependence were available. Of interested
individuals, 59% believed that testing would lead to better prevention or treatment and
48% believed that it would help address their concerns about their own children’s risk
(Gamm et al., 2004b). This research on testing attitudes for AD and other psychiatric
disorders reveal a substantial population that wants to know genetic information. This
research reveals a need for the careful evaluation of the clinical utility of genetic
information and subsequent education about genetic testing.
Research on genetic testing acquisition has shown one caveat about predicting
testing uptake before a test becomes available: although there appears to be an interest in
testing for psychiatric conditions, actual decisions to have testing may not be as high as
predicted once testing does become available. In the case of Huntington disease, a
smaller proportion of at-risk individuals pursued testing after the gene was found and
testing became available than the proportion that had been estimated to be interested in
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testing from survey studies performed before the availability of testing (Evers-Kiebooms
and Decruyenaere, 1998). Evers-Kiebooms and Decruyenaere showed in 1989 in a large
survey in Belgium that 66% of individuals at risk for Huntington disease and 74% of
their partners had indicated that they wanted to make use of testing (Evers-Kiebooms et
al., 1989). An assessment of testing published in 1998 about a decade after genetic testing
for Huntington disease became available showed that testing uptake was actually 6-20%
in at-risk individuals across different populations (Evers-Kiebooms and Decruyenaere,
1998).

How accurate risk prediction could influence management and prevention
If clinically valid variants were established for AD, the next step would be to assess the
clinical utility of genetic testing for AD. Genetic heterogeneity and genetic testing based
on information from genetic association studies can create increased uncertainty and
confusion if the usefulness of testing an individual for susceptibility genes of small effect
is not addressed. When determining whether individuals would benefit from genetic
testing for a psychiatric disorder, a primary question to ask is whether knowledge of
particular genetic risk factors changes management in a meaningful way. The hope is that
risk prediction will help tailor individual treatment for disorders in a number of ways.
Currently, a proportion of pharmacological treatment for psychiatric disorders
consists of trial and error. Pharmacogenetics utilizing panels of variants that predict
treatment metabolism and response may reduce delay in treatment and remove additional
toxicity from medication due to inappropriate dosage and drug type (Smoller et al., 2008).
Heterogeneity in causes within different individuals with alcohol dependence may
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prompt differences in treatment. Several genetic variants have been shown to have
potential pharmacogenetic utility for individualized therapy for AD. For example,
naltrexone, an opioid receptor antagonist that is used as pharmacological treatment for
alcohol dependence targeted towards mitigating the rewarding response to alcohol, has
been shown to be differentially effective based on OPRM1 genotype. OPRM1 77G
carriers have been suggested to have increased mesolimbic dopamine activity in response
to alcohol and subsequently a greater treatment response to naltrexone (Heilig et al.,
2011).
Additionally, Wray et al. asserted that environmental interventions might have the
greatest impact on risk reduction in those who have the greatest risk to begin with (Wray
et al., 2008). Therefore, identification of individuals at the highest level of genetic risk for
targeted intervention may be an effective risk-reducing strategy for a disorder for which
interventions are available. Knowing risk may help categorize individuals into groups of
clinical significance for targeted treatment. In the case of AD, previous research has
suggested that risk variants for AD may confer additional risks for trajectories of
externalizing behavior across development (Dick et al., 2009). GABRA2 has been
associated with externalizing trajectories and was shown to interact with parental
monitoring (Dick et al., 2009). Early prediction of AD may therefore also lead to the
prediction and interventions for additional categories of risk and phenotypes across the
lifespan.
Knowledge about genetic information for a disorder has been suggested to have a
potentially unique impact on an individual’s physical and emotional response to
behavioral recommendations, known as the adherence response (McBride et al., 2012).
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Testing that provides individualized knowledge of genetic susceptibility may increase
motivation to make behavioral changes compared with not having information on genetic
testing. While individuals who seek out genetic tests have been shown to be
knowledgeable about and motivated to improve health-promoting behaviors, less is
known about precisely how best to customize interventions based on genetic information
for individuals across a spectrum of interest in genetic testing (McBride et al., 2012).
Studies on smoking cessation rates show limited change in cessation after individuals
receive knowledge about genetic testing information, with either no change in smoking
rates, or decreases in smoking only during a finite period directly following education
about genetic testing information. These earlier studies focused on single-gene variants
that may confer increased susceptibility for lung cancer. More recent preliminary studies
have shown that individuals who received information on more risk variants resulted in a
greater likelihood of quitting smoking than individuals who received feedback about
fewer risk variants (McBride et al., 2010). For alcohol dependence, a clinical scenario
involving testing for multiple variants would be more likely than testing only for a few
single gene variants, as AD is a complex trait with multiple genetic influences. The
question of whether or not testing for multiple genetic variants that increase susceptibility
to AD would affect behavioral outcomes would need further evaluation.

Ethical, legal, and social implications
Genetic information is unique in that it may have implications for the health of not only
the individual being tested, but also that of the individual’s family and future progeny.
Issues of autonomy may come into play when one person’s decision to test or not to test
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affects a group of individuals. For the proband, the desire to maintain personal privacy in
regard to medical information may conflict with a duty to warn family members about
information that may affect their health. The right not to know genetic information may
be violated in relatives of an individual who decides to have testing.
Genetic information specific to multi-allelic disorders of complex etiology may
have less predictive implications for family members than genetic information for higher
penetrance Mendelian disorders with single causative alleles. However, intuitive
knowledge of the familial nature of a complex disorder may still exert a blanket of
influence on perceptions and decision-making in relatives based on genetic testing in one
proband. Ultimately, decisions made using genetic information by individuals may
influence the greater community and population (Smoller, 2008). Individuals who elect
genetic testing could face the possibility of being labeled and treated with stigma.
Unaffected individuals with an increased risk resulting from a genetic test may
experience psychological distress as well as experience discrimination from society,
insurance companies, and employers, including “anticipatory stigma”, which means
discrimination to the same extent as affected individuals of unaffected individuals who
are perceived to be at risk for a disorder (Austin and Honer, 2007). Thus, the ethical
issues that accompany genetic testing for psychiatric and other complex disorders must
be addressed alongside research advances.
There has been a recent emergence of direct to consumer (DTC) personal genomics
testing for many multifactorial disorders, including addiction, despite limited information
about the clinical validity and utility of genetic variants associated with these disorders
(Mathews et al., 2012). General public perceptions of the clinical utility of direct-to24

consumer genomic profiling have been shown to be more optimistic than those of
genetics professionals (Leighton et al., 2012; McGuire et al., 2009; Wilde et al., 2011).
Public interest in genetic testing may be due in part to a misunderstanding of how
predictive genetics can be for complex disorders (Lawrence and Appelbaum, 2011). The
potential harm of inaccurate information for consumers emphasizes the need to couple
gene-finding efforts with rigorous evaluation of predictive accuracy, and subsequent
education for the general public about genomic testing (Khoury et al., 2009).

Genetic risk prediction studies
There exists debate about whether aggregate profiles of associated markers could
be used to predict risk for complex diseases (Janssens et al., 2006; Lee et al., 2008; Evans
et al., 2009). Previous efforts to study risk prediction for complex disorders have assessed
the predictive ability of genetic sum scores based on number of risk alleles that have been
associated with a particular disorder.
Previous studies have investigated the potential for risk prediction for a number of
common complex disorders. A clinical test is evaluated within the A.C.C.E framework,
based on the test’s analytical validity, clinical validity, clinical utility, and ethical, legal,
and social implications surrounding testing (Khoury et al., 2009). Analytical validity is
the reliability and accuracy of the test measure itself, such as the accuracy of genotyping
calls on a SNP array. Clinical validity is the degree to which the test can explain and
predict risk for a disorder. Measures such as sensitivity, or the probability of a positive
test among individuals with a disorder, and specificity, or the probability of a negative
test among individuals without the disorder, are indicators of a test’s clinical validity.
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Clinical utility is the benefits and limitations of the test in changing management of a
disorder for an individual. Clinical utility can encompasses changes in screening
procedures, treatment, and preventative behavioral or pharmaceutical measures. It can
also represent personal utility, in which knowledge about the test results alone can make
a difference in an individual’s perspective in a beneficial way (Foster et al., 2009). For
example, an individual who may be suffering from self-blame for having a psychiatric
disorder may benefit from knowledge that genetics played a role in the disorder’s
etiology. This individual may be better able to cope with the disorder, even if there are no
direct changes in treatment or prevention based on the genetic test results alone (Khoury
et al., 2009; Foster et al., 2009).
The ability of a clinical test to distinguish between individuals with and without a
disease is typically assessed based on the test’s sensitivity and specificity. A frequent
measure of clinical validity is the receiver operating characteristic (ROC) curve (Figure
1.1), which plots the sensitivity vs. 1-specificity for every cut-off of a continuous
predictor to distinguish between presence and absence of a disease diagnosis (Spitalnic,
2004). The area under the ROC curve (AUC) for a continuous predictor corresponds to
the probability that an individual with the disease would have a higher measured or
predicted risk than an individual without the disease, and therefore reflects the proportion
of individuals classified correctly as cases or controls based on the predictor. This
measure of concordance is also known as the c statistic. An AUC of 0.50 means that the
predictor can accurately classify 50% of individuals, or no greater than chance, whereas
an AUC of 1.0 means that the predictor can correctly classify 100% of individuals,
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corresponding to perfect discriminative ability. An AUC of 0.80 is typically used as a
target cut-off for screening and 0.99 for diagnosis (Janssens et al., 2006).
The AUC is a measure of the ability to discriminate between a case and a control,
as opposed to the positive predictive value (PPV), which is a direct measure of whether a
person with a positive test result will develop a disease (Cook, 2007). A predictor that has
perfect discriminatory accuracy will have a single cut-off on the upper leftmost point on
the ROC curve (Figure 1.1) that corresponds to 100% sensitivity, or 100% true positive
rate, and 100% specificity, or 100% true negative rate (Attia et al., 2009).

Figure 1.1 Sample ROC curve for a hypothetical continuous
predictor
Percentages on the curve represent the sensitivity and 1-specificity
corresponding to every risk score cut-off.
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Using simulated data of 100,000 individuals with an incidence of 10% for
coronary heart disease (CHD), van der Net et al. (2009) calculated the area under the
receiver operating characteristic curve (AUC) to determine the ability of genetic risk
profiles to discriminate between individuals who will and will not develop CHD. Using
ten identified variants with odds ratios that varied from 1.13 to 1.42, the AUC was 0.59
(van der Net et al., 2009). A study by Jakobsdottir et al. showed that a model of 12 SNPs
for type 2 diabetes had an AUC of 0.64, a model of 2 SNPs for prostate cancer had an
AUC of 0.56, and a model of 5 SNPs for Crohn’s disease had an AUC of 0.66
(Jakobsdottir et al., 2009).
In addition to assessing the ability of using only genetic markers to predict disease,
the predictive value that a group of genetic markers adds to current clinical predictors of
disease has been evaluated (Pencina et al., 2008; Greenland, 2008). Gail (2008) showed
that adding seven SNPs identified from candidate gene studies and genome-wide
association studies with per allele odds ratios (ORs) ranging from 1.07 to 1.20 to the
clinically used National Cancer Institute’s Breast Cancer Risk Assessment (BCRAT) tool,
which takes into account family history, personal history of breast biopsies, and age at
menarche and first live born for the prediction of breast cancer, only improved the AUC
from 0.604 to 0.632. This increase was less than that of adding mammographic density to
the BCRAT (Gail, 2008). In the case of Alzheimer disease, the addition of the APOE
genotype to existing clinical criteria produced only a nominal increase that was not
statistically significant (Attia et al., 2009). Talmud et al. (2010) showed that sum scores
of risk alleles for 20 SNPs associated with type II diabetes did not appear to add to the
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phenotype-based risk models, Cambridge risk score and Framingham offspring risk score,
in discrimination for type II diabetes.
One reason that genetic variants may not add significantly to risk models that take
into account other, more easily measured, risk factors is that they may also contribute to
the very risk factors that are part of the original prediction model (Janssens and van
Duijn, 2008). Therefore, adding the variants does not add additional information to the
model. For example, in the Whitehall II prospective cohort study on type II diabetes
(Talmud et al., 2010), a risk model containing both genetic and clinical predictors was
assessed, but this risk score could be confounded by the inclusion of family history along
with genetic sum scores in the models. In light of this, the study showed whether genetic
variants could add additional information despite possible correlation with family history
information (Talmud et al., 2010). Another reason is that the ROC may be different for
populations of patients with different genetic and environmental backgrounds, in which
case the sensitivity and specificity of a test may not be the same within each background
profile. Finally, a prediction model that consists primarily of genetic variants has a
maximum AUC constrained by the heritability of the trait as well as the disease
prevalence in a population (Wray et al., 2009). This stresses the importance of taking into
account other medical and environmental predictors when assessing the utility of adding
genetic components of disease to risk prediction.
Prior analysis comparing the use of odds ratios to the AUC shows that an OR of
16 is needed for an AUC of 0.84 (Pepe et al., 2004). Many predictors of multifactorial
common diseases do not have ORs of this magnitude. A combination of a large number
of multiple predictors, however, may have greater discriminative power. For example, the
29

Framingham score, an established and validated discriminator of risk of cardiovascular
disease that discriminates disease status with an AUC of 0.80, includes a number of risk
factors that have ORs of less than 2.2, much lower than that of the overall score itself;
none of the factors have enough discriminatory ability individually (Pepe et al., 2004).
The ORs of associated SNPs for a complex disease such as alcohol dependence in no way
come close to an OR of 16; SNPs associated with AD often have ORs less than 1.30. A
panel of SNPs taken together, on the other hand, despite individually small ORs for each
SNP, may have better discriminatory ability.

Project rationale and design
This project examined genetic and environmental variables to create risk profiles for
alcohol dependence, in an effort to provide a clinical interpretation of current research on
alcohol dependence in the context of risk prediction. The project first studied the
potential predictive power for AD, and prediction of other complex multifactorial
psychiatric disorders such as major depressive disorder and schizophrenia, by examining
the effect of specific characteristics of disease and genetic predictors on clinical
discrimination using simulated data. Existent data was then used to test how different
methods of capturing genetic information could be used to predict clinical status for
alcohol dependence. We assessed several different sources of predictive information
encompassing genetic and other clinical predictors: data from previously associated
candidate genes from the literature, family history information, data from genome-wide
association studies (GWAS), and data from additional environmental and clinical
variables in addition to genetic information.
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Information about genetic variants contributing to alcohol dependence came from
the Collaborative Study on the Genetics of Alcoholism (COGA), which is a National
Institute on Alcohol Abuse and Alcoholism (NIAAA) sponsored project aimed at
identifying genes involved in alcohol dependence, with 10 collaborative sites across the
United States. Both a high-density family-based association sample and a case-control
genome-wide association study sample have been ascertained. COGA has previously
reported positive family-based association results for alcohol dependence with 114 SNPs
in 21 genes using the high-density family sample. Many of these genes have also been
associated with alcohol dependence in other studies. We created genetic sum scores
based on risk alleles of associated SNPs in these genes. We then compared the sum score
with family history in its ability to discriminate between cases and controls for alcohol
dependence in a subset of the COGA GWAS sample that is independent of the genefinding family sample and in a subset of independent individuals in the Study of
Addiction: Genes and Environment (SAGE) GWAS sample, which is a separate casecontrol study for alcohol dependence that also contains individuals with cocaine and
nicotine dependence. Next, the impact of GWAS results was assessed using both the
COGA and SAGE GWAS samples. The effects of SNPs across the genome were
explored by creating genetic sum scores based on subsets of SNPs meeting varying pvalues and creating genetic sum scores consisting of the individual effects of all
genotyped markers across the genome. Finally, we assessed risk prediction using
different gene-finding designs based on phenotypes targeted towards reducing the
heterogeneity of a binary alcohol dependence phenotype and increasing study power to
detect small effects by studying alcohol dependence symptom count and alcohol
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dependence subtypes. Together, these studies aimed to combine genetic and
environmental variables associated with alcohol dependence in order to evaluate how
both could lead to better risk prediction.
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Chapter 2: Assessment of predictive ability of genetic information
for common psychiatric disorders in simulated data

Abstract
Simulation studies were conducted to determine the maximum discriminatory accuracy of
genetic information for models of three psychiatric disorders using receiver operating
characteristic (ROC) curve analysis. The models broadly reflected the heritabilities and
lifetime prevalences for major depressive disorder (MDD), alcohol dependence (AD),
and schizophrenia (SCZ). We found that the highest areas under the ROC curve (AUCs)
were obtained from polygenic scores created based on results from a gene-finding
discovery sample of 10,000 cases and 10,000 controls, for all three disorders. For a model
based on schizophrenia, with a heritability of 80% and prevalence of 1%, the AUC just
passed 0.90. For major depressive disorder, with a heritability of 30% and prevalence of
13%, the AUC approached 0.80. If all genetic contributions are included in a prediction
model for AD, given AD’s heritability of around 50%, AUCs approached 80%. Adding
environmental risk effects increased the maximum AUC to 0.95 (Maher et al., in
preparation).
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Introduction and background
The question of whether or not genetic information can be used to predict risk for
complex disorders has been addressed in multiple studies using both existent data and
data simulations (Janssens et al., 2006; Purcell et al., 2009; Wray et al., 2007; Wray et al.,
2010; Evans et al., 2009). For multifactorial disorders of complex etiology, a single
genetic variant is likely to have a small effect on the phenotype, and therefore would
likely not have significant predictive accuracy. We know that because the heritability of
complex disorders such as alcohol dependence is not 100%, the predictive accuracy of
genetic information alone for alcohol dependence would not be 100%. Many studies of
risk prediction using genetic information have used a “genomic profiling” approach of
combining multiple SNPs that have been associated with the disorder in question into
polygenic scores based on the number of risk alleles carried by an individual (Manolio,
2010; Khoury et al., 2004; Janssens and van Duijn, 2009). The purpose of this study was
to assess the potential maximum discriminatory accuracy, as measured by the area under
the receiver operating characteristic curve (AUC), for alcohol dependence (AD), major
depressive disorder (MDD), and schizophrenia (SCZ) using information from known true
loci through a genomic profiling approach.
Janssens et al. (2006) used data simulations to determine the potential AUCs that
could be reached for complex disorders based on multiple genetic variants. They assessed
the impact of number of genes involved, risk allele frequency, disease prevalence,
heritability, and odds ratios of risk genotypes. They found that high AUCs could be
reached for several different models. For a group of variants that explained 30% of the
phenotypic variance, the maximum AUC was 0.83 for a disease with 30% prevalence and
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0.97 for a disease with 1% prevalence. Wray et al. (2007) commented that the study by
Janssens et al. did not incorporate error into an individual’s true genetic risk, but instead
calculated the correlation between genetic risk and disease status to be equal to the square
root of the broad-sense heritability on the observed scale. Wray et al. presented a
different model for the predictive ability of genome-wide scores based on disease
heritability of 0.10-0.20 and prevalence of 0.05 and 0.10 using simulated data. They
created for these parameters models that differed by the mean and maximum relative risk
(RR) and maximum proportion of genetic variance explained by one locus, and
calculated the expected number of loci contributing to the complex phenotype using this
information. The number of loci is proportional to RR, heritability, and prevalence of a
disorder. They found that the predictive accuracy of genetic risk was highest when
10,000 cases and controls were used for a model with heritability of 10% and prevalence
of 5% caused by 100 loci with RR of 1.15, the accuracy of prediction was 0.97 when
calculating the correlation between logarithms of the true and predicted probability of the
disease based on the following:
P(D | G)P(G)
= P(G | D)
P(D)
, where D = disease, G = genotype

 Posterior probability of disease, given genotype:
!
P(D | G) =

P(G | D)P(D)
P(G)

These simulation studies show that in aggregate, information from SNPs may
account for!more of the variability in disease, and therefore be more predictive of
diseases in independent samples. We do not know whether a disease model specific to the
epidemiological model of psychiatric disorders such as alcohol dependence, major
35

depressive disorder, and schizophrenia has the potential for predictive accuracy.
Accordingly, we examined the effect of specific characteristics of disease on predictive
power for alcohol dependence, schizophrenia, and major depressive disorder using
simulated data. Accordingly, data simulations were implemented to mirror polygenic
etiological models. Polygenic scores were simulated for each sample based on specific
disease attributes, including heritability, prevalence, allele frequency, genotypic relative
risk (GRR), p-value threshold used to select associated SNPs in discovery samples,
genetic correlation between discovery and validation samples, and the sample sizes of the
discovery and target samples. We addressed whether it is possible to achieve an AUC
that is generally accepted as a screening threshold, 0.80 (Janssens et al., 2006), using
genetic information, and then assessed the maximum AUC for a model for alcohol
dependence with the addition of an environmental effect.
One environmental effect that we modeled that has been shown to increase risk
for alcohol dependence was child sexual abuse. According to the Centers for Disease
Control and Prevention (CDC) Adverse Childhood Experiences (ACE) Study of 9,367
females and 7,970 males, 20.7% of participants experienced child sexual abuse
(http://www.cdc.gov/ace/index.htm). Child sexual abuse has been shown to lead to
increased risk for alcohol and substance use disorders (Table 2.1). The environmental risk
factor effect from child sexual abuse was used in the model to determine how much
predictive accuracy could be obtained from combining genetic information with effects
of environmental factors. Table 2.1 summarizes studies reporting the effect sizes that
child sexual abuse has on alcohol and substance use disorders.
Table 2.1 Childhood sexual abuse and risk for alcohol dependence
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Study
(Dinwiddie et al.,
2000)

Trauma
CSA

Odds Ratio
2.81 (CI = 1.89-4.17)
in females

CSA
CSA

1.91 (CI = 1.08-3.39)
in males
3.28 in F, 3.79 M

Any CSA

~3 for AD

CSA with
intercourse

4-6.5 for AD

(McLaughlin et al.,
2010)

CSA

2.02 (CI = 1.45–2.80)
for AD

Adjusted for co-twin AD
status, zygosity, and
interaction between zygosity
and co-twin AD status

(Nelson et al.,
2002)

CSA, with
intercourse

3.6 for AD

Prevalence of having at least
1 CSA in study subject =
16.7% in females, 5.4% in
males

CSA, no
intercourse
Sexual abuse

1.81 for AD

CSA

1.47 for alcohol
consumption

(Kendler et al.,
2000)

(Sartor et al., 2007)

1.6 for SUD

Details about study
Prevalence of CSA was 5.9%
in females and 2.5% in male

ORs after controlling for
parental alcohol problems
and birth cohort
Prevalence of CSA in study
subjects: 17-21%, females
only; see table for CIs

OR for SUD was highest for
sexual abuse

Brief summary from several studies on CSA (child sexual abuse): ORs roughly ranged from ~1.46.5 AD = alcohol dependence; SUD = substance use disorder

Methods
In collaboration with Dr. Brion Maher, we simulated discovery samples, calculated the
number of true loci based on different genetic and epidemiological models of disease,
created polygene scores based on associated loci at varying p-value thresholds, and then
assessed for discriminatory accuracy for the disease of the scores using receiver operating
characteristic (ROC) curve analyses. We investigated the following models for effects of
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polygene scores on discriminatory ability, based on prior epidemiological studies:
schizophrenia and bipolar disorder, with a prevalence of 1% (Perala et al., 2007;
Weissman et al., 1996) and heritability of 80% (Sullivan et al., 2003); major depressive
disorder, with a prevalence of 13% (Hasin et al., 2005) and a heritability of 30%
(Sullivan et al., 2000), and alcohol dependence, with a heritability of 50% (Kendler et al.,
1992; Heath et al., 1997) and a prevalence of 13% (Hasin et al., 2007; Kessler et al.,
1994). The total number of independent SNPs assessed in the Stage I discovery sample
was 100,000. The mean AUC in the Stage II validation sample was calculated over 100
iterations for each model.
We varied the minor allele frequency to be 0.05, 0.1, 0.2, 0.3, and 0.4. The GRR
was ranged from 1.0 to 2.0. The p-value thresholds for significance in Stage I disease for
selection of SNPs to predict risk in Stage II disease used were Pt < 1x10-4 , Pt<0.001,
Pt<0.01, Pt=0.05, Pt=0.1, Pt=0.2, Pt=0.3, Pt=0.4, and Pt=0.5. The discovery and target
sample sizes included 1,000 cases and 1,000 controls, 2,000 cases and 2,000 controls,
5,000 cases and 5,000 controls, and 10,000 cases and 10,000 controls. The number of
disease loci was calculated based on the equation derived by Wray et al. (2007):

𝑁=

(log(ℎ! + (1 − h! )𝐾) − log(𝐾))
{2[log(1 + MAF(GRR ∗ 2 − 1)) − log((1 + MAF(GRR − 1))2)]}

where N = number of disease loci, ℎ! is the heritability of the disease, K is the
prevalence of the disease, MAF is the minor allele frequency of the variant, and GRR is
the genotype relative risk, or the ratio of disease risks between those with and those
without the susceptibility genotype(s) for the disease loci.
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The baseline genetic risk for a homozygous genotype for the normal allele, b, was
calculated as:
𝑏=

{ 1 − MAF

!

𝐾
+ 2 1 − MAF MAF GRR + MAF ! 1 + 2(GRR − 1) }

The probability of affection status, given genotype is:
P (D | G) = b (1+2(GRR-1))
Using Bayes’ Theorem, the probability of genotype, given affection status, is:

𝑃(𝐺|𝐷) =

𝑃 𝐷 𝐺 𝑀𝐴𝐹 !
𝐾

Mitra’s non-centrality parameter was calculated based on sample size and case-control
minor allele frequency for association tests (Mitra, 1958) . Varying critical values were
set for each p-value cutoff. The mean polygenic sum scores and the variance of the
polygenic sum scores were calculated from results for each significance threshold, based
on the probability of genotypes given affection status, minor allele frequency, and
proportion of null loci vs. disease loci at each threshold. The polygenic scores were then
used to assess discriminatory accuracy in the Stage 2 target/validation case-controls
samples. The AUCs for the polygenic scores were calculated based on the Wilcoxon
rank-sum test. All data simulations and analyses were performed in SAS (SAS Institute
Inc., Cary, NC, USA).

Results
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Results showed that as GRR increased, the number of susceptibility loci decreased and as
heritability increased, so did the maximum AUC. At a Stage I discovery phase with
10,000 cases and 10,000 controls, AUC was highest and was just over 0.90 for a model
with heritability of 0.80. Similar patterns were shown for the models for alcohol
dependence, with a heritability of 0.50 (AUCs approaching 0.80), and major depressive
disorder, with a heritability of 0.30, though the AUC is not as high (AUCs approaching
0.80, but not as high as those for AD). As p-value thresholds used to select SNPs to
create polygenic scores become less stringent, at p<1x10-4, the AUC was highest than for
more liberal p – value thresholds. Adding the effect of environmental risk factors
increased the AUC substantially.
Figure 2.1 illustrates the AUCs corresponding to each polygenic score for models
for major depressive disorder, alcohol dependence, and schizophrenia. The genotype
relative risk (GRR) is plotted on the x-axis. Plots are shown separately for scores
composed of variants with different minor allele frequencies. Rho represents the genetic
correlation between the discovery (Stage 1) and target (Stage 2) sets. In the scenarios
shown below in which the same phenotype is assessed for Stage 1 and Stage 2 datasets,
rho is 1 between the discovery and target samples. Shown below are the maximum AUC
estimates obtained from the models. The results from the largest Stage 1 discovery casecontrol set of 10,000 cases and 10,000 controls had the highest AUCs. Changes in the
number of Stage 2 validation cases-control set did not change the AUC estimates.
Smaller discovery sample sizes reduced the maximum AUC.

Figure 2.1 AUC estimates for polygenic scores for three different psychiatric disorders.
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Details specific to each disorder are listed, including heritability and prevalence.
Polygenic scores selected at different p-value significance thresholds are plotted in
separate panels for each condition. The number of independent SNPs represents SNPs
used in the association analyses in Stage 1 samples. The number of Stage 1 (discovery
sample) and Stage 2 (target sample) cases and controls are specified. The y-axis plots
the AUCs corresponding to each model. The x-axis lists genotypic relative risk (GRR).
Results are plotted separately for varying minor allele frequencies (MAF).

Major Depressive Disorder
10,000 Stage 1 Cases, 10,000 Stage 1 Controls
1,000 Stage 2 Cases, 1,000 Stage 2 Controls
100,000 Independent SNPs, rho = 1, h2 = 30%, Prevalence = 13%

Alcohol Dependence
10,000 Stage 1 Cases, 10,000 Stage 1 Controls
1,000 Stage 2 Cases, 1,000 Stage 2 Controls
100,000 Independent SNPs, rho = 1, h2 = 50%, Prevalence = 13%
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Schizophrenia
10,000 Stage 1 Cases, 10,000 Stage 1 Controls
1,000 Stage 2 Cases, 1,000 Stage 2 Controls
100,000 Independent SNPs, rho = 1, h2 = 80%, Prevalence = 1%
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Based on the model for AD, Table 2.2 summarizes AUCs resulting from
prediction using polygenic scores that include increasing proportions of true loci, and
conversely, decreasing proportions of null loci for a hypothetical model containing 100
true loci, with minor allele frequency of 0.30 and genotypic relative risk of 1.20. When a
polygenic score consisting of 100% true loci and 0% null loci is included as the sole
predictor for AD, with a prevalence of 13% and heritability of 50%, then the score has an
AUC of approximately 0.78, under the maximum AUC conditions described shown in
Figure 2.1. Figure 2.2 illustrates the AUCs of scores that include both genetic and
environmental effects for a model including all 100 true loci.
Table 2.2 AUCs for polygenic scores consisting of mixture of true
and null loci.
Proportion
of true loci

N true loci

N null loci

AUC

1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1

100
90
80
70
60
50
40
30
20
10

0
10
20
30
40
50
60
70
80
90

0.77980444
0.75846888
0.7340018
0.71060652
0.68497332
0.65534604
0.63169552
0.59919648
0.56812712
0.53579312

This table displays the corresponding AUCs for increasing
proportions of true loci (N true loci) compared with number of null
loci (N null loci) contributing to AD for a model in which there exists
100 true loci.

Figure 2.2 Plot of AUC estimates for polygenic scores combined
with environmental effects.
The y-axis shows the AUC estimates for the polygenic scores for alcohol dependence.
The green line in this figure plots the AUCs corresponding to a genetic score composed
of 100% of 100 true loci, with the addition of environmental factors that contribute to
alcohol dependence. Plotted on the x-axis are increasing effect sizes for environmental
factors. The red line plots the AUC = 0.50 point, which is equivalent to the AUC a score
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that can classify accurately 50% of cases and controls, or predicting no better than
chance.

Discussion
Data simulations presented here show that using a highly-powered sample with a large
discovery sample size to detect a greater proportion of true loci contributing to three
common psychiatric disorders produces higher AUCs for polygenic scores created based
on SNPs meeting more stringent p-value thresholds of p < 10-4. Discovery sample sizes
of 10,000 cases and 10,000 controls resulted in polygenic scores that had the highest
discriminatory accuracy, and showed that discovery samples of this magnitude are
necessary for AUCs approaching 0.80. As expected, AUCs of polygenic scores were
highest for the most heritable condition, schizophrenia, lower for alcohol dependence,
and lowest for the condition with the lowest heritability of the three, major depressive
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disorder. AUCs of greater than 80% were achieved for schizophrenia. For alcohol
dependence and major depressive disorder, AUCs approached 0.80.
These results differ from results using existent data from the Welcome Trust Case
Control Consortium (WTCCC) and the International Schizophrenia Consortium (ISC) in
that SNPs in the latter two studies that were selected based on the most liberal thresholds
actually resulted in the highest proportion of variance accounted for in the trait in
question. The reason for this difference lies in failure to fully correct for population
stratification in the real data. Population stratification can occur if cases and controls
differ in a variable other than disease status, and concurrently differ in frequencies of
alleles that are correlated with this additional variable. If this occurs, allele frequency
differences between cases and controls that are attributable to differences in the
additional variable could mistakenly be attributed to disease status if differences in the
third variable are not corrected for. For example, if there exist differences in ancestry
between cases and controls and these differences are not accounted for, alleles
attributable simply to ancestry differences could be spuriously associated with the disease
phenotype. In the case of WTCCC, because population stratification was not fully
accounted for, only more liberal significance thresholds would be able to incorporate a
greater proportion of true loci in the polygenic score. Scores composed of variants
meeting more stringent p-value thresholds in this case would incorporate more spurious
results due to population stratification that would therefore fail to replicate in independent
samples (Evans et al., 2009).
As the size of the discovery sample increases, there is more power to detect
individual SNPs of small effects. Similar to our results, Purcell et al. (2009) showed
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through simulations that in cases of a larger discovery sample size with more power, a
more stringent p-value threshold would be able to select SNPs that account for more of
the variance in a trait in a target sample than SNPs selected at the same threshold in a
smaller discovery sample with less power. In a large sample, a less stringent threshold
would include more null loci that outweigh the true loci that have been detected in the
sample at more stringent thresholds, and therefore SNPs selected at more liberal
thresholds would actually account for less variance in a trait in a target sample (Purcell et
al., 2009). This is consistent with our results in larger discovery sample sizes of 10,000
cases and 10,000 controls, which had the highest AUCs for the most stringent p-value
thresholds. The fact that AUCs increased with increasing discovery sample sizes, but did
not change with increasing validation sample sizes stresses the importance of developing
sample sizes with high power to detect true associations before assessing for replication
or clinical validation in independent samples. Smaller discovery sample sizes have
insufficient power to detect true risk loci with small GRRs. Collaborative projects and
consortia are underway for psychiatric conditions, making studies with sample sizes of
10,000 cases and 10,000 controls a reality, particularly in the Psychiatric GWAS
consortium, which is a large-scale collaboration studying five major psychiatric diseases:
ADHD, autism, bipolar disorder, major depressive disorder, and schizophrenia (Sullivan,
2010). The largest study to date for an alcohol-related trait consists of 12 European
American samples, including a total of 21,607 individuals, with a replication sample of
21,185 individuals. This study reported an association between alcohol consumption and
the autism susceptibility candidate 2 gene (AUTS2) and was one of the first studies to
report a genome-wide significant finding for an alcohol-related trait (Schumann et al.,
46

2011). However, the combined sample for alcohol consumption was population-based;
none of the 12 samples was ascertained based on alcohol dependence diagnosis.
Currently, many alcohol dependence samples have modest sizes; many include fewer
than 1,000 alcohol-dependent cases. Alcohol dependence consortia combining multiple
samples are currently underway. In Europe, the Alcohol-GWAS (AlcGen) Consortium
was created as a part of the European Network on Genomic and Genetic Epidemiology
(ENGAGE) Program, which studies a variety of common complex diseases
(http://www.euengage.org/). In the United States, a meta-analysis of alcohol consumption
is being undertaken using European American samples in the National Cancer Institute
(NCI; N = 17,000) and the Gene Environment Association Studies Consortium
(GENEVA; N = 17,000), which includes the collaborative alcohol dependence sample,
the Study of Addiction: Genes and Environment (SAGE; N = 4121) (Agrawal et al.,
2012) .
The results of these data simulations show that there is potential for
discriminatory accuracy that reaches higher AUCs typical of screening tools for
psychiatric conditions with similar genetic models to the one presented here for
schizophrenia. For alcohol dependence, when all genetic contributions are known and
used to predict risk in independent samples, then the AUC could potentially approach
0.80. Adding larger environmental effects such as the one modeled by the lower end
estimate of the effect of child sexual abuse on AD (odds ratio ~2) increases the AUC for
classifying AD even more to 0.95, which exceeds the 0.80 marker of a good screening
tool. As we continue to pursue the identification of risk factors for alcohol dependence,
we will learn more in depth about the genetic architecture of alcohol dependence. This
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knowledge may in turn lead to better risk assessment using genetic and environmental
factors.
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Chapter 3: Genetic risk prediction using candidate gene variants
and family history

Abstract
A number of studies investigating the clinical utility of genetic variants associated with
complex disorders have illustrated the limitations and potential benefits of using genetic
information in risk prediction for complex traits (Evans et al., 2009). The focus of this
study was to assess the clinical validity of previously published genetic variants
associated with alcohol dependence (AD) in predicting risk for AD in an independent
sample. The predictive ability of these variants in aggregate was compared to family
history. Using the Collaborative Study on the Genetics of Alcoholism (COGA) and the
Study of Addiction: Genes and Environment (SAGE) genome-wide association study
(GWAS) samples, we performed receiver operating characteristic (ROC) curve analysis
to estimate the ability of a panel of SNPs to correctly classify cases and controls for
DSM-IV AD. Specifically, sum scores of risk alleles were generated for a panel of 22
semi-independent SNPs correlated at r2 <0.50, covering 15 genes, and a panel of 18
SNPs, correlated at r2<0.25, covering 15 genes, that had reported associations with
alcohol dependence in the COGA high-density family-based association sample. We
identified a subset of individuals consisting of 627 cases and 454 controls from the
COGA GWAS sample and 610 cases and 992 controls from the SAGE GWAS sample
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that were not part of the original family-based association sample. We then performed
ROC analysis for the sum scores in these subsets. These analyses did not result in
significant discriminative ability for the sum scores; the area under the ROC curve
(AUC) for the panel of SNPs correlated at r2<0.50 was 0.498 (95% CI = 0.463, 0.533, p =
0.915) in COGA and 0.496 (95% CI = 0.466, 0.525, p = 0.782) in SAGE. For the SNPs
panel correlated at r2<0.25, the AUC was 0.491 (95% CI = 0.456, 0.525, p = 0.595) in
COGA and 0.492 (95% CI = 0.462, 0.521, p = 0.583) in SAGE. These results suggest
that the SNPs are not predicting better than chance. The presence or absence of family
history for AD was a better classifier of case control status in the COGA sample, with an
AUC of 0.686 (95% CI = 0.654, 0.718, p < 0.001) and 0.587 (95% CI = 0.558, 0.617, p <
0.001) for a paternal history of AD-related traits in SAGE. This study shows that these
SNPs currently have limited clinical validity and illustrates the need for further expansion
of prediction panels for a complex disorder that encompasses both environmental and
genetic risk factors of small effect such as AD.
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Introduction
Alcohol dependence (AD) is a complex psychiatric disorder with approximately 50-60%
heritability (Kendler et al., 1992; Heath et al., 1997; Gelernter and Kranzler, 2009) and
12.5% lifetime prevalence in the United States (Hasin et al., 2007). Numerous genetic
variants have been reported to be associated with AD. Many of these gene-finding
measures were carried out in the Collaborative Study on the Genetics of Alcoholism
(COGA), which is a large-scale collaborative study consisting of families with
individuals who meet both DSM-IIIR and Feighner criteria for AD recruited from alcohol
treatment centers across the United States. Family-based association studies in a highdensity subset of the COGA sample consisting of families with 3 or more first-degree
relatives who meet lifetime criteria for AD yielded many associated genes, many of
which have been replicated in other studies (Edenberg and Foroud, 2006).
Genes that have been associated with AD in COGA include genes involved in
alcohol metabolism, such as the alcohol dehydrogenase and aldehyde dehydrogenase
genes (ADH and ALDH) (Edenberg et al., 2006; Luo et al., 2005b; Edenberg, 2007a;
Guindalini et al., 2005) . Genes encoding subunits of receptors that respond to gammaaminobutyric acid (GABA), the major inhibitory neurotransmitter in the central nervous
system, including GABRB3, GABRG3, and GABRA2, as well as dopamine receptor gene
DRD2 and the neighboring gene ANKK1, have been associated with AD, providing
evidence that variation affecting reward pathways could be involved in susceptibility to
AD (Edenberg et al., 2004; Covault et al., 2004; Lappalainen et al., 2005; Drgon et al.,
2006; Fehr et al., 2006; Soyka et al., 2008; Enoch, 2008; Enoch et al., 2006; Dick et al.,
2007d; Dick et al., 2004; Noble et al., 1998; Song et al., 2003). Additional genes
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encoding receptors such as the nicotinic receptor CHRNA5 (Wang et al., 2009; Saccone
et al., 2007), the opioid receptor genes PDYN and OPRK1 (Xuei et al., 2006; Xuei et al.,
2007; Gerra et al., 2007; Williams et al., 2007), the muscarinic receptor CHRM2 (Wang
et al., 2004; Luo et al., 2005a; Kendler et al., 2011), and the neurokinin receptor TACR3
(Foroud et al., 2008), and ACN9 (Dick et al., 2008b), which is involved in
gluconeogenesis have all been associated with AD in COGA. Table 3.1 lists the genes
that have been associated with AD in the COGA high-density subset, with its
corresponding COGA family-based association study and replication studies.

Table 3.1 Genes Associated with Alcohol Dependence in COGA
Study
(Edenberg et al., 2004)

Gene
GABRA2

Replication
(Covault et al., 2004; Fehr et
al., 2006; Lappalainen et al.,
2005; Soyka et al., 2008;
Enoch et al., 2006; Drgon et
al., 2006)

(Dick et al., 2004)

GABRB3 and
GABRG3

(Noble et al., 1998; Song et
al., 2003) (GABRB3)

(Wang et al., 2004)

CHRM2

(Luo et al., 2005a; Kendler et
al., 2011)

(Hinrichs et al., 2006)

TAS2R16

(Wang et al., 2009)

CHRNA5

(Saccone et al., 2007)
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(Xuei et al., 2006)

PDYN and OPRK1

(Williams et al., 2007; Gerra
et al., 2007)

(Edenberg et al., 2006)

ADH genes: ADH4,
ADH1A, ADH1B

(Luo et al., 2005b; Guindalini
et al., 2005)

(Edenberg et al., 2008)

NFKB1

(Kendler et al., 2011)

(Foroud et al., 2008)

TACR3

(Dick et al., 2008b)

ACN9

(Dick et al., 2007)

ANKK1/DRD2

(Comings et al., 1994; Blum
et al., 1990; Blum et al., 1991;
Noble et al., 1991; Amadeo et
al., 1993; Amadeo et al.,
2000; Foley et al., 2004;
Hietala et al., 1997; Ishiguro
et al., 1998; Konishi et al.,
2004; Kono et al., 1997; Dick
et al., 2007d)

The association of genetic variants with complex disease has spurred dialogue on
and assessment of risk prediction using genetic information for common multifactorial
disorders (Jostins and Barrett, 2011; Janssens et al., 2006). For some complex disorders,
such as diabetes, risk algorithms based on clinical measures such as the Cambridge and
Framingham risk score have a high degree of clinical validity for screening; the area
under the receiver operating characteristic (ROC) curve (AUC) exceeds 0.80 for type II
diabetes. In these cases, genetic information has not been shown to add predictive value
(Talmud et al., 2010). A risk model for alcohol dependence based on clinical variables
does not exist. The process of genetic counseling for a complex psychiatric disorder such
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as alcohol dependence involves helping individuals understand, manage and cope with
genetic risk so that they have less anxiety and more empowerment over what many
consider to be a devastating disorder over which one has little control (Peay and
Sheidley, 2008).
A discussion for an individual who is concerned about risk for alcohol
dependence may focus on current knowledge about the etiology of alcohol dependence
and a detailed history of clinical and sub-clinical features for alcohol dependence and
possible co-occurring conditions in both sides of the family. Risk assessment combines
family history, environmental risk factors, and empiric risk estimates for alcohol
dependence across family studies (Peay and Sheidley, 2008).
Current risk assessment does not include genetic testing for common variants and
the predictive value of genetic testing for alcohol dependence has yet to be determined.
This study investigates whether a panel of candidate gene SNPs that have been associated
with alcohol dependence can be used in risk prediction for alcohol dependence. Most of
the genetic variants contributing to complex disorders such as type II diabetes and
alcohol dependence have small effect sizes. This, along with the fact that alcohol
dependence has both genetic and environmental risk factors, means that any one SNP
alone is not expected to be a good predictor of alcohol dependence. This study aims to
explore the aggregate impact of multiple genetic variants with small effect sizes on
clinical risk prediction.
This study also assesses the validity of family history in predicting risk for
alcohol dependence. Of the general population, approximately 40% report some family
history of AD and approximately 7-9% of the population report having both first and
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second-degree relatives with AD (Gamm et al., 2004). Family history can account for
more of the latent genetic vulnerability and parental environment contributing to alcohol
dependence that is not captured on panels of candidate gene SNPs alone. Research has
shown that family history can be a powerful tool for prognosis and prediction and can
have practical clinical utility for both complex diseases and Mendelian syndromes. It can
be used to help predict illness severity and stratify individuals into specific prognosis
groups with distinct treatment and prevention needs (Pyeritz, 2012; Odgers et al., 2007;
Milne et al., 2009).
In this study, we created additive genetic sum scores based on genetic variants in
candidate gene studies from the high-density family-based association analyses in COGA
that are summarized in Table 3.1. We determined the allele conferring increased risk for
AD in the high density family-based association sample and then created sum scores by
adding the number of risk alleles carried by individuals in two independent samples: the
portion of the COGA Genome-Wide Association Study (GWAS) sample that was not
part of the COGA high-density family-based association sample and a portion of the
Study of Addiction: Genes and Environment (SAGE) GWAS sample that is independent
of the COGA sample. We also explored the effect on risk prediction when family history
information and genetic information were combined. We tested whether individual
variants may add more specific information for an individual’s risk profile, beyond that
of the latent genetic factors captured by family history alone, and therefore increase risk
prediction. Furthermore, because the variants associated with AD from candidate gene
studies were associated in more densely affected samples with multiple affected family
members, we assessed whether the candidate gene sum scores would be more informative
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in determining affection status in the context of a positive family history of AD compared
with a negative family history of AD. In these analyses, we stratified the sample into
positive and negative family history of AD before performing subsequent ROC curve
analyses.

Materials and methods
Sample and measures
COGA family-based association analysis sample
COGA is a large-scale multi-center family study with 10 collaborative sites across the
United States. The sample consists of families containing probands meeting both DSMIIIR and Feighner criteria for AD ascertained since 1989 from outpatient and inpatient
alcohol treatment centers at 7 sites across the United States: Indiana University, State
University of New York Health Science Center, University of Connecticut, University of
Iowa, University of California/San Diego and Washington University in St Louis, and
Howard University (Begleiter et al., 1995) . Families were interviewed using a polydiagnostic instrument, the Semi-Structured Assessment for the Genetics of Alcoholism
(SSAGA), which assesses Feighner, DSM-IIIR, DSM-IV, and ICD-10 criteria for major
psychiatric disorders (Feighner et al., 1972; American Psychiatric Association, 1987;
American Psychiatric Association, 2000; World Health Organization, 2008) . More than
1300 probands with AD have been recruited. Unaffected subjects were defined as
individuals who drank but did not meet criteria for AD or other substance abuse disorders
(Wang et al., 2008). In order to obtain normative measures and provide a comparative
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general population sample, unscreened control families were selected from the
community through a variety of methods (Edenberg et al., 2005; Edenberg and Foroud,
2006). A subset of the COGA sample was identified as a group of high-density families
with 3 or more first-degree relatives who met lifetime criteria for AD. This sample
consists of more than 300 extended families for a total of more than 3000 individuals
(Edenberg and Foroud, 2006).
SNPs included in this analysis were selected from 9 COGA papers reporting
family-based association analyses for AD using individuals from the high-density subset
(Table 3.1). The number of individuals included varied across studies: association
analyses that encompassed all ancestries ranged from 2139 to 2310 individuals from 262
families; 35 of these families, comprising a total of 298 individuals, are of African
American (AA) ancestry. Analyses conducted in the European American (EA) subset
ranged from 1172 to 1923 individuals from 217-219 families. Genotyping for these
individuals is described in detail in the original COGA papers. Briefly, SNPs within and
flanking candidate genes were selected from public databases including dbSNP
(http://www.ncbi.nlm.nih.gov/SNP), HapMap (http://www.hapmap.org), and LocusLink
(http://www.ncbi.nim.nih.gov/LocusLink/refseq.html). Genotyping was done using a
modified single nucleotide extension reaction, with allele detection by mass spectrometry
(Sequenom MassArray system; Sequenom, San Diego, CA, USA). SNPs were in Hardy
Weinberg Equilibrium. Genotypes were checked for Mendelian inheritance using
programs including PEDCHECK. USERM13 was used to calculate marker allele
frequencies and heterozygosities (Edenberg et al., 2008).
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COGA GWAS sample
A case-control sample of 1945 phenotyped subjects was selected from the larger COGA
sample for genome-wide association studies. Cases had a lifetime diagnosis of AD by
DSM-IV criteria. Controls reported consuming alcohol but did not have a diagnosis of
AD or alcohol abuse by any of the diagnostic criteria assessed by SSAGA and did not
meet diagnostic criteria for dependence on cocaine, marijuana, opioids, sedatives, or
stimulants. Controls could not share a known common ancestor with a case and were
preferentially selected to be above the age of 25 years. 1081 individuals in the COGA
GWAS EA sample were independent of the COGA family sample.
Genotyping was completed using the Illumina Human 1M DNA Analysis
BeadChip at the Center for Inherited Disease Research (CIDR). Additional details on the
COGA GWAS sample can be found in Edenberg et al. (2010).

SAGE GWAS sample
The Study of Addiction: Genes and Environment (SAGE) is part of the Gene
Environment Association Studies initiative of the National Human Genome Research
Institute to identify genetic contributions to addiction through large-scale genome-wide
association studies. The entire SAGE sample consists of 4,121 cases and unrelated
controls from subsets of three large studies on addiction: the Family Study of Cocaine
Dependence (FSCD), the Collaborative Genetic Study of Nicotine Dependence
(COGEND), and COGA. All cases in SAGE have DSM-IV lifetime diagnosis of AD.
Controls were exposed to alcohol. Some controls met criteria of nicotine dependence
based on the Fagerström Test for nicotine dependence, but none met criteria for a DSM58

IV lifetime dependence diagnosis for alcohol, marijuana, cocaine, opiates or other drug.
The FSCD and COGEND portions of the SAGE GWAS EA sample were extracted for
use as a second independent sample to assess for discriminative ability.
Genotyping for all three studies that are part of the SAGE GWAS sample was
completed at CIDR using the Illumina Human 1M DNA Analysis BeadChip. Additional
details on the SAGE GWAS sample can be found in Bierut et al. (2010).

Family history measures
Family history information for the COGA GWAS sample was obtained for both cases
and controls as a dichotomous “yes” / “no” variable for any existence of a family history
of AD in relatives, as reported by the subject. The SAGE GWAS sample included a “yes”
/ “no” variable about history of AD in specifically the proband’s mother and father. The
presence or absence of family history was primarily used as a binary variable in order to
reflect clinical scenarios in which an individual is asked whether or not she or he has a
family history of alcohol dependence. Both COGA and SAGE had information about
parental history of AD based on a more inclusive, or “relaxed” criterion and a more
stringent “strict” criterion. Family history information was also expanded further into an
ordinal variable based on parental history that addressed whether an individual had 0, 1,
or 2 parents with a history of alcohol dependence.

Data analyses
Data analysis overview
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SNPs that were previously associated with AD in candidate gene studies in the COGA
high-density family-based association sample were used to create a candidate gene sum
score to assess prediction of AD in independent individuals from the COGA and SAGE
GWAS samples. Because the SNPs contributing to the candidate gene sum scores were
previously reported to be associated in either all-EA or >85% EA samples, a genetic sum
score based on results from these studies would possibly be applicable primarily to EA
individuals. Therefore, we assessed predictive ability in the EA subsets of the COGA and
SAGE samples. We first determined the alleles conferring risk for AD using the familybased association study, and then used the alleles to create additive genetic sum scores to
assess for risk in the COGA and SAGE GWAS samples (Figure 3.1).
Figure 3.1 Study Overview
Sample size
varied by study

COGA family-based
association sample

Association
analysis with AD
Candidate genes

114 SNPs in 21 genes

Select and
prune SNPs
Pruned list of SNPs
Create sum scores

627 cases
454 controls

ROC curve analysis
in COGA GWAS
sample independent
of family study

22 SNPs in 15 genes

Create sum scores

ROC curve analysis
in SAGE GWAS
sample independent
of family study
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610 cases
992 controls

Family-based association analysis
In order to create genetic sum scores for prediction of alcohol dependence, risk alleles
needed to be determined for each SNP that had been associated with alcohol dependence
in prior reports. Because the exact allele conferring increased risk for alcohol dependence
was not explicitly reported for each COGA paper, analyses were repeated for each study
using the Pedigree Disequilibrium Test (PDT) in UNPHASED (PDTPHASE), as
described in the original COGA papers (Table 3.1). The statistic used for association,
specific measure for alcohol dependence, and the population selected for analyses varied
across the published COGA studies. For example, the study reported by Edenberg et al.
(2004) used the PDT average statistic, which averages all association statistics across
families, to study the association of GABRA2 SNPs with AD diagnosed using DSM-IV
criteria, whereas the study by Xuei et al. (2006) also reported the PDT average statistic,
but examined the association of PDYN with AD based on DSM-III and Feighner criteria.
In contrast to the PDT statistic used by Xuei et al. and Edenberg et al., the study by Dick
et al. (2007) used the PDT sum statistic, which places greater weight on families with
more informative trios and discordant siblings. All results in our study were generated to
match the statistic, diagnosis, and population used by each previously published COGA
candidate gene study. The PDT average statistic was used in the majority of the COGA
candidate gene studies. Wang et al. (2004) reported the PDT sum statistic in addition to
the PDT average statistic. In order to match the majority of studies, statistics used in our
association analysis consisted of the PDT average and/or sum statistics. In addition to
PDT, Dick et al. (2004) also performed a classic TDT analysis in TRANSMIT using one
trio selected from each COGA family. Wang et al. (2008) used the family-based
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association test (FBAT); risk alleles for these analyses were obtained via correspondence
with Dr. Wang. In the family-based association analyses, multiple outcomes were used
across studies. Depending on the diagnosis used in the study, the DSM-IV, DSM-IIIR, or
DSM-IIIR + Feighner Criteria for the COGA definition of alcohol dependence were used
as outcomes.

SNP selection
Several criteria were used in the selection of the panel of SNPs used for classification of
alcohol dependence status. An initial list of 114 SNPs across 21 genes was generated
based on prior association with alcohol dependence according to either DSM-IV or
COGA (DSM-IIIR + Feighner) criteria. A smaller proportion of the sample had earlyonset (≤ 22 years of age) alcohol dependence (N = 454 in COGA and N=811 in SAGE).
SNPs associated only with early onset alcohol dependence were removed from the list so
that SNPs in the candidate gene panel would be applicable to the wider range of ages of
individuals in the full COGA and SAGE validation samples. The age of onset for AD in
the independent COGA GWAS sample ranged from 12 to 65 years of age. Age of onset
in the FSCD and COGEND portion of the SAGE GWAS sample ranged from 13 to 55
years of age. Because assessment of discriminative accuracy was to be performed in
European American individuals, SNPs that were associated only in the African American
subset were removed from the list. Forty-two of the SNPs showing association in the
original papers were present on the Illumina Human 1M DNA Analysis BeadChip. Proxy
SNPs on the Illumina chip with an r2 > 0.70 were found for 32 SNPs based on LD
calculations in the HapMap CEU data using Haploview (Barrett et al., 2005) and Plink
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version 1.07 (Purcell et al, 2007). Thirty-two of the SNPs did not have proxies. Seven of
these SNPs had proxies in the list of COGA family sample SNPs for which proxy SNPs
existed on the Illumina chip, based on LD calculations using Haploview. The final list
contained 81 SNPs.
In order that genes with a large number of associated SNPs in high LD were not
disproportionately represented in the risk panel, we generated a list of semi-independent
SNPs for the panel. We explored the effect of pruning SNPs based on different r2
thresholds; SNPs that were more correlated than these thresholds were removed from the
list. We first assessed the use of a more inclusive panel with a pruning threshold of r2 <
0.50, and then used a more stringent threshold of r2 < 0.25. All SNPs in this panel were
included in the HapMap list, but not all SNPs were part of the Illumina 1M SNP chip. In
order to create the panel without using information from the independent validation
samples, LD estimations used for pruning the SNPs were based on the HapMap Phase 3
CEU data rather than data from the COGA GWAS sample. Calculations for LD were
performed using the Plink version 1.07 LD function (Purcell et al., 2007). Selection of
which SNP of a pair of correlated SNPs to remove depended on a ranked list of SNPs
based on the level of significance from the family-based association results and how
closely the SNP on the Illumina chip matched the original family-based SNP. SNPs were
rank-listed in the following order:

1. SNPs from the family studies with exact matches in the COGA GWAS list of
SNPs, ranked in descending order for their corresponding p-values from the
family studies.
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2. Proxy SNPs in the COGA GWAS sample for the SNPs in the family sample, with
r2 > 0.70 based on HapMap data, listed in descending order first for r2 and then
for p-value of the original SNP in the family study.
3. Proxies in the COGA GWAS sample to proxy SNPs in the COGA family SNPs
(in HapMap) to the remaining list of SNPs that are not in HapMap. Ranked in the
same way as the above proxy SNPs, listed in descending order first for r2 and then
for p-value of the original SNP in the family study.

Both pruning thresholds of r2 < 0.50 and r2 < 0.25 created a set of 15 genes from the
original 21 genes, primarily due to correlations among the ADH SNPs. Table 3.2
summarizes the list of SNPs after pruning for LD based on a threshold of r2 < 0.50.
Pruning resulted in a set of 22 SNPs from a threshold of r2<0.50 and 18 SNPs from a
threshold of r2<0.25. SNPs selected at the threshold of r2 < 0.25 were the same as SNPs
selected based on r2 < 0.50, with the exception of 4 SNPs that were pruned out based on
this more stringent threshold: rs2235749 and rs6045819 in PDYN, rs7794886 in ACN9,
and rs997917 in OPRK1.

Table 3.2 Pruned set of candidate gene SNPs at r2 < 0.50.

SNP

Status

Gene

COGA
family
study
p-value

rs10499934

In_sample

ACN9

0.003

0.23

0.22

0.23

A

rs12671685

In_sample

ACN9

0.027

0.11

0.12

0.11

A

rs7794886

In_sample

ACN9

0.006

0.35

0.36

0.35

T

rs4147531

In_sample

ADH1A

0.007

0.43

0.46

0.47

C

rs1229982

In_sample

ADH1B

0.048

0.22

0.20

0.19

T

rs1126672

In_sample

ADH4

0.010

0.29

0.28

0.29

C
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MAF
Fam

MAF
COGA

MAF
SAGE

Risk
Allele

rs17115439

In_sample

ANKK1

0.096

0.33

0.32

0.32

C

rs680244

In_sample

CHRNA5

0.114

0.42

0.41

0.42

G

rs1799978

In_sample

DRD2

0.168

0.06

0.05

0.05

G

rs279858

In_sample

GABRA2

0.010

0.38

0.42

0.42

A

rs1897356

In_sample

GABRB3

0.020

0.17

0.15

0.15

C

rs16918941

In_sample

OPRK1

0.023

0.06

0.06

0.07

G

rs6985606

In_sample

OPRK1

0.004

0.48

0.50

0.48

T

rs997917

In_sample

OPRK1

0.011

0.27

0.29

0.27

C

rs1997794

In_sample

PDYN

0.011

0.37

0.36

0.35

C

rs2235749

In_sample

PDYN

0.010

0.27

0.27

0.26

A

rs6045819

In_sample

PDYN

0.038

0.10

0.12

0.12

G

rs11722288

In_sample

TACR3

0.022

0.29

0.29

0.29

G

rs3762894

In_sample

ADH4

0.050

0.16

0.15

0.16

C

rs1391175

Use_proxy
(rs13120165)

GABRG1

0.036

0.06

0.03

0.03

A

rs3097490

Use_proxy
(rs1571281)

GABRG3

0.137

0.44

0.44

0.46

G

rs324640

Use_proxy
(rs324649)

CHRM2

0.038

0.43

0.42

0.42

T

“Status” indicates whether or not the SNP was directly genotyped on the Illumina 1M SNP chip or
a proxy SNP was used. The SNP numbers are SNPs from candidate gene studies, with proxy
SNPs indicated as such in the “status” column. The COGA family-based association p-values
from the previously published studies are listed. MAF Fam shows the minor allele frequency of
the SNP in the COGA family-based candidate gene association sample. MAF COGA and MAF
SAGE correspond to the MAF in the COGA and SAGE GWAS samples, respectively. The risk
allele corresponds to the GWAS alleles matched by allele frequency to the risk allele in the
family-based candidate gene association sample.

Genetic sum scores
Additive genetic risk scores were created using the --score option in PLINK v1.07
(Purcell et al, 2007). This follows an additive model for risk variants, as described by
Evans et al. (2009):
𝑁 𝑟𝑖𝑠𝑘 =

𝓍i
𝑛

xi = # of risk alleles (0, 1, 2) at SNPi
𝑛 = number of nonmissing genotypes
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The number of risk alleles for each candidate gene SNP was added and then divided by
the total number of non-missing genotypes to create a normalized allele count for each
individual. Because odds ratios associated with the risk alleles varied across family-based
analyses in COGA and replication studies, the additive score was created without
weighting alleles by effect size. The risk allele in the SAGE and COGA samples was
determined by matching by frequency with alleles that were associated with AD in the
family sample. Minor allele frequencies across the family-based association sample,
COGA GWAS sample, and SAGE GWAS sample were similar for each SNP (Table 3.2).

Association analysis of candidate gene sum score with AD:
The genetic sum scores were tested for association with DSM-IV AD in the case-control
COGA and SAGE samples using logistic regression with sex as a covariate in COGA and
sex, age quartiles, and study site as covariates in SAGE. The GWAS association models
were selected to follow the methods used in the previously reported primary COGA and
SAGE GWAS analyses (Bierut et al., 2010; Edenberg et al., 2010). In addition to testing
the aggregate genetic sum scores for association with AD in the sample used for
prediction, the individual SNPs contributing to the scores were each tested for association
with AD. All candidate gene SNPs were tested for association before performing LDbased pruning in order to assess the overall replication of the candidate gene SNPs in the
independent COGA and SAGE GWAS samples. All association analyses were completed
in the case-control samples using logistic regression using an additive model in PLINK
v1.07. In order to assess replication across ancestries, and to account for the ethnicity
differences in samples used in the previously reported candidate gene studies, association
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analyses were performed in both the EA subset of the sample and the entire sample,
which includes individuals of non-EA ancestry. Association analyses in the entire GWAS
samples that included individuals of non-EA ancestry included molecularly derived
principal components factor covariates, PC1 and PC2, distinguishing primarily between
European and African ancestry.

ROC curve analyses
Discriminatory accuracy of genetic sum scores and family history was measured using
ROC curve analysis in SPSS/PASW v17.0 (SPSS Inc., Chicago IL) with alcohol
dependence as the binary outcome.
The genetic sum scores and family history variables were used as the predictors.
Additionally, in order to assess whether a panel of SNPs associated with AD in a highdensity family sample would be more informative in predicting risk for individuals with a
positive family history of AD compared with individuals without a known family history,
ROC analysis for the genetic sum score was also split by presence of family history. For
example, in COGA, AUC was calculated for risk panels separately for those with a
positive family history of alcohol dependence and those with a negative family history of
alcohol dependence. In SAGE, analysis was split based on a variable created for positive
family history or negative family history in the proband’s parents based on strict standard
criteria.
We assessed the value of combining information from the candidate gene panel
with family history, as family history and the candidate gene sum scores were not
correlated (Pearson’s r = 0.021, n = 1081 for the candidate gene sum scores pruned at
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both r2 < 0.50 [p=0.490] and r2 < 0.25 [p=0.480] in COGA, Pearson’s r = -0.038, n=1566
for the candidate gene sum scores pruned at r2 < 0.50 [p=0.137] in SAGE, and Pearson’s r
= -0.017, n=1566 for the candidate gene sum scores pruned at r2 < 0.25 [p=0.497] in
SAGE). Predicted probabilities from logistic regression using genetic sum scores +
family history information were calculated and then used as continuous predictors of
alcohol dependence in order to determine whether or not genetic sum scores added to
family history information in risk prediction.

Results
Family-based association analysis
The re-run family-based association analyses resulted in p-values that matched those of
the previously published studies for the majority of SNPs (Table 3.2). Several SNPs had
different p-values in our repeat analysis due to differences in the sample inclusion criteria
used in the COGA papers compared with our analysis. Because the exact individuals
included was not explicitly reported in the studies, we did not have exact p-value matches
in our analysis for several of the SNPs from the COGA family studies; however, p-values
for the SNPs remained significant, with the exception of one SNP in ANKK1, for which
our p-value was considerably different and not significant. This SNP was therefore not
included in these analyses. For the two studies that used TRANSMIT and FBAT for
association, Dick et al., 2004 and Wang et al., 2008, we used information about the risk
allele obtained directly from Dr. Wang and matched the association results using
PDTPHASE for several of the SNPs for Dr. Dick’s study.
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ROC curve and logistic regression analysis
ROC curve analysis showed that neither of the genetic sum scores created based on the
pruning thresholds of r2 < 0.50 and r2 < 0.25 had an AUC estimate that reached statistical
significance at p < 0.05 for discrimination of alcohol dependence status in the COGA or
SAGE GWAS samples. The family history variables, however, did produce statistically
significant AUCs. ROC curve analysis results for discriminative ability of family history
compared with the genetic sum scores are summarized in Table 3.3 for the COGA
GWAS sample. Estimates in the SAGE GWAS sample are summarized in Table 3.4. The
distribution of genetic sum scores was similar in cases and controls in both the COGA
and SAGE GWAS samples. Figure 3.2 displays the distributions of the candidate gene
sum scores separately for cases and controls in the COGA GWAS sample.

Table 3.3 AUC Estimates of Predictors in the COGA GWAS Sample
Asymptotic 95% Confidence
Interval
Diagnostic Classifier
Family history
c
SCORE25
d
SCORE50

AUC
0.686
0.491
0.498

Std.
a
Error
0.016
0.018
0.018

Asymptotic
b
Sig.
< 0.001
0.595
0.915

Lower Bound
0.654
0.456
0.463

Upper Bound
0.718
0.525
0.533

a. Under the nonparametric assumption
b. Null hypothesis: true area = 0.5
2
c. Genetic sum score based on pruned list of COGA variants at an r of 0.25
2
d. Genetic sum score based on pruned list of COGA variants at an r of 0.50

Table 3.4 AUC Estimates of Predictors in the SAGE GWAS Sample

Diagnostic Classifier
c

SCORE25
d
SCORE50
e
History of alcoholism in mother-relaxed
f
History of alcoholism in mother-strict

Area

Std.
a
Error

Asymptotic
b
Sig.

Asymptotic 95%
Confidence Interval
Lower
Upper
Bound
Bound

0.492
0.496
0.556
0.547

0.015
0.015
0.015
0.015

0.583
0.782
< 0.001
0.002

0.462
0.466
0.527
0.518
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0.521
0.525
0.586
0.577

g

History of alcoholism in father-relaxed
h
History of alcoholism in father-strict
History of AD in either mother or father
i
(relaxed)

0.587
0.582

0.015
0.015

< 0.001
< 0.001

0.558
0.552

0.617
0.612

0.614

0.015

< 0.001

0.584

0.643

a. Under the nonparametric assumption
b. Null hypothesis: true area = 0.5
2
c. Genetic sum score based on pruned list of COGA variants at an r of 0.25
2
d. Genetic sum score based on pruned list of COGA variants at an r of 0.50
e.- i. Family history predictors based on a binary absence or presence of parental family history of
alcohol dependence.

Figure 3.2 Distribution of genetic sum scores based on candidate
gene SNPs pruned at r2<0.50 in cases and controls for AD in the
COGA GWAS sample

Summary of distributions:
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Controls
Cases

N
454
627

Min
0.25
0.25

Max
0.705
0.659

Mean
0.45552
0.45517

Std.
Deviation
0.075985
0.078184

COGA sample is independent of the COGA high-density family-based association
sample. The figure shows the frequency of normalized allele counts in bins after sum
scores were created by adding the number of risk alleles of SNPs associated with AD in
candidate gene studies, and then dividing by the number of non-missing genotypes for
each individual. The table summarizes the mean sum score, and range for the sum
score separately for cases and controls.

Logistic regression showed that none of the candidate gene sum scores created in
COGA and SAGE was significantly associated with alcohol dependence (p = 0.940 for
the candidate gene sum score pruned at r2 < 0.50, p = 0.753 for the score pruned at r2 <
0.25 in the COGA GWAS sample, p = 0.627 for the candidate gene sum score pruned at
r2 < 0.50, and p = 0.501 for the score pruned at r2 < 0.25 in the SAGE GWAS sample).
Many of the individual SNPs contributing to the genetic sum scores were not
significantly associated with alcohol dependence. Of the 22-SNP panel pruned at r2 <
0.50, two of the SNPs met a nominal threshold of p < 0.10 in the independent European
American subset of the COGA sample, one in the ADH4 gene and one in the ANKK1
gene. Two SNPs, one in the TACR3 gene and one in the GABRB3 gene, met this
threshold in the SAGE GWAS European American sample, and one SNP in the GABRG1
gene had a p-value < 0.05 in the sample. In the entire COGA GWAS sample including
individuals of African American and other ancestries, one SNP in the DRD2 gene had a
p-value < 0.05 and the same ADH4 SNP nominally associated with AD in the EA sample
had a p-value < 0.10 in the COGA sample. In the entire SAGE GWAS sample, the same
GABRB3 and GABRG1 SNPs met a threshold of p < 0.05. The p-values resulting from
logistic regression analyses for individual SNPs contributing to the candidate gene sum
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score panels post-LD-based pruning are shown in Table 3.5. The expanded list of all
SNPs prior to pruning based on LD included a greater number of SNPs that met the
nominal replication p-values of 0.05 and 0.10. Table 3.6 shows SNP association results of
all SNPs before performing LD-based pruning.

Table 3.5 The association of individual SNPs contributing to
candidate gene sum scores in COGA and in SAGE GWAS samples.

CHR
4
4
4
4
4
4
4
7
7
7
7
8
8
8
11
11
15
15
15
20
20
20

SNP
rs13120165
rs279858
rs1126672
rs3762894
rs4147531
rs1229982
rs11722288
rs10499934
rs7794886
rs12671685
rs324649
rs997917
rs16918941
rs6985606
rs17115439
rs1799978
rs1897356
rs1571281
rs680244
rs2235749
rs6045819
rs1997794

Gene
GABRG1
GABRG1
ADH4
ADH4
ADH1A
ADH1B
TACR3
ACN9
ACN9
ACN9
CHRM2
OPRK1
OPRK1
OPRK1
ANKK1
DRD2
GABRB3
GABRG3
CHRNA5
PDYN
PDYN
PDYN

P-val
COGA EA
0.104
0.681
*0.073
0.510
0.571
0.104
0.121
0.859
0.941
0.746
0.868
0.937
0.516
0.495
*0.077
0.133
0.570
0.296
0.779
0.696
0.840
0.255

P-val
COGA All
0.842
0.429
*0.069
0.128
0.940
0.337
0.148
0.385
0.476
0.452
0.610
0.989
0.712
0.439
0.238
**0.040
0.847
0.749
0.923
0.680
0.687
0.655

P-val
SAGE EA
0.388
**0.024
0.922
0.592
0.806
0.604
*0.061
0.224
0.590
0.252
0.429
0.956
0.773
0.851
0.964
0.239
*0.064
0.926
0.909
0.513
0.652
0.470

P-val
SAGE All
0.569
**0.017
0.449
0.501
0.508
0.594
0.266
0.412
0.512
0.307
0.121
0.954
0.499
0.522
0.825
0.480
**0.048
0.905
0.239
0.381
0.535
0.833

P-values are shown for logistic regression results of each individual SNP for association
with AD. P-val COGA_EA indicates results of association analyses in the European
American subset of the COGA GWAS sample that is independent of the COGA highdensity family-based association sample. P-val SAGE_EA reflects association results in
the FSCD and COGEND portion of the SAGE European American sample. COGA_All
and SAGE_All show results in samples that are included in the EA portion of the COGA
high-density family-based association sample, as well as independent individuals of
other ancestries. ** SNPs with p < 0.05 for association with AD; * SNPs with p < 0.10
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Table 3.6 Results of logistic regression for AD for all SNPs
associated with AD in candidate gene family-based association
studies
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Family history expanded results
ROC curve analysis based on presence or absence of family history
ROC curve analyses stratified by presence of family history of AD did not result in
significant AUCs or differences in discriminatory accuracy of genetic sum scores in the
positive or negative family history groups. Tables 3.7a and 3.7b show the AUC results
and level of significance for the genetic sum scores in discriminating between cases and
controls by presence or absence of family history in the COGA and SAGE GWAS
datasets.
Table 3.7a COGA GWAS Sample
Family History
No
Yes

Classifier
24 SNPs (r2 threshold = 0.50)
18 SNPs (r2 threshold = 0.25)
24 SNPs (r2 threshold = 0.50)
18 SNPs (r2 threshold = 0.25)

AUC
p-value *
0.521
0.4
0.517
0.493
0.454
0.109
0.439
0.036

95% CI
0.472, 0.571
0.468, 0.567
0.4, 0.508
0.385, 0.494

*null hypothesis: AUC=0.50

Table 3.7b SAGE GWAS Sample
Family History
No
Yes

Classifier
24 SNPs (r2 threshold = 0.50)
18 SNPs (r2 threshold = 0.25)
24 SNPs (r2 threshold = 0.50)
18 SNPs (r2 threshold = 0.25)

AUC
p-value *
0.497
0.864
0.492
0.648
0.520
0.553
0.506
0.857

95% CI
0.462, 0.535
0.457, 0.527
0.453, 0.586
0.439, 0.573

*null hypothesis: AUC=0.50
A “yes” for family history in the SAGE GWAS sample means that either the participant’s
mother or father has a personal history of AD, by strict standard criteria and a “no”
means that neither the participant’s mother nor father has a personal history of AD by
strict standard criteria.
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Analyses exploring the combination of family history and genetic sum scores
showed nominal, but not significant, improvements in discriminatory accuracy. For
example, we found that the AUC for family history increased nominally from 0.686 to
0.690 in COGA after adding the candidate gene sum score pruned at r2<0.50. Table 3.7
summarizes the AUC estimates for the original family history binary variable, the family
history ordinal variables, and the family history variables plus the genetic sums scores. A
test of the statistical difference for the family history alone vs. family history plus
candidate gene sum score pruned at r2<0.50 performed using DeLong’s method for
comparing ROC curves using the pROC package in R 2.10.2 showed that the difference
between the two ROC curves was not significant (z = 0.4508, p = 0.6521).

Table 3.7 Summary of expanded family history analyses
Predictor

AUC

AUC FH+SCORE50

Results in the COGA GWAS sample independent of the family sample:
SCORE50 = SNPs with r2 < 0.50
0.498
SCORE25 = SNPs with r2 < 0.25
0.491
Original FH binary variable
"No": N = 536
"Yes": N = 545 (any FH)
Total N = 1081

0.686

Ordinal FH var based on relaxed
criteria
0.621
"No": N = 850 (maternal and paternal Hx only)
"1 parent": N = 147
"Both parents": N = 24
Total N = 1021
Ordinal FH var based on strict criteria
"No": N = 850
"1 parent": N = 141
"Both parents": N = 22
Total N = 1013

0.618

76

AUC
FH+SCORE25
-

0.690

0.693

0.620

0.624

0.617

0.621

Results in the SAGE sample independent of the COGA sample:
SCORE50 = SNPs with r2 < 0.50
0.496
SCORE25 = SNPs with r2 < 0.25
0.492
Original FH binary variable
"No": N = 1246
"Yes": N = 356 (based on relaxed criteria)
Total N = 1602
Ordinal FH var based on relaxed
criteria
"No": N = 1246
"1 parent": N = 309
"Both parents": N = 47
Total N = 1602

-

0.614

0.614

0.618

0.617

0.616

0.620

Ordinal FH var based on strict criteria
0.614
0.615
0.617
"No": N = 1246
"1 parent": N = 303
"Both parents": N = 30
Total N = 1579
The AUC estimates of the family history variables alone and family history (FH) with the
addition of genetic sum scores are shown. SCORE50 refers to the genetic sum scores
created based on variants pruned at r2 < 0.50 and SCORE25 indicates a score based on
variants pruned at r2 < 0.25. The original AUC measures for the genetic sum scores are
included in the table for comparison purposes.

Discussion
This study aimed to evaluate the clinical validity of genetic variants that have been
associated with AD by exploring the aggregate effect of associated SNPs on risk
prediction for AD. Prior studies on the clinical use of genetic information in predicting
risk for other complex disorders have investigated the effect of genetic sum scores in risk
assessment and shown significant, but small, AUCs. In our study, genetic sum scores
were created based on results from SNPs that were associated with AD in family-based
candidate gene studies. ROC curve analysis was used to assess the ability of the sum
scores to classify cases and controls for AD. Results did not show significant AUCs for
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the candidate gene sum scores, suggesting that these sum scores are not predicting better
than chance. The individual variants contributing to the sum scores did not yield
significant results in the independent samples in which discriminative ability was
assessed. Because of the lack of replication for individual SNPs and sum score
associations with AD, AUC estimates were not significant. Family history, on the other
hand, did have significant discriminative ability for AD.
This assessment of discriminatory accuracy shows that these panels of SNPs
currently have limited clinical validity. One reason that many of the candidate gene SNPs
did not replicate in the independent samples used to assess for clinical validity could be
due to heterogeneity across samples; different genetic variants may contribute to risk in
different populations containing varying subsets of alcohol-dependent individuals.
Therefore, genetic risk could be unique to the samples used in these association analyses.
For example, several variants have been found to have stronger association with AD in
individuals with co-occurring drug dependence. Dick et al. showed that CHRM2 is
associated with a form of AD that is comorbid with drug dependence, but not with AD
alone (2007a). Individuals with this comorbidity were also found to have more severe
alcohol problems. In another case, Foroud et al. found that SNPs in TACR3 that were
associated with AD in EA COGA families had the strongest association in individuals
with more severe AD and comorbid cocaine dependence (2008). Furthermore, Agrawal et
al. showed that GABRA2 is associated with AD only in individuals with comorbid drug
dependence. When these individuals were removed from the analysis, no association
remained (2006). A next step in developing genetic risk models for AD would be to
assess for prediction for different subtypes of AD. SNPs from primary analyses in the
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family-based portion of the study may not have replicated in independent COGA and
SAGE GWAS individuals due to sampling differences between the GWAS sample and
the family-based association sample. One possibility is that the high-density family-based
sample may be more severely affected than a case-control sample and therefore show
differences in underlying genetic etiology. There was not a significant difference in mean
DSM-IV symptom count for AD between the COGA high-density family-based sample,
(mean=5.33, SD=1.82), and the SAGE (mean=4.87, SD=1.51) or COGA GWAS
(mean=5.45, SD=1.42) samples. Although the difference in symptom count between the
two samples was not significant, there is a nominal difference in symptom count; larger
sample sizes may have more power to detect a difference between the two samples.
Furthermore, severity of alcohol dependence may differ in ways beyond criterion count.
For example, the severity of the individual symptoms themselves may differ between
individuals with the same symptom count. This difference may manifest in ways beyond
individual symptom count, such as the extent of tolerance and withdrawal, duration of
symptoms, and number of episodes.
Many of the candidate gene SNPs used to compute the genetic sum score in the
GWAS sample displayed allelic effects that were in the opposite direction. Prior literature
has reported significant association in both directions for the same genetic variant in
different samples. For some variants, the direction of effect for some loci could be
different in different samples due to heterogeneity across samples. Differences in
population structure may correspond to allele frequency differences across samples so
that different variants are in LD with the causal variant in distinct samples (Zuo et al.,
2012). Differences in phenotype between the samples may mean that alleles could
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increase risk specifically for one phenotype in one sample, and not increase risk for a
different phenotype in another sample. For example, the GABRA2 gene has been
associated with AD in different samples, but the allele conferring risk is different in
different samples – in some, the major allele was associated with increased AD and in
others, the minor homologous allele was associated. Further investigation suggests that
the risk allele for GABRA2 may vary across the studies due to differences in a cooccurring phenotype with AD. Trait anxiety, or harm avoidance based on the
Tridimensional Personality Questionnaire (TPQ), has been suggested to have an
influence on whether a GABRA2 allele would increase risk for AD, with the major
haplotype associated with AD in individuals with alcohol dependence who have high trait
anxiety, and the minor haplotype associated with AD in individuals with low trait
anxiety, and intermediate frequency haplotypes to be associated with unaffected status
(Enoch, 2008; Enoch et al., 2006). In the COGA high-density family-based association
sample, individuals with alcohol dependence have been shown to have higher trait
anxiety than individuals without alcohol dependence (Ducci et al., 2007; Enoch, 2008).
These results show that family history is a better classifier than current
conceptualizations of SNP panels, based on candidate genes for AD. Family history is
currently likely a better predictor than this panel of SNPs because it accounts for more of
the latent genetic factors contributing to AD, whereas the contribution to risk of the panel
of SNPs is less clear. Family history also contains non-genetic predictors, which could
account for a significant proportion of the risk as well, as family history could influence
to some extent the environment that an individual is exposed to during development.
Family studies show some evidence for influence of parental alcohol dependence on risk
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for substance use disorders in children, or cultural transmission (Koopmans and
Boomsma, 1996; Newlin et al., 2000). Furthermore, the etiology of AD may be different
for one family versus another. Therefore, risk prediction based on one individual’s family
history may encompass genetic factors that are more specific to that individual than a
general panel of SNPs, which may not explain risk for the particular subgroup to which
that individual belongs. The nominal increase of the AUC after adding candidate gene
SNP scores that are not correlated with family history to the family history variables
suggests that variants associated with AD may provide additional risk information to
family history alone.
Importantly, before assessment on clinical validity is made, the contribution of
genetic sum scores, rather than individual associated SNPs, must be determined. Because
variants contributing to AD have small effect sizes, and the outcome used in the
association studies is a dichotomous diagnosis rather than a continuous outcome, larger
sample sizes are needed for increased power to detect causal variants that replicate across
studies (Bierut et al., 2010). GWA studies have shown replication of many of the SNPs
associated with AD in the COGA candidate gene studies (Edenberg et al., 2010; Bierut et
al., 2010), the results of which are shown in Table 3.6; however, in an effort to create
SNPs that capture unique information by pruning them based on LD, some of the
replicated SNPs were not included in the model. SNPs that were included represented
ones with the lowest p-values from the family-based candidate gene association studies,
and ones that are captured on the current GWAS arrays. To explore the effect that having
more replicated variants, despite correlation between the variants, on a genetic sum
score’s predictive accuracy, we created an expanded candidate gene sum score without
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pruning. This expanded score did not have a significant AUC (AUC = 0.493, p = 0.642);
the AUC was not significantly different from the two candidate gene sum scores pruned
at r2 < 0.50 (AUC = 0.498 in COGA and 0.496 in SAGE) and r2 < 0.25 (AUC = 0.491 in
COGA and 0.492 in SAGE). Continued investigation of the genetics of AD will further
refine the prediction model to include SNPs that have replicated and that capture unique
associations.
In the COGA and SAGE GWAS samples, previous analyses have demonstrated
that the missense SNP rs1229984 in the ADH1B gene encoding alcohol dehydrogenase
was associated with AD at p < 5x10-8 (Bierut et al., 2012). This variant, previously wellrecognized for its protective influence on alcoholism in Asian populations, has also been
found to exert an influence on alcoholism risk in European Americans and African
Americans. However, it is fairly uncommon in non-Asian samples (<5%) and is poorly
captured by content on commercially available GWAS platforms such as the Illumina
platform used in the COGA and SAGE GWAS samples, due to lack of LD with
neighboring SNPs. We assessed the discriminatory accuracy of this ADH1B SNP for AD
and found that it alone has an AUC of 0.538 (p = 7.58 x 10-4) in COGA. The inclusion of
this SNP in the candidate gene sum score increased the AUC from 0.498 to 0.503, but
this AUC was not significant, presumably partly due to the very low allele frequency in
this population. This suggests that including known variants that replicate in the
validation sample used for prediction could have a greater AUC, but a panel of several
dozen SNPs may still include false positives in addition to true findings of small effect.
Noise from null loci could outweigh effects from true loci in a small panel of SNPs,
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which would decrease the predictive accuracy of the aggregate SNP panel. Expanding the
panel to include additional replicated true variants could increase the AUC further.
The maximum AUC for a risk model containing only genetic variants is
constrained by the heritability of the trait, as well as the disease prevalence in a
population (Wray et al., 2010). As heritability of a disease goes down and as prevalence
goes up, the maximum AUC goes down (Wray et al., 2010). This stresses the importance
of taking into account other factors contributing to the variability in AD for risk
prediction, particularly since AD is a fairly prevalent disorder. Additional measures to
increase power may include reducing heterogeneity by refining the phenotype used as the
outcome in the association study (Bierut et al., 2010). Large-scale meta-analyses, along
with expanded individual association studies for AD, may improve the detection of
disease variants.
We do not yet have enough information about the specific variants contributing to
AD to use genetic data for clinical risk prediction. Family history is currently a better
predictor of alcohol dependence, though a variant that was associated in the GWAS
sample used for prediction was shown to have a significant AUC. This study suggests
that expanding the number of replicated variants associated with AD would account for a
greater portion of the genetic variance for AD and therefore improve risk prediction.
Because AD also has a substantial unique environmental etiology in addition to genetic, a
prediction tool based on genetic information alone would not have the highest AUC; the
addition of environmental factors would account for more of the variability in AD and
therefore a model that takes into consideration both could have better predictive ability.
Data simulations that we have conducted show that adding environmental effects could
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potentially raise the predictive accuracy to an AUC of 0.95 (Maher et al., in preparation).
While genetic information may be of limited clinical validity at the moment, as we
continue to identify genes successfully, and incorporate information from both genetic
and environmental risk factors, there is potential for future clinical validity.
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Chapter 4: Risk prediction using information from genome‐wide
association studies for AD

Abstract
Genome-wide association studies (GWAS) of alcohol dependence (AD) have reported
numerous variants. The clinical validity of these genetic variants to discriminate between
cases and controls for DSM-IV AD has not been reported. The Collaborative Study on
the Genetics of Alcoholism (COGA) and the Study of Addiction: Genes and Environment
(SAGE) GWAS samples were used to examine the aggregate impact of multiple genetic
variants with small effect sizes on clinical risk prediction for AD using receiver operating
characteristic (ROC) curve analysis. In these analyses, subsets of the COGA and SAGE
samples were used as gene discovery and validation samples in two sets of analyses, in
which genetic sum scores were created by adding risk alleles of associated SNPs in
discovery samples and then assessed for their ability to discriminate between cases and
controls in independent validation samples. SNPs from GWAS analysis that met nominal
association levels in two discovery subsets and SNPs from GWAS analysis that met
varying “significance” criteria based on p-value thresholds from 0.0001 to 0.5 were
assessed separately for predictive accuracy. ROC curve analysis using scores created
from semi-replicated SNPs did not result in significant discriminatory ability for the
genetic sum scores, suggesting that the SNPs are not predicting better than chance. SNPs
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that met less stringent p-value thresholds of 0.01 to 0.50 in GWAS analyses did yield
significant area under the ROC curve (AUC) estimates, ranging from mean AUC
estimates of 0.549 for SNPs with p < 0.01 to 0.565 for SNPs with p < 0.50. This study
shows that these SNPs from GWAS analyses account for some of the risk in AD, but
have limited clinical validity. This illustrates the need for further development of
prediction panels that incorporate replicated variants contributing to risk for AD.
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Introduction
A number of genome-wide association studies have been performed for alcohol
dependence (AD) and alcohol-related phenotypes. (Treutlein and Rietschel, 2011b;
Treutlein et al., 2009; Frank et al., 2012; Bierut et al., 2010; Edenberg et al., 2010;
Agrawal et al., 2011; Heath et al., 2011; Lind et al., 2010; Schumann et al., 2011; Wang
et al., 2012; Wang et al., 2011; Zuo et al., 2012; Kendler et al., 2011; Zuo et al., 2011).
Genome-wide associations studies (GWAS) have the benefit of a hypothesis-free
approach to finding variants associated with common diseases without prior information
on putative chromosomal regions or genes. The studies could provide coverage of
common markers across the genome based on correlation due to linkage disequilibrium
(LD) between loci (Visscher et al., 2012). Prior to the technical feasibility of the GWAS
era, Risch and Merikangas projected that using association studies to study common
variants that contribute to common diseases would be more powerful and require fewer
markers and sample sizes to detect small effects than using linkage studies, which are
more suited to detecting loci with larger effects sizes (Risch and Merikangas, 1996).
For alcohol dependence, many of the reported genome-wide association studies to
date have reported variants that did not meet the genome-wide significance threshold of p
< 5x108 based on Bonferroni correction for one million tests for a GWAS using one
million markers, though many have shown variants that were associated with low pvalues (p < 1x10-5). Two studies have reported genome-wide significant findings for
variants that have been replicated in other samples (Zuo et al., 2012; Lind et al., 2010).
The results of GWA studies for alcohol dependence have supported previous candidate
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gene associations and implicated many new genes and pathways in risk for alcoholrelated phenotypes.
Among the few studies that have reported genome-wide significant findings, two
studies found significant associations of the alcohol dehydrogenase (ADH) genes at this
threshold. Frank et al. (2011) found rs1789891, located between the ADH1B and ADH1C
genes, to be associated with AD in a treatment-based sample of 1333 male individuals
with severe AD and 2168 controls, all of German descent. Bierut et al. (2012) reported
genome-wide support for the low-frequency rs1229984 SNP in the ADH1B gene in the
SAGE GWAS sample, totaling 2298 individuals with AD and 3334 controls without
dependence, and including individuals of both European and African ancestry. This study
provided new support for association of the ADH1B variant that was previously limited to
individuals of East Asian descent.
In the first reported GWAS of AD, Treutlein et al. (Treutlein et al., 2009)
performed a case-control study in which cases were recruited from treatment centers in
Germany. They further assessed their top results in a follow-up sample and found
evidence for two correlated SNPs in the 3’ flanking region of the peroxisomal trans-2enoyl-CoA reductase gene (PECR) located in the 2q35 region. Regions on chromosome
2q have previously been implicated in linkage studies of alcohol-related phenotypes
(Schuckit et al., 2001; Nurnberger et al., 2001; Dick et al., 2010). Thus, this finding
provided additional support for possible involvement of genes in this region for alcohol
dependence. Primary analyses in the COGA GWAS sample did not result in SNPs that
met genome-wide significance, but convergent evidence from the case-control GWAS
sample, COGA family-based association sample, and gene expression analyses supported
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association of a group of chromosome 11 genes (SLC22A18, PHLDA2, NAP1L4,
SNORA54, CARS, and OSBPL5), particularly for early-onset AD (Edenberg et al., 2010).
The primary SAGE GWAS did not result in genome-wide significant association with
AD, but showed modest replication for the previously implicated GABRA2 gene; all
GABRA2 SNPs were nominally associated at p < 0.05 in the SAGE sample (Bierut et al.,
2010). In meta-analysis of an Australian and Dutch sample, the top hit was the
semaphorin 3E gene (SEMA3E), which is involved in synaptic specificity of motor
circuits in mice. Gene network analyses revealed evidence for ion channel and cell
adhesion molecule genes in this study (Lind et al., 2010). Lind et al. also found SNPs that
met genome-wide significance for association with comorbid alcohol/nicotine
dependence in MARK1, which is involved in phosphorylation of microtubule-associated
proteins, DDX6, which encodes a putative RNA helicase, and KIAA1409, which is
thought to be part of a sodium channel complex. The KIAA0040 gene was associated with
AD in both Zuo et al.’s study (2012) and Wang et al.’s meta-analysis (2011). Wang et al.
also found an association between AD and THSD7B and NRD1, and found replication of
PKNOX2. Studies of quantitative traits such as alcohol consumption have identified a
genome-wide significant association with the AUTS2 gene (Schumann et al., 2011) and
evidence of association for the TMEM108 and ANKS1A genes (Heath et al., 2011). In a
study of an alcohol factor score based on DSM-like symptoms, Kendler et al. (2011)
found the most significant SNP to be KCNMA1, AKAP9, and PIGG in the EA sample and
CEACAM6, KCNQ5, SLC35B4, and MGLL in the AA sample. They also found support
for previously associated candidate genes for ADH1C, NFKB1, and ANKK1 in the EA
sample and ADH5, POMC, and CHRM2 in the AA sample (Kendler et al., 2011).
89

ROC curve analyses of prior complex diseases have shown modest predictive
ability of genetic sum scores (Jostins and Barrett, 2011). Several studies have shown that
when a greater number of genetic variants meeting more liberal p-value thresholds were
included in an aggregate genetic sum score, then the score accounted for more of the
variability in phenotype compared with a score consisting of fewer variants meeting more
stringent p-value thresholds. Purcell et al. showed in the International Schizophrenia
Consortium sample of 3,322 cases with schizophrenia and 3,587 controls that thousands
of variants associated at less stringent p-value thresholds of p <0.10, p <0.20, p <0.30, p
<0.40, and p <0.50, accounted for more of the variance in schizophrenia. Of the different
p-value threshold scores, the scores created from SNPs meeting increasingly large pvalue thresholds accounted for more of the variance in schizophrenia. A threshold of p <
0.50 explained the most phenotypic variance – about 3% – in schizophrenia in an
independent target sample (Purcell et al., 2009). This corresponds to an AUC of 0.65 in
discriminating case-control status for schizophrenia (Jostins and Barrett, 2011). The score
was also found to explain 1-2% of the variance in bipolar disorder, but did not account
for a significant proportion of phenotypic variance in non-psychiatric disorders,
supporting a shared polygenic component between schizophrenia and bipolar disorder
(Purcell et al., 2009). Genetic risk profile studies for depression and anxiety showed
similar polygenic models. Demirkan et al. (2011) used results from the Genetic
Association Information Network (GAIN) major depressive disorder (MDD) GWA study
to select SNPs meeting varying p-value thresholds ranging from p < 0.00001 with
incremental threshold changes including p < 0.0001, 0.001, 0.01, 0.1, and 0.2, up until p
< 1.0. They created genetic sum scores using these SNPs and tested them for association
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with MDD in independent samples. Risk scores associated with MDD at p < 0.1 to p <
0.4 in the GAIN-MDD discovery sample explained significantly 0.65% of the variance in
MDD in an independent sample. They found that risk scores created based on SNPs
meeting p<0.1 to p<1.0 in the GAIN-MDD discovery sample explained 1-2.1% of the
variance in anxiety in an independent sample, with increasing variance explained with
each incremental increase in the p-value threshold used to select the discovery SNPs
(Demirkan et al., 2011).
The method of selecting variants based on less stringent thresholds has also been
used previously to assess risk prediction for the disease cohorts in the Wellcome Trust
Case Control Consortium (WTCCC), many of which had previously associated variants
(Evans et al., 2009). Evans et al. examined the predictive ability of genome-wide
information for the 7 common diseases in the WTCCC: bipolar disorder, coronary heart
disease, hypertension, Crohn’s disease, rheumatoid arthritis, type I diabetes, and type II
diabetes. Because the effect sizes of alleles contributing to these complex diseases are
often in the range of 1.1-2, and are therefore likely to have individually small effects on
prediction, they created genetic sum scores composed of many SNPs at liberal
significance thresholds. They found that many of the genome-wide scores produced
significant AUCs, with an AUC of 0.549 for bipolar disorder to an AUC of 0.784 for type
I diabetes. AUCs were highest for disorders with known genetic regions of larger effect,
such as the involvement of variants in the MHC region in type I diabetes and Crohn’s
disease. Genome-wide scores added to the discriminatory accuracy of known variants,
particularly for diseases in which the effects of known variants were smaller. Scores
based on SNPs meeting more liberal thresholds had the best discriminatory accuracy for
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disease that did not have known large-effect loci, such as bipolar disorder, coronary heart
disease, hypertension, and type II diabetes. For some conditions, the AUC peaked at
SNPs selected at p < 0.50, and for others, the AUC was higher at p < 0.80. This suggests
that more liberal thresholds capture more of the polygenic effects, but as p-value
thresholds continue to increase, the polygenic scores may be too diluted by null effects to
have increasing discriminatory accuracy (Evans et al., 2009).
These studies show that although effect sizes of common SNPs are individually
too small to meet genome-wide significance thresholds, selecting SNPs at more liberal pvalue thresholds would include a greater proportion of true loci that could in aggregate
account for variance in a complex polygenic trait, despite noise from null loci. Most of
the genetic variants contributing to AD have small effect sizes. A genetic sum score
composed of many genetic variants at liberal thresholds would provide an aggregate
predictor without necessitating knowledge of specific true loci. This study explored the
cumulative impact of multiple genetic variants with small effect sizes from genome-wide
association studies, with a focus on risk prediction, in order to provide a clinical
assessment of genetic contributions from GWAS data to AD.
We used results from the Collaborative Study on the Genetics of Alcoholism (COGA)
and the Study of Addiction: Genes and Addiction (SAGE) GWAS samples to capture
genetic effects on alcohol dependence in order to predict risk in independent sample
subsets. We first created genetic sum scores created based on semi-replicated variants
that met nominal p-value thresholds in two separate halves of the SAGE sample, with the
idea that SNPs that had replicated may be more likely to represent “true positives” and
enhance predictive ability of genetic sum scores composed of these replicated SNPs. We
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then assessed genetic sum scores based on variants that met varying p-value thresholds.
We combined the COGA and SAGE GWAS samples and then split the combined sample
randomly in half. One half of the combined sample was used as a discovery sample and
the other half a validation sample. We created genetic sum scores based on SNPs that met
a range of p-value thresholds from p < 0.0001 to p < 0.50 in the discovery sample and
then assessed for prediction in the validation sample, testing that using SNPs meeting less
stringent p-value thresholds may better detect variants of small effect.

Materials and methods
Sample and measures
COGA GWAS sample
The Collaborative Study on the Genetics of Alcoholism (COGA) is a large-scale multicenter family study developed to identify genes that contribute to alcohol-related
outcomes. The sample consists of families containing probands meeting both DSM-IIIR
and Feighner criteria for alcohol dependence who were ascertained from outpatient and
inpatient alcohol treatment centers at six sites across the United States. Families reported
information about family history and were interviewed using a poly-diagnostic
instrument, the Semi-Structured Assessment for the Genetics of Alcoholism (SSAGA),
which assesses Feighner, DSM-IIIR, DSM-IV, and ICD-10 criteria. A case-control
sample of 1945 phenotyped subjects was formed by COGA for a genome-wide
association study (GWAS). Cases had a lifetime diagnosis of alcohol dependence by
DSM-IV criteria. Controls reported consuming alcohol but did not have a diagnosis of
alcohol dependence or abuse by any of the diagnostic criteria assessed by SSAGA
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(Feighner, DSM-IIIR, DSM-IV, and ICD-10) or DSM-IIIR or DSM-IV criteria for
cocaine, marijuana, opioids, sedatives, or stimulants. They could not share a known
common ancestor with a case and were preferentially selected to be above the age of 25
years.
Genotyping was completed using the Illumina Human 1M DNA Analysis
BeadChip at the Center for Inherited Disease Research (CIDR). DNA was extracted from
blood and lympoblastoid cell lines. The Ilumina Infinium II assay protocol was followed
with hybridization to Illumina Human 1M BeadChips (Illumina, San Diego, CA). A total
of 1,069,796 SNPs were used, with a mean spacing of 2.4 kb (Edenberg et al., 2010). The
dataset had a total of 1,041,465 SNPs with genotypes that had Gencall quality scores of
0.15 or higher. Samples with genotypes for less than 98% of SNPs were removed. All
samples were screened for cryptic relatedness and population stratification. Principal
components analysis clustered samples along HapMap reference panels. Principal
components-derived covariates were created to separate the sample into individuals of
European American and African American descent. Additional details about the quality
control steps taken to process the genotypic information in the COGA dataset can be
found in (Edenberg et al., 2010).

SAGE GWAS sample
The Study of Addiction: Genes and Environment (SAGE) is part of the Gene
Environment Association Studies (GENEVA) initiative of the NHGRI to identify genetic
contributions to addiction through large-scale genome-wide association studies of cases
and controls. The SAGE sample consists of 4,121 cases and unrelated controls from
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subsets of three large studies on addiction: the Family Study of Cocaine Dependence
(FSCD), the Collaborative Genetic Study of Nicotine Dependence (COGEND), and
COGA. Individuals from FSCD with cocaine dependence were recruited from treatment
units for chemical dependency in the St. Louis metropolitan area. Age, race, sex, and
residency-matched controls were recruited through the community-based Missouri
Family Registry. The COGEND study is a community-based study of participants
recruited in St. Louis, MO and Detroit, MI. Although the SAGE sample consists of three
samples that were ascertained differently, cases in SAGE are defined as having DSM-IV
lifetime diagnosis of alcohol dependence, and all participants in SAGE were assessed
using the Semi-Structured Assessment for the Genetics of Alcoholism (SSAGA).
Controls were exposed to alcohol. Some controls met criteria for nicotine dependence
based on the Fagerström Test for nicotine dependence, but none met criteria for a DSMIV lifetime dependence diagnosis for alcohol, marijuana, cocaine, opiates or other drug.
Parallel to the COGA GWAS, genotyping was completed using the Illumina
Human 1Mv1_C DNA Analysis BeadChip and the Ilumina Infinium II assay protocol
(Illumina, San Diego, USA) at the Center for Inherited Disease Research (CIDR). The
quality control process involved checking for Mendelian errors, batch effects, cryptic
relatedness, potential chromosomal anomalies, and deviation from Hardy Weinberg
equilibrium. Additional details about the sample can be found in the primary SAGE
GWAS manuscript by Bierut et al. (Bierut et al., 2010).

Data analysis
Analyses overview
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Figure 4.1 illustrates the overview of the analyses, which were broken down into two
parts:
Part I, which evaluated panels of SNPs that have been replicated in two samples, and Part
II, which assessed the discriminatory accuracy of SNPs meeting varying significance
thresholds in genome-wide association analyses.

Figure 4.1 Study overview
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Part I. SAGE GWAS SNP panel with replication
Sample selection and association analyses
In order to select an independent gene-finding sample, the FSCD and COGEND subset of
the SAGE GWAS sample without COGA individuals was selected for this part of the
study. This selected subset was split randomly in half. Association analysis was
performed in each half of the sample subset using logistic regression with covariates for
sex, age, and the FSCD and COGEND study site variables.
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Because removing COGA individuals and then splitting the sample in half
substantially reduced the SAGE sample size, all analyses were completed in the entire
sample including individuals of different ancestries, as well as in the subset of European
American individuals. For association analysis in the entire sample, molecularly derived
principal components factors for ethnicity, PC1 and PC2, were added as covariates.
Figure 4.1 summarizes the number of individuals included in the analyses separately for
the entire sample and for the EA sample. The entire SAGE sample consisted of 2484
individuals (1450 controls and 1034 cases). Of the entire SAGE GWAS sample, 1425
individuals who were part of COGA were removed from the entire SAGE sample. The
remaining FSCD and COGEND subset of the entire SAGE sample consisted of 1220
individuals for one half of the subset and 1207 individuals for the other half of the subset.
The SAGE GWAS European American sample contained 801 individuals for each half of
the subset after removing COGA individuals and then performing a 50% split.

SNP selection and pruning
SNPs that met a p-value threshold of p < 0.001 in the first half of the SAGE sample and a
threshold of p < 0.05 in the second half of the sample, and vice versa, were selected for
further analysis (Figure 4.1). The direction of effect of the minor allele on alcohol
dependence risk was matched for SNPs meeting both p-value thresholds. Because a
nominal p-value threshold of p < 0.001 was used in the discovery subsample, many of the
SNPs meeting this threshold may be false positive associations. It can therefore be
expected that the direction of an associated null allele may flip in the second SAGE
subsample. SNPs that share the direction of effect across both SAGE subsamples are
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more likely to be true findings. SNPs that did not have the same direction of effect in the
two halves of the sample were eliminated from the combined list of semi-replicated
SNPs. The combined list of SNPs that showed association and had the same direction of
effect across both halves of the discovery sample was then pruned based on an r2
threshold of 0.50 using an LD-based pruning function in PLINK version 1.07 (Purcell et
al., 2007). This method calculated pairwise genotypic correlations for the list of SNPs.
One of each pair of SNPs with correlations greater than an r2 of 0.50 was removed.
Because LD estimates are more accurate in larger samples, LD calculations for SNP
pruning were performed in the complete SAGE GWAS sample, including individuals
from COGA.

Genetic sum scores and ROC curve analyses
Additive genetic sum scores of risk alleles were created in the COGA GWAS sample
based on pruned SNPs from SAGE GWAS results. Because the odds ratios varied across
the SAGE discovery samples, risk alleles were not weighted. The genetic sum score was
then used to classify case-control status in individuals from the COGA GWAS sample
using ROC curve analyses. Association between alcohol dependence and the genetic sum
scores and individual pruned SNPs was performed in the COGA sample.

Part II. GWAS results from varying p-value thresholds
Sample selection
In Part II of the analyses, a combined GWAS sample was created by merging the COGA
and SAGE GWAS samples. This combined COGA-SAGE GWAS sample was then split
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into discovery and validation subsamples. The discovery and validation subsets of the
sample were created based on an initial combined sample in an attempt to reduce
heterogeneity across the discovery and validation samples compared with using discovery
and validation samples gathered using different ascertainment procedures. In order to
control for differences in association between African American and European American
subjects, analysis for this part of the study was performed only in the European American
subset. The FSCD and COGEND subset of the SAGE EA sample was combined with the
COGA GWAS EA sample. Because the COGA GWAS sample contains individuals who
are not part of the COGA subset of the entire SAGE sample, combining the COGA
GWAS sample with the nicotine and cocaine studies created a larger GWAS sample than
the SAGE GWAS sample alone. This combined sample allowed for more power when it
was split in half into discovery and validation samples. Controls who endorsed 3 or more
symptoms for DSM-IV AD, but did not cluster within a 12-month period, were removed
from the combined sample, as these individuals could still represent increased genetic
risk for alcohol dependence (N = 49, all from the SAGE GWAS sample). The combined
sample included 2951 individuals, comprised of 1495 cases and 1456 controls (Table
4.1).

Table 4.1 Summary of cases and controls by study for combined
COGA and SAGE GWAS sample
Study
COGA
COGEND
FSCD
Total

DSM-IV AD
Controls
Cases
552
846
702
335
241
275
1495
1456

100

Total
1398
1037
516
2951

The FSCD and COGEND subset of the SAGE EA sample and COGA GWAS EA
combined sample was split randomly in half so that each half contained 50% of cases and
50% of controls. In order to account for chance effects, repeated random sub-sampling
cross-validation was implemented by performing this subsetting procedure100 times to
obtain 100 subsamples in which analyses were completed.

SNP pruning
Before logistic regression analyses were performed, the LD-based pruning function in
PLINK version 1.07 was used to prune the 1,041,983 SNPs genotyped in the combined
sample. The SNPs were pruned at r2 < 0.50 using a sliding window of 50 base pairs
shifted by 5 base pairs following each pruning step. Pruning resulted in 385,060 of the
original SNPs pruned in, which represented 36.95% of all SNPs in the combined sample.

Association analyses
Association was performed in PLINK version 1.07 using logistic regression under an
additive model with sex and a dummy-coded site covariate distinguishing between the
COGA, FSCD, and COGEND study sites. Figure 4.1 lists the p-value thresholds used to
select SNPs from association results in the first half of the sample.

Genetic sum scores and ROC curve analyses
Because both the COGA and SAGE GWAS samples had the same SNPs genotyped, and
were confirmed to share the direction of the genotyped strand, GWAS results were
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matched directly by allele. Genetic sum scores were created for autosomal SNPs. Scores
of total allele count were weighted by the natural log of the odds ratio for each reference
minor allele, and then divided by the number of non-missing genotypes for each
individual using PLINK version 1.07:
Genetic sum score =

[!! × !"(!"! )] [!! × !"(!"! )]
!

!

where 𝑥! 𝑥! is the number of reference alleles at the ith SNP, OR is the
corresponding odds ratio, and N is the number of non-missing genotypes for each
individual.
Discriminatory accuracy of genetic sum scores was measured using ROC curve analysis
in the caTools package (Tuszynski, 2011) in R version 2.12.2 (R Development Core
Team, 2011). The p-values associated with the AUCs for these sum scores were
calculated based on the Wilcoxon rank-sum test using R version 2.12.2. Following
completion of the 100 iterations of the subsampling procedure, the mean of the AUC
estimates and confidence intervals of mean estimates were calculated using SPSS/PASW
v17.0 (SPSS Inc., Chicago IL).

Results
Figure 4.2 summarizes the resultant number of SNPs at each step of analysis for both the
EA sample and the entire sample. GWAS analyses of the entire SAGE sample including
all individuals across ethnicities in Part I of the study resulted in 52 SNPs that met
significance criteria at p < 0.001 in one discovery sample and p < 0.05 in the second
discovery sample and had the same direction of effect in both discovery samples. After
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LD-based pruning at r2 < 0.50, 39 SNPs remained. ROC curve analysis showed that the
genetic sum score created based on these 39 SNPs did not have significant discriminatory
accuracy in the COGA GWAS sample (Table 4.2). Association analysis of this genetic
sum score with alcohol dependence in the entire COGA sample using logistic regression
did not result in a significant association (p = 0.206). One SNP out of the 39 used for
prediction had a p-value < 0.05 for association with alcohol dependence: rs1950231 on
chromosome 14 (p = 0.0496).
Analyses in the EA subset of the SAGE GWAS sample resulted in 24 SNPs that
met significance criteria and shared direction of effect in both of the SAGE discovery
sample subsets. After pruning, 21 SNPs remained. The genetic sum score created using
these 21 SNPs was not a significant classifier for case-control status in the COGA GWAS
sample. The AUC estimate for the sum score is shown in Table 4.2. The test of
association of the genetic sum score with alcohol dependence in European-American
subset of the COGA sample using logistic regression was not significant (p = 0.176).
None of the 21 SNPs in the panel used for prediction in the European-American subset of
the sample was associated with alcohol dependence at p < 0.05.

Figure 4.2 Number of SNPs resulting from GWAS analyses with
semi-replicated SNPs
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Gray boxes show samples used for each step of analyses. White boxes display the
selection criteria for SNPs at each step. The number of SNPs resulting from each step of
analysis is shown in separate columns for the EA sample and for the entire SAGE
GWAS sample.
Table 4.2 ROC curve analysis results of semi-replicated SNPs from
GWAS analyses

Diagnostic
Classifier
AUC Std. Error a
39 SNPs in all
individuals c
0.521
0.014
21 SNPs in EA
individuals d
0.520
0.016
a. Under the nonparametric assumption
b. Null hypothesis: true area = 0.5

Asymptotic
Sig.b

Asymptotic 95%
Confidence Interval
Lower
Upper
Bound
Bound

0.126

0.494

0.548

0.203

0.489

0.551
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c. Genetic sum score created using GWAS results in the entire sample including
European American, African American, and other ancestries
d. Genetic sum score created using GWAS results in the European American sample

In Part II of the study assessing SNPs that met varying p-value thresholds, SNPs
meeting increasingly stringent significance thresholds of p < 0.001 and lower did not
have significant AUCs in ROC curve analyses. Subsets of SNPs meeting more liberal pvalue thresholds of p < 0.01 and greater had AUC estimates that were significant (p <
0.05 for AUC). Table 4.5 summarizes mean AUC estimates for each set of SNPs meeting
p-value thresholds across the 100 random divisions of the SAGE-COGA combined
sample. The median of the p-values associated with each AUC estimate was determined
(Table 4.5) because the distribution of these p-values was significantly skewed across the
subsets of SNPs. Figure 4.3 illustrates the AUC estimates of genetic sum scores created
based on varying p-value thresholds. Although the significance threshold at which the
AUC value peaked varied across each random sample subset, AUC point estimates
showed an increasing trend as the p-value threshold used for SNP selection became less
stringent.

Table 4.5 Results of SNP subsets from varying P-value thresholds
95% Confidence Interval
P-value
score
P-value
P-value
P-value
P-value
P-value
P-value
P-value
P-value
P-value

threshold
<
<
<
<
<
<
<
<
<

0.50
0.40
0.30
0.20
0.10
0.05
0.01
0.001
0.0001

N subsets
100
100
100
100
100
100
100
100
100

Mean AUC
0.565
0.565
0.564
0.564
0.562
0.559
0.549
0.528
0.517

Lower
0.562
0.562
0.561
0.561
0.559
0.556
0.546
0.526
0.515
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Upper
0.568
0.568
0.567
0.567
0.565
0.562
0.552
0.531
0.519

Median p-value for
AUC
1.37E-05
1.42E-05
1.82E-05
2.62E-05
4.81E-05
1.04E-04
0.00167
0.0632
0.291

Summary statistics for 100 random 50% splits of the combined COGA-SAGE sample
into discovery samples and validation samples. Sum scores were created based on
SNPs meeting each p-value threshold, by adding minor alleles weighted by the log of the
odds ratio for AD. Confidence intervals are based on 100 AUC estimates from 100
separate sum score calculations at each p-value threshold. Median p-value threshold
was calculated because distributions of p-values were skewed.

Figure 4.3 Mean AUC estimates for varying P-value thresholds

0.58

Mean of AUC Estimates

0.57
0.56
0.55
0.54

AUC

0.53

Lower
Upper

0.52
0.51
0.50

P-value threshold

The mean of all 100 AUC estimates for sum scores created using SNPs that meet
different p-value thresholds in discovery samples is plotted here in the solid line. Dashed
lines represent the upper and lower bounds of the 95% confidence intervals of the mean
of the AUC estimates.
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Discussion
This study aimed to evaluate the clinical validity of genetic variants that have been
associated with alcohol dependence by exploring the aggregate effect of associated SNPs
on risk prediction for alcohol dependence. Prior studies on the clinical use of genetic
information in predicting risk for other complex disorders have investigated the effect of
genetic sum scores in risk assessment and shown significant, but small, AUCs. In our
study, genetic sum scores were created based on results from two sources of genomewide association results: SNPs from a semi-replicated list of variants that were associated
with alcohol dependence in two “separate” GWAS samples and SNPs that met varying pvalue significance thresholds in GWAS analyses. ROC curve analysis was used to assess
the ability of the sum scores to classify cases and controls for alcohol dependence. The
scores created based on semi-replicated SNPs at nominal p-value thresholds of p < 0.001
and p < 0.05 in the two separate discovery and replication samples in Part I of the study
did not show significant AUCs or significant association with alcohol dependence in the
independent clinical validation sample. Results from Part II of the study showed
significant, albeit small, AUC estimates for sum scores based on SNPs that met p-value
thresholds ranging from p < 0.10 to p < 0.50. Significant AUC estimates were under 0.60.
These results support a polygenic model involving hundreds of variants of small
effect contributing to risk for AD that are consistent with other findings on alcohol
phenotypes and other complex traits (Heath et al., 2011; Purcell et al., 2009; Frank et al.,
2012). Less stringent thresholds allowed for the selection of more true findings with
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effect sizes that would not otherwise have reached genome-wide significance. Combining
nominally associated SNPs in aggregate improved clinical validity because these true loci
could outweigh noise from null loci.
In Part I of the study, we created discovery and replication samples by splitting
just the FSCD and COGEND portion of the SAGE GWAS sample in half, and then
assessed for clinical validity in the COGA GWAS sample. This selection method studied
the COGA and SAGE GWAS samples as distinct populations in order to find more
variants that are associated in samples that are ascertained differently. Variants that
replicated across the discovery sample, FSCD/COGEND, and the validation sample,
COGA, would possibly contribute to AD risk in more general populations than variants
that replicated in samples with similar population structures, such as those that replicated
in both halves of SAGE. In Part II of the study, we combined the COGA and SAGE
samples before performing subsampling to create samples with similar population
structure across discovery and validation sets in order to address heterogeneity across
samples. Of the list of SNPs in Part I of the study that met nominal significance criteria in
both halves of the SAGE sample, the majority of SNPs did not share the same direction
of effect suggesting that many of these results could be false positives. It is expected that
many SNPs meeting the nominal p-values would represent type I error, particularly given
the high number of tests performed in GWAS analyses. The replication step was an
attempt to filter out SNPs that had opposite directions of effect in order to retain a greater
proportion of SNPs that could be true positives.
The finding that genetic sum scores created from SNPs meeting less stringent pvalue thresholds were significantly associated with AD and had significant discriminative
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ability suggests that varying p-value thresholds could better detect variants of small
effect. The samples used in this study did not have enough power to detect the entire
range of small effect sizes for individual variants assessed in these analyses at a genomewide significance level. Splitting the COGA-SAGE combined sample further reduced
power. The numbers of loci meeting each p-value threshold were close to what would be
expected by chance when selecting lists of SNPs at each threshold. Therefore, a genetic
sum score created based on these thresholds would encompass SNPs that may not
contribute to risk for AD. For these false positives, weighting by the log of the OR
obtained from logistic regression in the discovery samples for these SNPs could in fact be
weighting by the opposite direction of effect that some of the SNPs have in the validation
sample. This in turn would decrease the association between the genetic sum score and
alcohol dependence in the validation sample, and therefore the AUC. As sample sizes
increase for studies of alcohol dependence, and as meta-analyses combine results across
all genome-wide association studies of AD, a more precise odds ratio could be obtained
and more true loci may be found.
The polygenic nature of the AD indicates a spectrum of allele frequencies
contributing to AD. Larger sample sizes are necessary for detecting smaller effects
without including null markers at the same significance thresholds (Park et al., 2010) .
This would allow the creation of genetic sum scores diluted by fewer null effects. The
markers used in current GWAS platforms are common variants with minor allele
frequencies greater than 1% that also capture multiple variants in LD with the variants
directly genotyped on the SNP chip. There is evidence for alleles associated with AD
with low frequency not captured on the GWAS platforms that still have a significant
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effect on AD in the population. A previous report in the COGA and SAGE GWAS
samples demonstrated that the Arg48His variant, rs1229984 in the ADH1B gene encoding
alcohol dehydrogenase was associated with AD at p < 5x10-8 with a relatively large effect
size (Bierut et al., 2012). In this study, a meta-analysis across COGA, FSCD, and
COGEND showed that the allele encoding His48 had a significantly protective effect on
alcohol dependence (OR = 0.34, P = 6.6x10-9). This variant was previously wellrecognized for its protective influence on alcohol dependence in Asian populations, but
had low frequency in European Americans (MAF = 3-4% in the COGA and SAGE
GWAS EA samples) and African Americans (MAF = 1-2% in COGA and SAGE GWAS
AA samples). It is poorly captured by commercially available GWAS platforms such as
the Illumina platform used in the COGA and SAGE GWAS samples, due to lack of LD
with neighboring SNPs. Using the targeted genotyping data for the ADH1B SNP
available in the COGA GWAS sample, we assessed the discriminatory accuracy for AD
and found that rs1229984 alone has an AUC of 0.538 (p = 7.58 x 10-4) in COGA.
Additional investigation of variants with lower frequency and expanded genetic
association studies to include more variants not captured on GWAS arrays would allow
for the inclusion of additional associated SNPs into a predictive score that may have
better clinical validity.
The results of this particular study, along with prior genome-wide association
studies of alcohol dependence, reveals that the genetic architecture of alcohol dependence
includes many common alleles of small effect that may in aggregate account for
variability in AD. These results provide additional support for the theory of polygenic
inheritance for a disease model for alcohol dependence. This information, coupled with
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further studies on the nature of variants associated with AD, may help increase
understanding of the biology of AD and how to utilize associated variant effects in risk
prediction and treatment for AD.
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Chapter 5: Estimating the genome‐wide effect of common polygenic
variation and environmental factors on risk prediction for alcohol
dependence symptom count

Abstract
This study assessed the extent to which common genetic variation contributes to
variability in alcohol dependence (AD) symptom count, and how well aggregated effects
of single nucleotide polymorphisms (SNPs) on AD symptom count predict risk for AD in
independent samples. We used the genome-wide complex trait analysis (GCTA) tool
developed by Yang et al. (2011) to estimate the proportion of variance in AD symptom
count accounted for by genotyped SNPs in the Collaborative Study on the Genetics of
Alcoholism (COGA) genome-wide association study (GWAS) sample and the Study of
Addiction: Genes and Environment (SAGE) GWAS sample. We used the COGA and
SAGE samples reciprocally as discovery and validation samples. We first estimated SNP
effects using the discovery sample and then created additive genetic sum scores in the
validation sample, weighted by the discovery SNP effects. The genetic sum scores were
then assessed for their contributions to the variance in AD symptom count and the
accuracy with which they predicted AD in the validation sample. The proportion of
variance accounted for by SNPs across the genome was 53.19% in COGA and not
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significant in SAGE. The predictive accuracy for AD, measured by the area under the
receiver operating characteristic curve (AUC) was 0.549 in COGA and 0.527 in SAGE.
Both GCTA sum scores were significantly associated with AD symptom count in the
replication samples, accounting for 0.46% of the variance in SAGE and 0.57% of the
variance in COGA. Including additional covariates associated with AD was able to
account for an additional 18.80% of the variance in symptom count.
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Introduction
Alcohol dependence is a complex disorder that encompasses numerous medical, social,
and psychiatric problems and has an estimated lifetime risk of 12.5-14% (Hasin et al.,
2007; Kessler et al., 1994). About 50-60% of the variability in alcohol dependence is
attributed to genetic factors (Kendler et al., 1992; Heath et al., 1997). Alcohol
dependence, along with a vast number of other common, complex traits, has been
investigated using several genome-wide association studies (GWAS) over the past
several years. Numerous associated variants have been reported from GWASs of alcohol
dependence, though few have reached genome-wide significance levels (Treutlein and
Rietschel, 2011a; Frank et al., 2012; Wang et al., 2011; Zuo et al., 2012; Zuo et al., 2011;
Schumann et al., 2011). To date, more than 2,000 novel variants have been identified as
associated with complex disease (NHGRI catalogue www.genome.gov/gwastudies)
(Hindorff LA, MacArthur J (European Bioinformatics Institute), Wise A, Junkins HA,
Hall PN, Klemm AK, and Manolio TA) . For the majority of these traits, the amount of
phenotypic variance accounted for by discovered loci is substantially lower than the
estimated heritabilities for the traits based on twin and family studies (Visscher et al.,
2012). A number of explanations have been attributed to the problem of “missing
heritability” for common traits, including the contribution of epistasis, gene-environment
interactions, epigenetics, and rare variants not captured on current GWAS arrays.
Additionally, part of the missing heritability has been described as hidden heritability
attributed to effects that are in fact captured on current GWAS platforms – common
alleles with effects too small to be detected by genome-wide significance thresholds used
in GWA studies (Gibson, 2010; Manolio et al., 2009).
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Evidence for a polygenic etiology exists for many complex traits, leading to the
implication that a proportion of the missing heritability could be accounted for by the
aggregate effect of common SNPs already genotyped on current GWAS arrays (Gibson,
2010; International Schizophrenia Consortium et al., 2009). The Genome-Wide Complex
Trait Analysis (GCTA) method developed by Yang et al. (2011) uses a mixed linear
model to estimate the proportion of phenotypic variance accounted for by SNPs in total.
The method models all common SNPs genotyped in GWAS together by using restricted
maximum likelihood (REML) to provide an unbiased estimate of the variance explained
by all SNPs. In the mixed linear model, SNP effects are treated as random variables, with
additional covariates treated as fixed effects (Yang et al., 2010; Visscher et al., 2010).
Prior GWAS evidence for height in 183,727 individuals showed 180 associated variants
that explained 10% of the phenotypic variation in height, which is substantially lower
than the estimated 80% heritability for height based on twin and family studies (Lango
Allen et al., 2010). By modeling all 294,831 SNPs genotyped in the GWAS sample
together, Yang et al. showed that 45% of the variance in height could be attributed to the
aggregated effect of the genotyped SNPs. They found that when they accounted for
incomplete LD between causal SNPs and genotyped SNPs, they were able to explain the
remaining genetic variance in height (Yang et al., 2010; Visscher et al., 2010).
In our analyses, the European American (EA) portions of the COGA sample and
the SAGE GWAS sample without COGA GWAS individuals were used as discovery and
replication samples. We used the GCTA software tool developed by Yang et al.
(http://gump.qimr.edu.au/gcta/) to estimate the proportion of variance in DSM-IV alcohol
dependence (AD) symptom count explained by common SNPs separately for the COGA
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GWAS sample and the SAGE GWAS sample (Yang et al., 2011). We then used the best
linear unbiased prediction (BLUP) solutions for individual SNP effects to create genetic
sum scores weighted by the SNP effects in a second sample, either COGA or SAGE, that
was independent of the sample used to estimate the random SNP effects.
We also performed linear regression for AD symptom count in COGA and then
generated genetic sum scores based on SNPs meeting varying p-value thresholds. The
GCTA genetic sum scores from the mixed linear model and the genetic sum scores from
association using linear regression were assessed for association with alcohol dependence
symptom count and for predictive accuracy for alcohol dependence in an independent
sample.
Finally, we incorporated several environmental risk factors that have been shown
to influence risk for alcohol-related phenotypes into the prediction models. Specifically,
religiosity has been associated with decreased risk for substance use disorders (Kendler et
al., 2003; Koopmans et al., 1999). In independent samples, educational attainment has
been found to be associated with AD (Grant et al., 2012). Marital status has also been
shown to be associated with risk for AD (Dick et al., 2006). In data from the National
Longitudinal Alcohol Epidemiology Study and the National Epidemiologic Study on
Alcohol and Related Conditions, marital status and educational attainment were
associated with alcohol dependence and income was associated with alcohol abuse
(Caetano et al., 2011). We added these additional variables to baseline models including
the genetic sum scores into risk models for AD symptom count and AD diagnosis in
order to assess the contributions of different predictors for AD.
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Materials and methods

Sample Selection
The European American (EA) subsets of the Collaborative Study on the Genetics of
Alcoholism and the Study of Addiction: Genes and Environment GWAS samples were
used reciprocally as independent discovery and validation samples, after removing
overlap between the two samples. Both were described in detail previously in Chapter 4
and in the original COGA and SAGE GWAS reports (Edenberg et al., 2010; Bierut et al.,
2010). The entire SAGE EA sample consists of 1165 cases and 1376 unrelated controls
(N = 2541). For this study, the COGA portion of the SAGE EA GWAS dataset was
removed (N = 939, with 555 cases and 384 controls) in order to use the FSCD (N = 519,
with 275 cases and 244 controls) and COGEND (N = 1083, with 335 cases and 748
controls) portions of the SAGE dataset and the COGA GWAS dataset as independent
subsets. The total number of individuals from COGA was 1398 individuals (847 cases
and 552 controls) and the total number from SAGE was 1602 individuals (610 cases and
992 controls).

Data Analysis
Discovery sample analysis using the GCTA method
Figure 5.1 summarizes the study flow. The GCTA tool was used to estimate the
phenotypic variance explained by autosomal SNPs using the REML method for AD
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symptom count in the COGA and SAGE GWAS EA samples as described in Yang et al.
(2011). The tool uses a mixed linear model, with covariates treated as fixed effects and
genetic factors estimated as random effects. The phenotypic variance in AD symptom
count attributed to common SNPs was calculated based on a genetic relationship matrix
(GRM) across all individuals in the GWAS sample; the quantitative phenotype is
regressed on genetic similarity in the mixed linear model. Prior to estimating the variance
accounted for by SNPs using the genetic relationship matrix, we followed Yang et al’s
procedure to implement a genetic relationship cut-off of 0.025 – corresponding to cousins
2-3 times removed – in order to remove potential shared environmental and latent genetic
factors in more closely related individuals, which may account for additional proportions
of the phenotypic variance beyond that of the genotyped SNPs. Following pruning of the
genetic relationship matrix at a relationship of 0.025, 1261 individuals remained of the
1398 individuals in the COGA EA sample and 1524 of the 1602 individuals remained in
the SAGE EA sample. Two additional ancestry outliers from SAGE and two from COGA
were removed from the samples prior to estimation of variance components.
The model used in the GCTA tool is represented by the following equation:
𝑦 = 𝑋𝛽 + 𝑔 + 𝜀 𝑤𝑖𝑡ℎ 𝑉 = 𝐴𝜎!! + 𝐼𝜎!!
where y is the phenotypic value, 𝛽 is the fixed effects (i.e. covariates), g
represents the total genetic effects of individuals with g~N(0, A𝜎!! ).𝜎!! ).
𝑉 represents the variance of 𝑦.𝑦. 𝐴 represents the genetic relationship matrix
calculated from genotype data in the sample. 𝜎!! 𝜎!! corresponds to the variance
explained by all SNPs, estimated using restricted maximum likelihood. I is an
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NxN identity matrix and 𝜎!! 𝜎!! represents variance explained by residual effects
(Yang et al., 2011).
In our analyses, the following covariates were included as fixed effects in the
mixed linear model: age, sex, 20 eigenvectors, and year of birth. GCTA estimation of the
variance accounted for by SNPs in the SAGE GWAS sample included study site as an
additional covariate in order to account for site differences between the FSCD and
COGEND samples. The 20 eigenvectors were estimated using the GCTA tool and were
included in the model because the GCTA method could be particularly sensitive to
population stratification (Browning and Browning, 2011). Population stratification can
occur if cases and controls differ in frequencies of alleles due to variables other than
disease status that happen also to differ between cases and controls. If population
structure differences between cases and controls are not accounted for, alleles attributable
simply to ancestry differences could be spuriously associated with the disease phenotype.
For example, in the case of height, spurious associations may occur if there are subpopulations with different ancestries in the study sample and individuals from one
ancestry group happen to differ in the height phenotype compared with individuals from
another group, and there are allele frequency differences between these subgroups. These
alleles could very well have a contribution to height in the sample population; however,
they could also have frequency differences across the sub-populations simply because
individuals in different populations with distinct ancestral backgrounds often have
different allele frequencies and LD structure. A plot of the first two eigenvectors
indicated that the European American sample in COGA is not entirely homogeneous
(Figure 1). Age, sex and year of birth were included as covariates to account for
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differences in drinking patterns between cohorts and sex, and to control for possible
changes in lifetime AD symptom count endorsement with increasing age.

Figure 5.1 Overview of Study Design
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Figure 5.2 Principal components analysis plot of 1st eigenvector and
2nd eigenvector in the EA subset of the COGA GWAS sample

The number of alcohol dependence symptoms coded for each individual
represented the maximum number of alcohol dependence symptoms that the individual
ever endorsed across interview waves. The age variable corresponded to the age at the
interview during which the maximum symptom count was endorsed and was included as
a covariate because maximum lifetime symptom count could increase as an individual
ages and has had more time to experience symptoms. Furthermore, an individual who
endorses 7 symptoms at a young age may represent different etiology for AD compared
with an individual who endorses the same number of maximum symptoms at an age that
is several decades older. Year of birth, although correlated with age at interview, was
included as a continuous variable in the model in order to control for cohort effects, as
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patterns of AD symptom counts have differed across cohort years, particularly for
women.

Validation sample replication of GCTA genetic sum scores
The random effects of the SNPs were predicted in COGA and SAGE using the best linear
unbiased prediction (BLUP) method. The BLUP solutions for the individual SNP effects
were calculated based on these random effects. In the set of analyses using COGA as the
discovery sample, GCTA genetic sum scores of minor alleles of each genotyped SNP,
weighted by the BLUP solution of each SNP effect from COGA, were created in the
FSCD and COGEND portion of the SAGE EA GWAS sample using the --profile
function in PLINK version 1.07 (Purcell et al., 2007). The GCTA genetic sum scores
were then assessed for association with alcohol dependence symptom count using linear
models in the independent SAGE sample. These data analysis steps were then repeated
using SAGE as the discovery sample and COGA as the replication sample. Linear models
in the replication sample included sex, age at interview, and year of birth as covariates in
both COGA and SAGE, with the addition of study site as a covariate for SAGE analyses.
In the analyses using the SAGE sample as a discovery sample and the COGA
sample as the replication sample, additional covariates associated with alcohol
dependence including religious attendance, marital status, educational attainment, and
income were available in the COGA sample, which allowed for the inclusion of these
additional variables in the linear model. All linear models were performed using R
version 2.12.2 (R Core Development Team, 2011).
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Analysis of SNPs meeting varying p-value thresholds in GWAS of AD symptoms
Analyses on alcohol dependence symptom count were also performed using a linear
regression approach in the COGA EA sample in order to compare the results to the
GCTA genetic sum scores. Linear regression was performed using Plink version 1.07
(Plink et al., 2007) in the COGA EA sample with alcohol dependence symptoms as the
outcome and age, age at interview, and year of birth as covariates. SNPs were pre-pruned
at an r2 < 0.50 before they were included in the analyses, resulting in 386,545 SNPs.
Autosomal SNPs were selected from the results. Varying p-value thresholds were used to
select SNPs at p < 0.0001, 0.001, 0.01, 0.05, 0.1, 0.2, 0.3, .0.4, and 0.5. Genetic sum
scores were created in the independent FSCD and COGEND portions of the SAGE
GWAS sample with each subset of SNPs by adding minor alleles weighted by
standardized Betas obtained from the linear regression results in COGA. The proportion
of variance accounted for in AD symptom count by the genetic sum scores was assessed
in the FSCD/COGEND validation sample. Linear models in this assessment included the
same covariates as the ones used to assess the GCTA genetic sum scores.

Clinical validity assessment
The GCTA genetic sum scores created based on the BLUP solutions for SNP effects and
the genetic sum scores created based on linear regression results in COGA were assessed
for predictive ability for alcohol dependence in the independent SAGE sample.
Discriminatory accuracy was measured using the area under the receiver operating
characteristic curve (AUC) in SPSS/PASW version 17.0 (SPSS Inc., Chicago IL).
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Results
GCTA variance components estimation
Figure 5.3a and 5.3b displays the distribution of alcohol dependence symptom counts
across the COGA and SAGE samples, respectively, separately for cases and controls. The
proportion of phenotypic variance in alcohol symptom count that was accounted for by
common SNPs in COGA was 53.19% (SE = 25.7%). The proportion of variance
accounted for by common SNPs in SAGE was not significant at 0.0001% (SE = 24.60%).

Figure 5.3a. Alcohol dependence symptom count in the SAGE GWAS sample.
Distribution of alcohol dependence symptom count is shown, separated by case and
control status. Blue bars represent percentage of the controls endorsing the symptom
count labeled on the x-axis. Green bars represent percentage of the cases. Several
individuals who endorsed 3 or 4 symptoms were classified as controls because the
symptoms did not cluster in a 12-month period.
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Figure 5.3b Alcohol dependence symptom count in the COGA GWAS sample.
Distribution of alcohol dependence symptom count is show below, separated by case
(green) and control (blue) status. The COGA GWAS sample was preferentially selected
in order to maximize difference in phenotype between the cases and controls, as is
shown by the larger difference in symptom count frequencies between cases and
controls. Only three individuals in COGA endorsed 2 symptoms.
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Linear models
GCTA genetic sum scores in the SAGE sample
The base linear model including sex, year of birth, age, and the site covariate
distinguishing between COGEND and FSCD in SAGE showed that all covariates were
significantly associated with alcohol dependence symptom count (Table 5.1). The
adjusted r2 of the base model showed that the model accounted for 12.46% of the
variance in alcohol dependence symptom count. The GCTA genetic sum scores followed
a normal distribution (Figure 5.4). After the GCTA genetic sum score was added to the
base model, the score was significantly associated with alcohol dependence symptom
count (F1,1594 = 5.609, p = 0.00376). The proportion of variance in alcohol dependence
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symptoms accounted for by the GCTA genetic sum score was 0.46%. The new model
including the GCTA genetic sum score had an adjusted r2 of 12.87%. A comparison of
Beta estimates showed that the GCTA genetic sum score had a lower Beta compared with
the other predictors.

P-value threshold analyses in the SAGE sample
In the assessment of SNPs that met varying p-value thresholds in association with AD
symptom count in COGA, SNPs meeting increasingly stringent significance thresholds of
p < 0.0001 and lower did not account for a significant proportion of the variance in
SAGE. Genetic sum scores created based SNPs that met a p-value cutoff of 0.001 to 0.5
in COGA did account for a significant proportion of the AD symptom count variance in
SAGE (Table 5.2).
Each of the p-value threshold genetic sum scores was modestly correlated with
the GCTA genetic sum score (r = ~0.3, p <2.2x10-16). When both the genetic sum score
selected based on p < 0.5 and the GCTA sum score were added to the linear model in
SAGE, in combination the two genetic sum scores were able to account for a total of
1.52% of the variance in AD symptom count. However, the GCTA genetic sum score
was no longer significant when the additional score was added (p = 0.153), although the
p-value threshold score remained significant (p = 7.29x10-6).

Figure 5.4 Distribution of GCTA genetic sum scores in SAGE.
Sum scores plotted here are created based on the sum of the minor allele for each
genotyped SNP weighted by the COGA-derived BLUP solutions.
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GCTA genetic sum score analyses in the COGA sample
The base linear model including sex, year of birth, and age showed that all covariates
were significantly associated with alcohol dependence symptom count in the COGA
GWAS sample (Table 5.1). The base model accounted for 21.07% of the variance in
alcohol dependence symptom count. The GCTA genetic sum score was added to the base
model, and was shown to be associated with alcohol dependence symptom count (F1,1391
= 10.282, p = 0.001374). The proportion of variance in alcohol dependence symptoms
accounted for by the GCTA genetic sum score was 0.52%. The new model including the
GCTA genetic sum score had an adjusted r2 of 21.59%.
After incorporating into the model additional covariates that have previously been
found to account for some of the variance in alcohol dependence, including religious
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service attendance, income, educational attainment, and marital status, these covariates
together accounted for an additional 18.80% of the variance in alcohol dependence
symptom count. The final model accounted for 39.38% of the phenotypic variance in
alcohol symptom count. The GCTA sum score was still significant after adding the
additional covariates (p = 0.00360). A comparison of Beta estimates showed that the
GCTA genetic sum score had a higher Beta compared with several other covariates,
including age, year of birth, religious attendance, income, and educational attainment.

Table 5.1 Summary of linear models in SAGE and COGA including
GCTA sum score. All variables are centered in order to compare
Beta estimates. The GCTA genetic sum score was z-transformed.
Summary of linear models in SAGE based on COGA-derived SNP effects
Estimate

S.E.

Base model with covariates
Intercept
2.424
sex
-0.874
study site
0.761
year of birth
-0.431
age
-0.438
Model summary: F4,1595=57.9, p-value<2.2e-16, Multiple

t-value

0.053
0.110
0.120
0.055
0.056
r2=0.1268,

p-value

46.043
< 2e-16
-7.968
3.05E-15
6.336
3.06E-10
-7.826
9.08E-15
-7.832
8.71E-15
Adj. r2=0.1246

Model with covariates + GCTA genetic sum scores
Intercept
2.420
0.053
sex
-0.877
0.109
study site
0.757
0.120
year of birth
-0.432
0.055
age
-0.439
0.056
GCTA genetic score (z)
0.152
0.053
Model summary: F5,1594=48.22, p-value<2.2e-16, Multiple r2=0.1314,

46.15
< 2e-16
-8.018
2.05E-15
6.315
3.49E-10
-7.865
6.73E-15
-7.877
6.17E-15
2.902
0.00376
Adj. r2=0.1287

Proportion of variance in AD symptom count explained by GCTA genetic sum score= 0.46%
Summary of linear models in COGA based on SAGE-derived SNP effects

Base model with covariates
Intercept

Estimate

S.E.

t-value

p-value

3.4026

0.0689

49.377

< 2e-16
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sex
-2.4155
year of birth
0.0775
age
0.0300
Model summary: F3,1392=125.1, p-value<2.2e-16,

0.1382
-17.476
< 2e-16
0.0242
3.209
1.36E-03
0.0252
1.191
2.34E-01
2
2
Multiple r =0.2124, Adj. r =0.2107

Model with covariates + GCTA genetic sum scores
Intercept
3.4026
sex
-2.4076
year of birth
0.0832
age
0.0357
GCTA genetic score (z)
0.2210
Model summary: F4,1391=97.02, p-value<2.2e-16,

0.0687
49.5410
< 2e-16
0.1378
-17.4740
< 2e-16
0.0241
3.4490
5.79E-04
0.0251
1.4200
1.56E-01
0.0689
3.2070
1.37E-03
2
2
Multiple r =0.2181, Adj. r =0.2159

Proportion of variance in AD symptom count explained by GCTA genetic sum score= 0.57%
Model with covariates + GCTA genetic sum scores + additional variables
Intercept
2.4413
0.1046
23.3430
< 2e-16
sex
-1.9245
0.1448
-13.2860
< 2e-16
year of birth
0.1509
0.0347
4.3500
1.50E-05
age
0.1296
0.0358
3.6220
3.07E-04
GCTA genetic score
0.2102
0.0720
2.9180
3.60E-03
Religious attendance
-0.0095
0.0019
-4.8730
1.27E-06
Current income
-0.1235
0.0389
-3.1710
0.001565
Highest school grade
-0.1393
0.0346
-4.0240
6.16E-05
Marital status2
0.9239
0.6533
1.4140
0.157616
Marital status3
2.0339
0.3404
5.9750
3.20E-09
Marital status4
1.8790
0.1974
9.5170
< 2e-16
Marital status5
1.3563
0.2390
5.6760
1.80E-08
Model summary: F11,1005=61.01, p-value<2.2e-16, Multiple r2=0.4004, Adj. r2=0.3938
Proportion of variance in AD symptom count explained by additional variables = 18.8%

Marital status is dummy-coded with “married” as reference; marital status2 = widowed, marital
status3 = divorced, marital status4 = separated, marital status5 = never married

Table 5.2 Summary of linear models in SAGE and COGA using genetic sum scores
created based on SNPs meeting varying p-value thresholds.
Validation sample proportion of variance accounted for by sum score:
Summary of linear models in SAGE based on COGA-derived results

P-value threshold
score

Variance
accounted for in
AD sx count

p-value from
linear model

AUC estimate
for AD

p-value for
AUC

P-value < 0.50
P-value < 0.40
P-value < 0.30

0.0142
0.0140
0.0136

3.12E-07
4.03E-07
5.79E-07

0.570
0.569
0.567

2.88E-06
3.97E-06
6.41E-06
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P-value
P-value
P-value
P-value
P-value
P-value

<
<
<
<
<
<

0.20
0.10
0.05
0.01
0.001
0.0001

0.0131
0.0133
0.0144
0.0105
0.0054
0.0005

9.60E-07
7.76E-07
2.67E-07
1.13E-05
1.67E-03
3.55E-01

0.561
0.557
0.559
0.546
0.536
0.509

4.48E-05
0.0001123
7.25E-05
0.001993
0.01578
0.5343

Baseline models were the same as the models shown in Table 5.1. Reported are the change in r
attributed to the genetic sum score, and the associated p-value in the linear model. AUCs for
discriminative accuracy for alcohol dependence are reported with associated p-values.

2

Risk prediction assessment
Clinical validity determined for the GCTA genetic sum score using the receiver operating
characteristic curve showed an AUC of 0.527 (p = 0.070) for the GCTA genetic sum
score in discrimination for case-control status of alcohol dependence in SAGE. An
assessment of the predicted probabilities of the logistic regression model for alcohol
dependence including age, sex, study site, and year of birth covariates showed that the
covariates have greater discriminative accuracy than the GCTA genetic sum scores (AUC
= 0.690, p <0.001). The model with covariates and the GCTA genetic sum score had a
nominal increase in AUC compared with the covariates only model (AUC = 0.692, p
<0.001). (Figure 5.5a).
The p-value threshold scores had significant AUCs in ROC curve analyses for
SNPs that had met more liberal p-value thresholds of p < 0.001 and greater in the COGA
discovery sample (Table 5.2). AUC point estimates showed an increasing trend as the pvalue threshold used for SNP selection became more liberal.
Clinical validity analyses in COGA for the GCTA genetic sum score using the
ROC curve showed a significant AUC of 0.559 (p = 0.00194) for the GCTA genetic sum
score in discrimination for case-control status of alcohol dependence. An assessment of
the predicted probabilities of the logistic regression model for alcohol dependence
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including age, sex, and year of birth covariates showed that the covariates have greater
discriminative accuracy than the GCTA genetic sum scores (AUC = 0.765). The model
with covariates and the GCTA genetic sum score had a nominal increase in AUC (AUC =
0.771). The incorporation of additional variables increased the AUC further to 0.865. All
AUC estimates were significant (Figure 5.5b).

Figure 5.5a Discriminatory accuracy in SAGE
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Figure 5.5b Discriminatory accuracy in COGA
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Discussion
Previous candidate gene and genome-wide association studies of alcohol dependence and
other traits have reported a number of associated variants. Many of these variants only
account for a small fraction of the phenotypic variability in the complex trait. This study
aimed to assess the proportion of phenotypic variance explained by common SNPs for
DSM-IV alcohol dependence symptom count and to assess for replication and clinical
validity for alcohol dependence symptom count and alcohol dependence in independent
validation samples.
The results of the GCTA mixed linear model showed a significant proportion of
the variance in alcohol dependence symptom count accounted for by all GWAS SNPs in
COGA of about 53%, which is within the range of the estimated heritability of 50-60%
for alcohol dependence based on twin studies (Kendler et al., 1992; Heath et al., 1997;
Prescott and Kendler, 1999). The results from replication analyses showed significant
replication of the resulting GCTA genetic sum scores created using the BLUP solutions
for individual SNP effects in both the COGA and SAGE replication samples. Clinical
validity for models including the GCTA genetic sum score showed small AUCs for the
GCTA genetic sum score in discrimination for case-control status of alcohol dependence
in both COGA and SAGE. An assessment of the predicted probabilities of the logistic
regression model for alcohol dependence including age, sex, site, and year of birth
covariates showed that the covariates have greater discriminative accuracy than the
GCTA genetic sum scores.
Prior results in these analyses without year of birth as a covariate resulted in a
substantially higher estimate of heritability attributed to the common SNPs on the array.
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In COGA, the proportion of phenotypic variance in alcohol dependence explained by
common SNPs was 75.64% (SE = 25.51%) in the discovery sample and 0.75% in the
SAGE validation sample, in contrast to the 53.19% (SE = 25.8%) and 0.46% in the
analyses that included year of birth as a covariate. This contrast in results emphasized the
importance of accounting for a cohort effect in the model for alcohol dependence
symptom count, particularly since drinking patterns in the United States have changed
over time.
Genetic sum scores created based on linear regression results also accounted for a
significant proportion of the variance in alcohol dependence symptom count. Genetic
sum scores created based on a p-value cutoff of 0.001 to 0.5 in COGA accounted for a
significant proportion of the AD symptom count variance in SAGE, with scores based on
p < 0.001 accounting for about 0.54% of the variance and scores based on p < 0.1-0.5
accounting for 1-1.4% of the variance in alcohol dependence symptom count. In
combination, the genetic sum score selected based on p < 0.5 and the GCTA genetic sum
score based on a discovery COGA sample were able to account for 1.52% of the variance
in AD symptom count in SAGE. The observation that the GCTA genetic sum score was
no longer significant after adding the genetic sum score created based on SNPs with p <
0.50 in linear regression analyses and the modest correlation between the two scores
suggests that there are some shared polygenic effects captured by both genetic sum
scores.
Results in COGA showed that the variance accounted for by genome-wide SNPs
in aggregate is substantial at about 53%. The GCTA genetic sum score, however,
accounted for a much smaller proportion of variance (0.46%) in the independent SAGE
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sample. This shows that there could be a great degree of prediction error of individual
SNPs effects estimated by the GCTA tool. The sample sizes used in this study were
limited compared with the previous study on height in which the method was first
demonstrated, which had close to 4,000 individuals. In order to assess the impact of
sample size on variance estimate, the original study sampled 4 replicates of 1,000, 2,000,
and 3,000 individuals. They found that the average estimates were the same across
samples, but the standard error increased with decreasing sample size (Yang et al., 2010).
Although common SNPs as estimated by the GCTA tool did not in aggregate
account for a significant proportion of the variance in AD symptom count in SAGE, the
GCTA genetic sum scores created based on the BLUP solution of these individual SNP
effects in SAGE did significantly account for 0.57% of the variance in COGA. In order to
assess whether these could be spurious results, further follow-up analyses were
performed in which the GCTA tool was applied to a non-heritable quantitative phenotype
in SAGE. A random continuous phenotype was simulated in the SAGE sample to
determine whether a negative finding in the discovery sample using the GCTA tool could
still create SNP effects that accounted for a significant proportion of the variance in AD
symptom count in an independent sample. Similar to results in real SAGE data, aggregate
SNPs did not account for a significant proportion of variance in the continuous phenotype
in SAGE. Unlike the results of real SAGE data, the GCTA genetic sum score created
based on the BLUP solutions of SNP effects was not significantly associated with AD
symptom count in COGA (p = 0.554). This suggests that although the aggregate SNPs
did not account for a significant proportion of the phenotypic variance in AD symptom
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count in SAGE, individual SNP effects were still able to predict some degree of risk in
the independent COGA sample.
Results in SAGE were substantially different from COGA. One reason for this
discrepancy may be that individuals in COGA and SAGE differ in phenotypic severity
and therefore underlying etiology for AD. COGA was clinically ascertained from
treatment centers for alcohol dependence throughout the United States. The cocainedependent individuals from the FSCD sample in SAGE were also clinically ascertained
from chemical dependency centers; however, the nicotine dependence COGEND study in
the SAGE sample was designed as a community-based sample. The COGEND study
makes up the majority (about 2/3) of the SAGE sample. Because most of the SAGE
sample is community-based, the sample may represent a different range of phenotypes
with distinct risk for AD compared with the COGA sample. In fact, the COGA sample
was ascertained specifically to maximize difference in symptom count between cases and
controls, and therefore have fewer individuals who are controls endorsing the middlerange 2 symptoms compared with SAGE, which includes individuals across the range of
symptoms, including several controls who endorsed 3 AD symptoms, but did not cluster
in a 12-month period, which is necessary for an AD diagnosis. Furthermore, as shown by
Figure 5.4a and 5.4b, COGA has a greater number of individuals endorsing higher
symptom counts than SAGE. COGA may therefore have been more enriched to estimate
genetic effects for AD with higher symptom count.
These results support a polygenic model of risk for alcohol dependence symptoms
that is consistent with prior studies on psychiatric and other common complex disorders
(International Schizophrenia Consortium et al., 2009; Heath et al., 2011; Gibson, 2010).
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Although the GCTA genetic sum scores have replicated in the independent samples, the
proportion of variance accounted for the sum scores were less than that accounted for by
other variables such as religious attendance, income, educational attainment, and marital
status. The reason that the additional factors accounted for more of the variance in
symptom count could be due partly to the clinical nature of the ascertainment of the
COGA sample from treatment centers for alcohol dependence. These variables may
therefore have different contributions to alcohol-related outcomes in the COGA sample
than to alcohol-related traits in a general population.
This study shows that common variants, in aggregate, account for a significant,
but small, proportion of the variance in alcohol dependence symptom count. Genomewide association studies for alcohol-related phenotypes have provided more information
about the genetic architecture of AD. That there has not been an emergence of single
large-effect alleles accounting for a large proportion of variance in alcohol use
phenotypes, but rather multiple loci accounting for a small proportion of the phenotypic
variability suggests that a polygenic model could potentially improve risk prediction.
Prior studies by Aulchenko et al. for height found through simulation that when
predicting phenotypic extremes such as 1% of the highest and lowest values with an AUC
of 0.80, a genetic score needs to explain 17% of the variance in height (Aulchenko et al.,
2009). When predicting the phenotype with an AUC of 0.95, then genetic scores needed
to explain 53% of the variance in height. Our simulation studies conducted specific to
alcohol dependence suggest that when we have more exhaustively identified genes
contributing to the genetic susceptibility toward alcohol dependence, there is the potential
for AUCs approaching 80% to be reached with genetic information (Maher et al., in
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preparation; Chapter 2). Although genetic information has limited clinical validity at the
moment, we may have the potential for future clinical validity if we assess many genetic
variants and environmental factors together.
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Chapter 6: Genetic risk prediction for alcohol dependence subtypes

Abstract
Alcohol dependence (AD) is a complex psychiatric condition with a great deal of
phenotypic and etiologic heterogeneity. Multiple subtypes of AD have been described,
including an internalizing subtype that is often comorbid with major depressive disorder
and anxiety and an externalizing subtype that is often comorbid with other drug
dependence, conduct disorder, and adult antisocial personality disorder. Twin studies
have suggested that part of the co-occurrence of these phenotypes is due to shared genetic
factors. In this study, the Collaborative Study on the Genetics of Alcoholism (COGA)
and Study of Addiction Genes and Environment (SAGE) genome-wide association study
(GWAS) samples were used to investigate the etiology of phenotypes correlated with AD
and risk prediction for an internalizing subtype of AD, AD with major depressive
disorder (MDD), and an externalizing subtype of AD, AD with conduct disorder or with
illicit drug dependence. Results showed that sum scores of individual SNP effects derived
for AD symptom count also accounted for significant proportions of variance in
correlated phenotypes that did not appear to be driven solely by phenotypic correlation
with AD symptoms. Assessment of risk prediction for AD subtypes showed increasing,
but modest, areas under the receiver operating characteristic curve (AUCs) of 0.547 to
0.5610 for SNPs meeting p < 0.05 to p < 0.50 respectively, and non-significant results for
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MDD, which may be due to low power in this sample. This study suggests that the shared
genetic variance between AD-related phenotypes could be due in part to aggregated
genome-wide common polygenic variance of small effect, but that prediction of subtypes
is modest.
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Introduction
Alcohol dependence (AD) is a complex psychiatric condition with a large degree of
phenotypic and etiologic heterogeneity. A number of other psychiatric phenotypes often
co-occur with alcohol dependence, prompting the notion of subtypes of AD. There exists
extensive history for exploration of alcohol-related subtypes. In particular, Cloninger et
al. has described Type I alcoholism, which has later age of onset after 25 years, lower
novelty-seeking and antisocial behavior, anxious personality traits, and higher harm
avoidance than Type II alcoholism, which is characterized by earlier onset, higher
novelty-seeking and antisocial behavior, and lower harm avoidance (Cloninger et al.,
1988; Cloninger et al., 1981) . Another subtype that has been widely described is Babor’s
Type A and Type B typology (1992), in which Type A is characterized by later onset,
less severe dependence, with fewer alcohol-related problems and childhood risk factors,
and less comorbidity with other psychiatric disorders (Babor et al., 1992b; Babor et al.,
1992a). Studies using latent class analysis of AD phenotypes have shown the following
classes: a mild class with low likelihood of comorbid psychopathology, a severe class
characterized by high probability of comorbidity with psychopathology, and a class with
high probabilities of major depressive disorder (Sintov et al., 2010). A study by Del Boca
and Hesselbrock showed a mild class, a severe class, an internalizing class with high
probabilities of depression and anxiety, and an externalizing class with high levels of
antisocial personality disorder (Del Boca and Hesslebrock, 1996).
Researchers have debated whether the comorbidity between AD and major
depressive disorder (MDD) is attributed to a causation model in which major depressive
disorder increases risk for AD, and/or vice versa, or whether an additional factor
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influences risk for both (Nurnberger et al., 2002; Lyons et al., 2006). Studies have
suggested that MDD and AD are genetically related. Family studies show that the cooccurrence of AD and depression occurs across relatives. First-degree relatives of
alcoholic probands in the Collaborative Study on the Genetics of Alcoholism (COGA)
have been described to have an increased occurrence of depressive syndrome, or
depression that may or may not occur with increased alcohol consumption (Nurnberger et
al., 2002). Twin studies have found a genetic correlation of approximately 0.4-0.6
between major depressive disorder and alcohol dependence (Kendler et al., 1993) .
Linkage studies have identified that the same chromosomal region was linked to both AD
and MDD, suggesting that a common locus may increase risk for either AD or MDD
(Nurnberger et al., 2002). Candidate gene association studies have discovered
associations with AD that were particularly strong for AD that is comorbid with major
depressive disorder, compared with AD alone (Wang et al., 2004; Dick et al., 2007d).
Recently, a genome-wide association of comorbid AD and MDD in COGA reported top
results in several genes that had not been previously implicated, as well as multiple
pathways, including glutaminergic genes. The majority of results were shown to be
different between the comorbid phenotype and AD without MDD (Edwards et al., 2012).
Twin research has shown evidence for shared genetic contributions across alcohol
dependence and externalizing psychopathologies. Kendler et al., (2003) studied the
contributions of genetic and environmental factors to common psychiatric disorders and
found that 69% of the heritability of alcohol dependence was accounted for by a common
genetic factor contributing to a group of externalizing phenotypes, which included other
drug dependence, antisocial personality disorder, and conduct disorder (Kendler et al.,
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2003b) . Candidate gene studies have reported alcohol dependence associations that are
stronger for, or unique to, AD with comorbid drug dependence, conduct disorder, and
antisocial personality disorder, illustrating genetic contributions that may be specific to
these externalizing phenotypes. Foroud et al. found that SNPs in TACR3 that were
associated with AD in EA COGA families had the strongest association in individuals
with more severe AD and comorbid cocaine dependence (2008). Dick et al. showed that
variants in CHRM2 is associated with a form of AD that is comorbid with drug
dependence, but not with AD alone, and that the risk allele for CHRM2 based on
association of adult AD conferred increased risk for adolescent externalizing under
conditions of low parental monitoring (Dick et al., 2007b; Dick et al., 2011). Agrawal et
al. found GABRA2 to be associated with AD only in individuals with comorbid drug
dependence; when these individuals were removed from the analysis, no association
remained (2006). Variants associated in GABRA2 with AD have been further
characterized in a developmental sample and were found to be associated with
trajectories of externalizing (Dick et al., 2009).
The convergence of phenotypic, family, twin, and molecular genetics studies
suggests that distinct etiological contributions may underlie risk for internalizing and
externalizing subtypes of alcohol dependence. The studies described previously here in
Chapters 3 and 4 investigated the prediction of a binary diagnosis of AD. Using genetic
information from specific candidate genes did not result in significant predictive accuracy
for AD and GWAS results showed significant, but modest discriminatory accuracy for
AD. One reason for the low predictive accuracy could be that AD is a heterogeneous
phenotype, and an AD diagnosis that is comorbid with another condition may have
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different underlying risk than AD in general. Accordingly, genetic variants associated
with an AD subtype may be more predictive for that subtype.
In order to further characterize the comorbidity of alcohol-related phenotypes, and
to assess risk prediction for variants contributing to comorbid phenotypes, we performed
two sets of analyses. In the first part of the study, we assessed the extent to which
genome-wide SNP effects overlapped between phenotypes that are correlated with DSMIV AD symptom count in order to assess the genetic overlap due to common variants
between correlated phenotypes. We determined the proportion of variance accounted for
in traits that are correlated with AD symptom count by a genome-wide genetic sum score
estimated in the Collaborative Study on the Genetics of Alcoholism (COGA) GWAS
sample using the genome-wide complex trait analysis (GCTA) tool (Yang et al., 2011).
In the second part of this study, we used the COGA and the Study of Addiction:
Genes and Addiction (SAGE) GWAS samples to capture genetic effects on subtypes of
alcohol dependence in order to predict risk in AD subtypes in independent sample
subsets. We combined the COGA and SAGE GWAS samples and then split the
combined sample randomly in half. One half of the combined sample was used as a
discovery sample and the other half a validation sample. We then performed GWAS
analyses in the discovery sample separately for an externalizing and an internalizing
subtype of alcohol dependence. The prior studies described in Chapters 4 and 5 showed
that effect sizes of common SNPs for AD are individually small and that current studies
have been underpowered to detect these small effect sizes at genome-wide significance
thresholds. Selecting SNPs in aggregate across the genome and at more liberal p-value
thresholds would include a greater proportion of true loci that could in aggregate account
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for a significant, albeit small, proportion of the variance in AD, despite noise from null
loci (Evans et al., 2009; Purcell et al., 2009). Therefore, in this study, subtypes of AD
were assessed using varying significance levels in GWAS analyses, particularly as the
sample size was reduced with the selection of subtypes, though power to detect loci could
potentially increase with more homogeneous phenotypes. Variants meeting these
thresholds were then assessed for discriminatory accuracy for AD subtypes.

Materials and methods
Sample selection
In the first part of the study, we performed all analyses in the COGA GWAS EA sample.
In the second part of the study, we combined the COGA and SAGE GWAS samples,
after removing overlap between the two samples, and further categorized the sample into
case-control status for an internalizing subtype and an externalizing subtype of alcohol
dependence. We subsequently split the sample in half so that each half contained 50% of
cases and 50% of controls for the externalizing and internalizing phenotypes. In order to
reduce heterogeneity, the European American portion of the combined sample was used
in our analyses.
The internalizing subtype was defined as meeting DSM-IV criteria for alcohol
dependence and DSM-IV criteria for a major depressive episode. We included both the
“dirty” (depressive episode experienced with drugs and/or alcohol) and “clean” diagnosis
(not under the influence of drugs or alcohol) for a major depressive episode, but removed
individuals who met criteria for a major depressive episode due to bereavement. Table
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6.1 summarizes the number of individuals who met criteria for the comorbid internalizing
phenotype in each study.
The externalizing phenotype was defined by AD with illicit drug dependence
and/or with conduct disorder. Controls were selected to have no illicit drug dependence,
conduct disorder, or alcohol dependence. Individuals who had nicotine dependence were
also removed from the control group, as nicotine dependence may still encompass some
degree of shared genetic risk with an externalizing phenotype. Table 6.2 summarizes the
number of individuals who met criteria for the comorbid externalizing phenotype in each
study.

Table 6.1 Internalizing subtype sample size by study

COGA
COGEND
FSCD
Control (no AD or MDD)
461
671
202
Case (AD + MDD)
379
97
139
Total
840
768
341
AD = alcohol dependence; MDD = major depressive disorder

Total
1334
615
1949

Table 6.2 Externalizing subtype sample size by study

COGA

COGEND
FSCD
Total
Control (no ND, CD, or DD)
518
750
234
1502
Case (AD + CD or DD)
545
136
251
932
Total
1063
886
485
2434
AD = alcohol dependence; ND = nicotine dependence; CD = conduct disorder; DD =
illicit drug dependence
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Data analysis
GCTA correlated phenotypes analyses
The GCTA tool developed by Yang et al. (2011) was used to estimate the
phenotypic variance explained by autosomal SNPs using the restricted maximum
likelihood (REML) method for alcohol dependence symptom count in the COGA GWAS
EA sample. The GCTA tool, described in detail in Chapter 5, uses a mixed linear model,
with covariates treated as fixed effects and common SNPs genotyped on the GWAS array
estimated as random effects. The phenotypic variance in alcohol dependence symptom
count attributed to common SNPs was calculated based on a genetic relationship matrix
across all individuals in the GWAS sample after pruning the genetic relationship matrix
at a cut-off of 0.025 in order to remove potential shared environmental and latent genetic
factors in more closely related individuals that could account for additional proportions of
the variance beyond the genotyped SNPs. In prior analyses, we used the GCTA tool to
estimate the proportion of variance in DSM-IV alcohol dependence symptom count
explained by common SNPs in European American subset of the COGA GWAS sample.
The following covariates were included as fixed effects in the mixed linear model: age,
sex, 20 eigenvectors, and year of birth. Age, sex and year of birth were included as
covariates to account for differences in drinking patterns between cohorts and sex, and to
control for possible increasing lifetime alcohol dependence symptom count endorsement
with increasing age.
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Here, we used the best linear unbiased prediction (BLUP) solutions for individual
SNP effects estimated in the COGA GWAS sample to create genetic sum scores
weighted by the SNP effects within the COGA GWAS sample. The GCTA genetic sum
scores were then assessed for association with AD symptom count and the following
correlated phenotypes within the COGA GWAS sample: the maximum number of drinks
in 24 hours that the study participant reported consuming, antisocial personality disorder
symptom count, marijuana dependence symptom count, conduct disorder symptom count,
cocaine dependence symptom count, opioid dependence symptom count, other drug
dependence symptom count, and number of depressive symptoms, all measured by the
DSM IV (American Psychiatric Association, 2000), and the Fagerstrom Test for Nicotine
Dependence (FTND) score.
We also assessed two additional phenotypes to use as controls that are
hypothesized not to have shared genetic variance with alcohol dependence – one that was
correlated with alcohol dependence symptom count and one that was not. For the trait
that had a correlation with AD symptom count, height was assessed. For the uncorrelated
trait, a random, normally distributed quantitative phenotype was simulated in the COGA
dataset. We compared the results of these two phenotypes with those of the psychiatric
and substance use phenotypes.
A linear model was used to assess association of GCTA genetic sum scores in
correlated phenotypes using R version 2.12.2 (R Core Development Team, 2011). Linear
models included sex, age at interview, study site, and year of birth as covariates.

AD subtypes risk prediction analyses
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We created genetic sum scores based on SNPs that met p-value thresholds from p <
0.0001 to p < 0.50 in the discovery sample and then assessed for prediction in the
validation sample, separately for the internalizing and externalizing phenotypes.
Association analysis was performed in the discovery sample using logistic regression
with covariates for sex and the COGA, FSCD and COGEND study site variables in
PLINK v1.07 (Purcell et al., 2007).
Prior to association, SNPs were pre-pruned based on an r2 threshold of 0.50 using
an LD-based pruning function in PLINK version 1.07. This method calculated pairwise
genotypic correlations for the list of SNPs. One of each pair of SNPs with correlations
greater than an r2 of 0.50 was removed. LD calculations for SNP pruning were performed
in the combined COGA and SAGE GWAS sample, sans overlap. Pruning resulted in
385,060 SNPs kept for analyses.

Genetic sum scores and ROC curve analyses
Because both the COGA and SAGE GWAS samples had the same SNPs genotyped, and
were confirmed to share the direction of the genotyped strand, GWAS results were
matched directly by allele. Genetic sum scores were created for autosomal SNPs. Scores
of total allele count were weighted by the natural log of the odds ratio for each reference
minor allele, and then divided by the number of non-missing genotypes for each
individual using PLINK version 1.07:
Genetic sum score =

[!! × !"(!"! )] [!! × !"(!"! )]
!
!
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where 𝑥! 𝑥! is the number of reference alleles at the ith SNP, OR is the
corresponding odds ratio, and N is the number of non-missing genotypes for each
individual.

Discriminatory accuracy of genetic sum scores was measured using ROC curve analysis
in the caTools package in R version 2.12.2 (Tuszynski, 2011; R Core Development
Team, 2011). The p-values associated with the AUCs for these sum scores were
calculated based on the Wilcoxon rank-sum test using R version 2.12.2.

Results
Assessment of correlated phenotypes in the COGA GWAS sample
GCTA genetics sum scores created within COGA showed significant variance accounted
for in correlated phenotypes of GCTA genetic sum scores created based on AD symptom
count (Table 6.3). The amount of variance accounted for by the GCTA genetic sum score
was not directly proportional to the correlation between alcohol dependence symptom
count and the second phenotype. For example, number of depressive symptoms had a
lower correlation with AD symptom count than conduct disorder symptom count, but the
GCTA genetic sum score derived from AD symptom count accounted for more of the
variance in number of depressive symptoms than in conduct disorder symptom count.
Furthermore, opioid dependence symptom count was less correlated with AD symptom
count than height, but the GCTA genetic sum score accounted for a significant proportion
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of the variance in opioid dependence symptom count, compared with no significant
proportion of the variance in height. The GCTA genetic sum score did not account for a
significant proportion of the variance in the random continuous phenotype.

Table 6.3 Summary of variance accounted for by GCTA genetic sum score in COGA

Phenotype
AD Symptom Count
Maximum number of drinks in 24 hours
Antisocial Personality Disorder Symptom Count
Marijuana dependence symptom count
Conduct Disorder Symptom Count
Cocaine dependence symptom count
Other drug dependence symptom count
FTND Score
Number of depressive symptoms
Height
Opioid dependence symptom count
Random, normally-distributed quantitative
pheno

Correlation
with AD Sx
Count *
1*
0.694*
0.668*
0.485*
0.476*
0.466*
0.437*
0.387*
0.377*
0.294*
0.291*
0.006 (p =
0.823)

Proportion of
variance
accounted for
by COGA
aggregate
genetic sum
score
67.72%
24.07%
19.11%
10.79%
7.50%
10.88%
12.01%
11.21%
13.62%
0.10%
6.30%
3.88 x 10

-5

p-value
p < 2e-16
p < 2e-16
p < 2e-16
p < 2e-16
p < 2e-16
p < 2e-16
p < 2e-16
p < 2e-16
p < 2e-16
p = 0.10
p < 2e-16
p = 0.83

Assessment of comorbid phenotypes in the COGA and SAGE GWAS sample
Table 6.4 summarizes the resulting AUCs for genetic sum scores created based on SNPs
at each p-value for the comorbid subtypes. AUC estimates showed increasing AUCs for
genetic sum scores created based on SNPs meeting increasingly liberal p-value thresholds
for the externalizing phenotype. AUC estimates for the internalizing phenotype were not
significant and did not show a consistent pattern across p-value threshold cut-offs.
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Table 6.4 Summary of AUC estimates for AD subtypes

Binary AD

Externalizing
AD Subtype

P-value
for AUC

Internalizing
AD Subtype

P-value
for AUC

P-value < 0.50

0.565

0.5610

5.86E-04

0.5192

0.3393

P-value < 0.40

0.565

0.5599

7.28E-04

0.5221

0.2709

P-value < 0.30

0.564

0.5629

3.89E-04

0.5232

0.2468

P-value < 0.20

0.564

0.5628

3.97E-04

0.5229

0.2540

P-value < 0.10

0.562

0.5598

7.39E-04

0.5260

0.1950

P-value < 0.05

0.559

0.5465

0.0088

0.5337

0.0929

P-value < 0.01

0.549

0.5238

0.1793

0.5274

0.1716

P-value < 0.001

0.528

0.5063

0.7223

0.5340

0.0901

P-value < 0.0001

0.517

0.5060

0.7331

0.5066

0.7432

P-value threshold

Externalizing AD Subtype = alcohol dependence that is comorbid with drug dependence
or conduct disorder; Internalizing AD Subtype = alcohol dependence that is comorbid
with major depressive disorder.

Discussion
This study aimed to evaluate the clinical validity of genetic variants that have been
associated with alcohol dependence subtypes by exploring the aggregate effect of
associated SNPs on risk prediction for alcohol dependence subtypes. Assessing risk
prediction for a diagnosis of alcohol dependence has shown limited predictive ability
using candidate gene information and GWAS results for AD. In this study, we first
assessed the underlying genetic overlap between correlated phenotypes with DSM-IV
alcohol dependence symptom count. We then assessed risk for AD subtypes, with the
idea that risk prediction for a disorder may improve if specific predictors are identified to
be more informative for a subset of individuals.
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In order to further examine the genetic overlap between traits that have been
suggested to have shared genetic variance with AD, we assessed whether we could
quantify this genetic correlation using aggregated effects of common SNPs across the
genome. In this part of the study, the GCTA genetic sum score created based on AD
symptom count accounted for a significant proportion of the phenotypic variance in
multiple correlated phenotypes thought to be etiologically related to AD. As expected, the
GCTA genetic sum score accounted for a significant and substantial proportion of the
variance in AD symptom count (67.72%), though not all of the variance. One important
limitation to assessing genetic risk within the same sample in which the genetic sum
score weights were estimated is that results would be largely inflated; independent
samples are necessary for replication. A randomly simulated uncorrelated phenotype was
created and found to be associated with the GCTA genetic sum score, which suggests that
the sum score is not explaining risk indiscriminately for phenotypes within the discovery
sample. In order to control for inflation, model was also run on height so that we could
determine whether the GCTA genetic sum score accounted for variance in a correlated
phenotype simply because its correlation with AD symptom count rendered it a proxy for
AD symptom count rather than because there exists shared etiology between the two
phenotypes. Height is not thought to have shared etiology with AD, but is correlated with
AD symptom count. Its correlation with AD symptoms is driven by sex, for which there
is a higher prevalence of AD among males compared with females (Hasin et al., 2007).
There is no reported evidence of common genetic factors contributing to both sex
determination and alcohol dependence and genetic contributions to AD have been
estimated to be the same in males and females (Young-Wolff et al., 2012). Results
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showed that the AD symptom count-derived GCTA genetic sum score did not account for
a significant proportion of variance in height (r2 = 0.10%, p = 0.10). This supports the
notion that significant association of the GCTA genetic sum score with correlated
phenotypes may mean that common polygenic variation contributes to shared etiology
between the two phenotypes.
Results showed that phenotypic correlation did not directly correspond with
polygenic sharing. This provides possible insight into the extent to which polygenic
variation is shared between AD symptoms and correlated disorders. Although several
phenotypes had similar correlations, the proportion of variance accounted for by the
GCTA genetic sum score was not the same. For example, conduct disorder symptom
count, had a higher phenotypic correlation with AD symptom count compared with
number of depressive symptoms, but the GCTA genetic sum score derived from AD
symptom count accounted for more of the variance in number of depressive symptoms
compared with conduct disorder symptom count. This suggests that a greater proportion
of polygenic risk may be shared between major depressive disorder symptom count and
AD symptom count than between conduct disorder symptom count and AD.
Risk prediction assessment of an externalizing AD subtype showed significant
AUCs that increased with genetic sum scores created based on SNPs meeting less
stringent p-value thresholds. Results for the internalizing phenotype, however, did not
show a consistent significant pattern of AUCs across p-value threshold cut-offs. The
reason could be that the COGA-SAGE combined GWAS sample size was greatly
reduced in the analyses. Selecting only individuals meeting the subtype-defined
phenotypes reduced the sample, and splitting the samples into discovery and validation
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sets further reduced the sample sizes. Although a more narrowly defined phenotype could
confer increased power for a genetic association study, a reduction in sample size could
result in a corresponding reduction in power.
The results of this study support a shared genetic component to alcohol-related
phenotypic correlations that are consistent with twin and family studies. The substantial
proportion of variance accounted for by AD symptom count-derived scores in the
correlated phenotypes suggests that a proportion of the shared genetic variance is due to
aggregated genome-wide common polygenic variance of small individual effect. Risk
prediction for AD subtypes resulted in similar results to an AD binary diagnosis, with
non-significant results for MDD, likely due to limited power. Assessment in larger
samples may help uncover variants that are informative for predicting and possibly
diagnosing subtypes of AD.
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Chapter 7: Conclusions

A greater understanding of the biology of alcohol dependence and its interplay with the
environment is key to the advent of better treatment, prediction, and prevention of
alcohol dependence. Advances in gene identification are now yielding replicable
susceptibility loci for many complex traits, including alcohol dependence. However, each
accounts for only a small proportion of the phenotypic variance of a trait. These studies
assessed the predictive ability of currently known associated genetic variants, new
aggregate measures to capture genetic information across the genome, and environmental
factors associated with alcohol dependence phenotypes, with the aim of providing a
clinical interpretation of the current body of knowledge of factors contributing to risk for
alcohol dependence.
Based on data simulation results, there is potential for alcohol dependence risk
prediction; using only information on genetic contributions to alcohol dependence, it is
possible to have discriminatory accuracy close to 80%. A risk prediction algorithm based
on genetic information alone is not expected to reach an AUC of 100% because
environment also plays a substantial role in risk for alcohol dependence. Adding the
effects of environmental risk factors show that there is the potential for this AUC to
increase to 0.95. Results demonstrate that as more causative loci are uncovered, and as
environmental factors for alcohol dependence are found, then genetic susceptibility
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testing and environmental risk prediction for alcohol dependence may have high clinical
validity.
The series of studies reported here showed that risk prediction for alcohol
dependence is currently limited. Genetic sum scores based on candidate gene SNPs did
not have significant predictive value as assessed by receiver operating characteristic
curve analyses. Aggregate genetic sum scores including information on more variants
across the genome did, however, have significant discriminatory accuracy for predicting
alcohol dependence. This was particularly true for variants that met varying p-value
thresholds that were less stringent – a subsequent genetic sum score based on these
nominally associated SNPs had a higher AUC than SNPs meeting more stringent
thresholds. We found that a similar pattern was observed for repeated subsampling crossvalidation procedures. We also found that results were similar for alcohol dependence
internalizing and externalizing subtypes, as well as alcohol dependence symptom count,
though our sample size for the internalizing subtype may have been too small to detect a
significant effect. We also assessed the predictive ability of individual effects estimated
based on the best linear unbiased prediction (BLUP) solutions of SNP effects using
restricted maximum likelihood to estimate the phenotypic variance accounted for AD
symptom count using the GCTA method developed by Yang et al. (2011). Scores based
on markers across the genome accounted for a significant, but small proportion of the
variance in alcohol dependence symptom count. A polygenic theory of etiology exists for
many disorders of complex, multifactorial etiology (Fisher 1918). These results provide
evidence for a polygenic contribution to alcohol dependence.
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One reason that candidate gene sum scores associated in different populations did
not in aggregate replicate in the COGA and SAGE GWAS samples may be due to
phenotypic and genetic heterogeneity across the samples. In these analyses, several of the
candidate gene variants had an opposite direction of effect across the candidate gene
family-based association sample and the GWAS samples. Population differences between
the high-density COGA sample and the GWAS samples could account for differences in
direction of effect. According to Zuo et al., two different populations with distinct
structures could share causal variants, but the variants in LD with these causal variants,
which are the ones detected in genetic association studies, could be different across
distinct populations (Zuo et al., 2012). To address this issue, they suggested that focus be
placed on identifying risk regions, rather than individual variants, as these individual risk
markers could be different in distinct populations, but be tagging the same causal
variants. A next step would be to investigate prediction using regions with subsets of
variants rather than replicating all candidate gene variants, as different variants from
different regions may have different directions of effect and varying discriminatory
accuracy for specific populations.
In comparison with other risk prediction models, the AUCs of genetic sum scores
are similar to AUCs of some clinical prediction models, showing that despite low clinical
validity, genetic information for AD is in some circumstances comparative to existing
clinical risk models for complex diseases. For example, the Gail model, or the Breast
Cancer Risk Assessment Tool, is a commonly used tool to estimate 5-year and lifetime
risk for invasive breast cancer and to help determine whether or not chemopreventative
therapy is warranted. It assesses risk factors such as age, race, family history, personal
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reproductive history including age at menarche and age at first live-born, and medical
history such as atypical hyperplasia on biopsy and number of biopsies performed. A Gail
model five-year absolute risk estimate of breast cancer of 1.67% is used as the cut-off in
FDA guidelines for use of selective estrogen receptor modulators such as tamoxifen or
raloxifen in risk reduction for breast cancer. The model has been validated at the
population level, by comparing the expected (E) number of women who develop breast
cancer based on the model with the observed number of women in the population who
develop breast cancer (O). The calibration performance of the risk tool, or E/O ratio, has
been found to be >93% in U.S. women (Spiegelman et al., 1994; Rockhill et al., 2001;
Bondy et al., 1994; Costantino et al., 1999). Evaluation of clinical validity at the
individual level using ROC curve analyses, however, showed that this model has poor
classifier ability, with an AUC of 0.557 - 0.60 (Gail, 2008; Mealiffe et al., 2010;
Wacholder et al., 2010; Rockhill et al., 2001; Anothaisintawee et al., 2012). Despite the
low AUC, the Gail model is used as a screening tool in conjunction with personalized
risk-benefits analysis of the clinical utility of chemopreventative therapy, and has been
found to be particularly useful for younger women with increased risk based on the Gail
model (Gail et al., 1999). Large prospective studies, such as the Framingham Heart
Study, have developed extensive clinical risk algorithms, such as the Framingham Risk
Score, which uses clinical risk factors including age, sex, LDL cholesterol, HDL
cholesterol, total cholesterol, dyslipidemia, blood pressure, treatment for hypertension,
and smoking to predict risk for cardiovascular disease. The Framingham Risk Score has
been found to have AUCs of 0.72 – 0.86 for predicting cardiovascular disease mortality
(Siontis et al., 2012). The Cambridge risk score for predicting risk for type II diabetes
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includes family history, age, sex, drug treatment, smoking status, and body mass index
and has an AUC of 0.78 for classifying cases and controls for type II diabetes (Talmud et
al., 2010). Once more risk factors are found for AD, similar large, prospective
population-based studies will be necessary for validation of risk prediction algorithms for
alcohol-related phenotypes.
Our findings stress that despite interest in genetic testing, and the availability of
testing through direct to consumer (DTC) avenues, genetic testing for AD is not yet ready
to be applied in a clinical setting. Without additional studies of clinical utility and
validation of risk models for AD, the low clinical validity of genetic variants for AD
connotes limited predictive value for risk assessment and decision-making based on
information about specific genetic variants alone. Family history is shown here to be a
better predictor of alcohol dependence than information from SNPs in aggregate. Despite
its higher AUC, family history still does not have a discriminative accuracy that is close
to the typical target AUC of 0.80 for screening tools. Therefore, the prediction of alcohol
dependence has room to improve if it is to be used as a screening tool with high clinical
validity. Expanded family history information across multiple relationships may have
better predictive ability. In our analyses, an ordinal family history variable had a
nominally higher AUC compared with a binary family history variable based on the same
criteria for parental history of AD. Family history containing information about relatives
other than mother and father of a proband had a higher AUC than information about
parental AD history only. The cost of taking a sufficient family history must also be
weighed against the cost of having a genetic test, which should in turn be weighed against
the use of environmental factors, as well as a combination of all three predictors –
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specific genetic variants, environmental factors, and family history information. As
sequencing costs decrease, future cost-benefit analyses may show that for some
conditions with well-validated genetic information, the price of analyzing a panel of
SNPs from sequencing data may be lower than taking a detailed family and/or clinical
history to obtain the same risk estimates. Perhaps an even more effective way to predict
risk would be to combine family history information with genetic information in order to
uncover the degree of penetrance for a specific set of alleles, and to find out which
genetic markers are most informative for a particular family based on its history
(Ruderfer et al., 2010).
Continued studies on the clinical validity of genetic risk factors in cross-sectional
and retrospective studies may inform prospective clinical studies. Developmental studies
assessing the discriminatory accuracy of phenotypes across the lifespan can be assessed.
Since the maximum AUC of a disorder is dependent on its prevalence, and prevalence of
AD is age-dependent, the ability of genetic marker to discriminate affection status would
vary with age. Further research could show that environmental prediction and
intervention may be most helpful in particular subgroups. Genetic information may allow
for identification of subgroups that will respond better to prevention and treatment
measures, such as targeting alcohol metabolism with withdrawal phenotypes. Finally,
with knowledge of genetic contributions to AD, studies should help determine the best
way in which to communicate risk for a complex disorder such as AD in a clinically
meaningful way that minimizes fatalism and maximizes healthy behavior and
psychosocial adaptation.

162

Future extensions of this work would include the incorporation of gene-gene and
gene-environment interactions to create an additively coded composite risk score
weighted by the effect size associated with the interactions in both simulated data and
real data. Many of the “environmental” variables included in these analyses have been
shown to moderate genetic contributions to AD, and therefore augment genetic influences
under some conditions and mask them under other conditions. Consequently, these
interactions could affect how informative genetic variants may be for a given individual,
and may depend on existing background environmental risk for that individual. Data
mining techniques such as tree-based regression and classification are approaches
designed for incorporating all of the complex predictor interactions and main effects to
predict risk for a disorder. Several data mining techniques have been applied to GWAS
data. Pirooznia et al. (2012) used Bayesian networks, support vector machine, random
forest, radial basis function network, and logistic regression methods to investigate
predictors of bipolar disorder compared with the polygenic scores created based on
varying p-value thresholds. They found that the AUCs of data mining approaches did not
reach the AUC of the polygenic scoring approach, with the exception of results from
Bayesian networks, which produced an AUC of 0.550 compared with the AUC of 0.549
for a polygenic score (Pirooznia et al., 2012). Another recent study by Wong et al. (2012)
used the advance recursive partition approach (ARPA), a classificatory multidimensional
tree technique, to assess autosomal non-synonymous SNPs in 188 genes, comorbid
conditions, and covariates to predict major depressive disorder (MDD). They found a tree
structure that replicated in an independent sample and had a predictive accuracy of AUC
= 0.63 for MDD (Wong et al., 2012). Unlike traditional gene-finding approaches using
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association analyses, data mining approaches focus specifically on optimizing risk
prediction by modeling multiple correlations and interactions between variables that
predict risk significantly for an outcome of interest. Using an a priori set of expanded,
less correlated genetic markers to assess for a set of predictors in a data mining
framework that incorporates interactions between markers may improve risk prediction
for AD. Furthermore, including higher order interactions between genetic and
environmental variables could improve prediction using data mining, particularly in light
of the suggested importance of gene-environment interactions in risk for AD.
In summary, these studies aimed to find ways of utilizing the growing body of
knowledge in the development of alcohol dependence to find clinically meaningful
profiles of risk, and to place risk factors for AD in a clinical context. To date, the current
status of psychiatric disorders and other complex diseases have limited genetic prediction
options. Although variants from association studies are currently not sufficient to act as
predictors of disease status, data simulations show that by using larger studies, markers
that serve as good classifiers may be found. Growing interest in genetic counseling and
testing to determine and manage risk for complex phenotypes calls for continuous
evaluation of clinical validity and utility that should be concomitant with focused
investigation of the genetic influences on these traits. The hope is that by combining a
number of risk variants, more of the variance explained by genetic factors can be
accounted for even though the variance explained independently by each variant is small
(Wray et al., 2008). The increasing number of gene-identification studies, coupled with
decreasing costs of high-throughput genotyping and whole genome sequencing, may
allow for better detection of markers covering a range of frequencies and effects on
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alcohol dependence. By continuing to find biomarkers for disease risk and progression,
we may eventually be able to develop models for better risk prediction, diagnosis,
prognosis, treatment, and prevention.
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